New molecular insights into sperm epigenetics: regulation of LINE-1 elements by CpG methylation and histone-modifications, and its impacts on sperm quality by Gies, Sabrina Elisabeth
  
 
New molecular insights into sperm epigenetics: 
Regulation of LINE-1 elements by CpG methylation and histone-
modifications, and its impacts on sperm quality 
 
 
Inaugural Dissertation 
submitted to the 
Faculty of Medicine 
in fulfillment of the requirements 
for the PhD-Degree 
of the Faculties of Veterinary Medicine and Medicine 
of the Justus Liebig University Giessen 
 
 
by 
Gies, Sabrina Elisabeth 
of 
Frankfurt am Main  
 
 
Giessen (2019) 
 1 
 
 
From the Department of Urology, Pediatric Urology and Andrology 
Working group “Epigenetics of the Urogenital System” 
Head of the working group: Prof. Dr. rer. nat. Undraga Schagdarsurengin 
of the Faculty of Medicine of the Justus Liebig University Giessen 
 
 
 
First Supervisor and Committee Member:  
Prof. Dr. rer. nat. Undraga Schagdarsurengin 
 
Second Supervisor and Committee Member:  
Prof. Dr. med. vet. Christine Wrenzycki 
 
Committee Members:  
Prof. Dr. med. Thomas Haaf 
 
 
 
Date of Doctoral Defense: 
November 5th, 2019 
  
 
 2 
 
 
 3 
 
Table of contents 
1. Introduction .................................................................................................................................. 6 
1.1 Male infertility and possible treatments for couples ............................................................... 6 
1.2 Spermatogenesis ..................................................................................................................... 7 
1.3 Components and modifiers of the sperm epigenome.............................................................. 8 
1.3.1 DNA methylation: regulators and epigenetic reprogramming in human germ line ............ 9 
1.3.2 Post-translational Histone modifications (PTHMs) in spermatozoa ................................. 11 
1.4 Long interspersed nuclear element 1: LINE-1 (L1) .............................................................. 13 
1.4.1 L1 structure and its retrotransposition cycle ...................................................................... 14 
1.4.2 Association of remaining sperm nucleosomes with repetitive elements ........................... 15 
1.4.2.1 CpG methylation .................................................................................................... 16 
1.4.2.2 Post-translational Histone modifications (PTHMs) as L1 regulators .................... 17 
1.4.2.3 Transcription factors (TFs) of L1 ........................................................................... 18 
1.5 Aims of this work ................................................................................................................. 21 
2. Materials and Methods ............................................................................................................... 22 
2.1 Materials ............................................................................................................................... 22 
2.1.1 Chemicals .......................................................................................................................... 22 
2.1.2 Reagents, buffers and kits .................................................................................................. 22 
2.1.2.1 DNA, RNA and protein extraction ................................................................................. 22 
2.1.2.2 CpG methylation and mRNA analysis ........................................................................... 23 
2.1.2.3 Immunohistochemistry ................................................................................................... 24 
2.1.2.4 Western blot .................................................................................................................... 24 
2.1.3 Antibodies .......................................................................................................................... 26 
2.1.4 Equipments ........................................................................................................................ 26 
2.2 Methods ................................................................................................................................ 28 
2.2.1 Collection and preparation of human semen samples ....................................................... 28 
2.2.2 Human cancer cell line cultures ......................................................................................... 29 
2.2.3 DNA & RNA extraction .................................................................................................... 29 
2.2.4 CpG methylation analysis .................................................................................................. 31 
2.2.4.1 Bisulfite treatment and pyrosequencing ......................................................................... 31 
2.2.4.2 ELISA ............................................................................................................................. 32 
2.2.5 RT-qPCR analysis ............................................................................................................. 32 
2.2.6 Statistical analysis and Figure preparations ....................................................................... 34 
2.2.7 Protein extraction and western blot analysis of sperm nucleoproteins .............................. 34 
 4 
 
2.2.8 IHC on human/bull/mouse testis tissues and ICC with human spermatozoa .................... 35 
2.2.9 ChIP and ChIP-qPCR with human spermatozoa ............................................................... 36 
3. Results ........................................................................................................................................ 38 
3.1 In fertile men, DNMT1 and DNMT3A mRNAs are stored at high levels in motile 
spermatozoa and are strongly correlated to each other ............................................................... 38 
3.2 Analysis of the global DNA/RNA methylation & L1 methylation states in motile and 
immotile human spermatozoa ..................................................................................................... 39 
3.2.1 5-mC / 5-hmC DNA and m6A RNA methylation in motile human spermatozoa............. 39 
3.2.2 ELISA analyzes reveal that motile spermatozoa from healthy men possess higher L1 
methylation in comparison to that in subfertile men .................................................................. 41 
3.2.3 Immotile spermatozoa possess high levels of L1 mRNA .................................................. 43 
3.3 SIRT6 methylation and expression analyzes......................................................................... 45 
3.4 Analyzes on MORC2 mRNA in human sperm ..................................................................... 49 
3.5 YY1 expression analysis in human testis tissue ................................................................... 50 
3.6 Histone modifications & regulators associated with L1 ....................................................... 51 
3.6.1 IHC analyzes of H4K20me2 in human, mouse and bull testis samples ............................ 52 
3.6.2 ICC staining & Western blot of H4K20me2 on human spermatozoa ............................... 55 
3.6.3 IHC staining of H4K20me3 in human, mouse and bull testis samples ............................. 56 
3.6.4 ICC staining & Western blot of H4K20me3 on human spermatozoa ............................... 59 
3.6.5 Analysis of histone methyltransferases KMT5A, KMT5B and KMT5C regulating H4K20 
  .................................................................................................................................. 61 
3.7 ChIP-qPCR confirming H4K20me3 binding in gene regions evaluated by ChIP-sequencing
 .................................................................................................................................................... 64 
4. Discussion................................................................................................................................... 67 
4.1 Spermatozoa of subfertile patients possessed decreased DNMT1 and DNMT3A mRNA 
levels ........................................................................................................................................... 68 
4.2 Global DNA and RNA methylation status in human spermatozoa ...................................... 69 
4.2.1 Motile spermatozoa of healthy controls and subfertile patients did not differ in global 
DNA and RNA methylation levels ............................................................................................. 69 
4.2.2 Lowest L1 methylation was detectable in motile spermatozoa of subfertile patients using 
ELISA and L1 mRNA was highest in immotile spermatozoa of healthy controls ..................... 71 
4.3 SIRT6 was hypermethylated in motile spermatozoa of subfertile patients ........................... 73 
4.4 Increased MORC2 mRNA levels in motile spermatozoa of healthy controls ...................... 74 
4.5 No YY1 expression in male germ cells ................................................................................ 75 
4.6 H4K20me2 and H4K20me3 were present during human, bull and mouse spermatogenesis 
and in mature human spermatozoa, besides KMT5A and KMT5B, histone methyltransferases 
of H4K20 .................................................................................................................................... 76 
 5 
 
4.6.1 H4K20me2 and H4K20me3 were present during human, bull and mouse spermato-
genesis and were retained in mature human spermatozoa .......................................................... 77 
4.6.2 H4K20me3 was highly abundant in mature spermatozoa and was localized in L1 
elements   .................................................................................................................................. 78 
4.6.5 KMT5A and KMT5B were present in human spermatozoa, but not KMT5C .................. 79 
5. Limitations .................................................................................................................................. 81 
6. Summary..................................................................................................................................... 82 
7. Zusammenfassung ...................................................................................................................... 85 
8. References .................................................................................................................................. 88 
9. Supplementary Information ........................................................................................................ 99 
10. List of abbreviations ............................................................................................................... 114 
11. Acknowledgements ................................................................................................................ 116 
12. List of own publications ......................................................................................................... 117 
12.1 Publications & Articles ..................................................................................................... 117 
12.2 Conference abstracts, presentations and prices ................................................................ 117 
13. Declaration of honour ............................................................................................................. 119 
Introduction 
6 
 
1. Introduction  
According to the World Health Organisation (WHO), up to 15 % of couples worldwide are 
infertile.1 This means these couples are unable to achieve within one year a pregnancy on a natural 
way without prevention. The reasons for infertility can be detected in similar parts either on the 
male or female side (30 %, respectively). But also, reasons on both sides of a couple can accumulate 
to infertility (25 %). For the remaining 15 % of the couples no reason for their infertility can be 
found.2 This is referred to as unexplained or idiopathic infertility.  
1.1 Male infertility and possible treatments for couples 
Male infertility affects around 7 %3 of all men 
and is mainly induced by varicocele (17 %), 
hypogonadism (10 %) or urogenital infections 
(9 %).4 More causes of male infertility are 
illustrated in Figure 1. Very eye-catching is that 
for approximately one third of the cases the 
reason for male infertility remains unexplained 
(idiopathic) and is therefore challenging to treat. 
Associated reproductive technologies (ART), 
like intrauterine insemination (IUI), intracyto-
plasmic sperm injection (ICSI) or in vitro 
fertilization (IVF) can help couples to overcome their infertility. In the first case a prepared sperm 
sample from the male partner is transferred to the uterus of the female partner on the day of 
ovulation to enable pregnancy. The other two cases are mainly performed in an embryological 
laboratory, where an egg is either incubated with a prepared sperm sample (IVF) or directly 
fertilized with a single sperm (ICSI). Afterwards an embryo transfer (ET) of one or more embryos 
to the uterus of the hormone-pretreated woman is done to initiate pregnancy. Fertilization and life 
birth rates are not as high as desired and cause additional emotional stress on the couples besides 
the financial pressure of the costly ART treatments (2000-8000€).4 In Germany, ICSI is the most 
commonly used ART to treat severe male infertility (75 %)5 and its fertilization rates are between 
50 % and 80 %.6,7According to the German IVF Registry (DIR) live birth rates with IVF or ICSI 
are ranging from 30.4 to 31.3 % in young women (age 25-29 years) and decrease to 15.1-14.0 % 
in older women (age ≥ 40 years).8 So, there is a need to reveal and treat the infertility causes not 
Figure 1: Causes of male infertility.4 
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only on the male but also on the female side to increase baby-take-home-rates. Many studies 
indicate that aberrations in the sperm epigenome can lead to male infertility, due to lifestyles and 
environmental exposures and can also impair offspring health.9–11 
1.2 Spermatogenesis 
Male fertility is ensured by the production of mature spermatozoa and starts with spermatogenesis. 
Spermatogenesis is a well-structured and continuous process (Figure 2), which starts in the young 
male at puberty, on the surface of somatic Sertoli cells within the germ epithelium of the 
seminiferous tubules. Because of the steady proliferation and differentiation steps, germ cells occur 
as different cell groups and migrate from the basement membrane to the luminal area. During this 
time, the germ cells go through three characteristic developmental phases. At first, the mitotic 
proliferation, a spermatogonium type A divides into type B through mitosis, whereby one cell 
persists as stem cell. Then a spermatogonium type B differentiates through several mitoses into 
one primary spermatocyte and doubles during that time its DNA content (2n). At the second 
developmental phase, the first meiotic division of a primary spermatocyte yields two secondary 
spermatocytes and these multiplicate during the second meiotic division into four round spermatids 
(1n). At the third developmental phase, spermiogenesis, the differentiation of four round 
spermatids into elongated spermatids takes place, in which the nuclear chromatin is condensed, the 
acrosome is formed, and the flagellum is developed. Finally, maturing spermatozoa are released 
into the lumen and further transported to the epididymis, where they acquire motility and become 
fertile.12,13  
 
Figure 2: Spermatogenesis in human and epigenetic processes.9 
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The whole process of spermatogenesis in healthy men requires 64 days, with a new cycle starting 
every 16 days, plus a 2-week epididymal maturation period.9,14 During all this time epigenetic 
processes have to be strictly regulated to ensure the production of feature complete spermatozoa, 
which are able to inseminate an egg cell and provide full development capacity. Therefore, it is 
necessary for males to monitor their environmental health at least two months earlier before they 
want to father a child.15  
1.3 Components and modifiers of the sperm epigenome 
The epigenome represents the total 
amount of all heritable epigenetic ele-
ments that determine the targeted expres-
sion of a gene and thus the development 
of a cell without modifying its DNA se-
quence.15 Especially the components of 
the sperm epigenome (Figure 3), like the 
DNA methylation profile, non-coding 
RNAs and post-translational histone 
modifications (PHTMs) are highly vul-
nerable to alterations and must be pre-
cisely regulated to ensure male fertil-
ity.16,17  As mentioned above, aberrations 
in the sperm epigenome, due to lifestyle 
(e. g. smoking, alcohol consume, diet or 
overweight) and environmental expo-
sures, can harm offspring health and lead 
to male infertility.9–11 In a meta-regression analysis was shown, that in the last 40 years (1973-
2011) sperm concentration and total sperm count have declined over 50-60 % in human.18 This 
decline may be due, for instance, to the susceptibility of the sperm epigenome to modifiers such as 
parabens in cosmetic products19 or bisphenol A in drinking bottles20, which both negatively affect 
male fertility by lowering testosterone levels and sperm production. In order to examine and iden-
tify aberrations in the sperm epigenome, an understanding of the chromatin structure is essential.  
Figure 3: The components of the sperm epigenome.17
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In somatic cells, DNA is packaged in so called nucleosomes in which about 147 bp of DNA is 
wrapped around a histone octamer, consisting of four core histones, with two copies of each (H2A, 
H2B, H3, and H4). During spermiogenesis, these histones are replaced by the roughly ten times 
smaller protamines in order to not only shut down transcription and protect the paternal DNA 
against harmful substances, but also to condense the sperm head and simplify its motility.21  
1.3.1 DNA methylation: regulators and epigenetic reprogramming in human germ line 
The best analyzed epigenetic modification, also in sperm cells, is the DNA methylation. DNA 
methylation (Fig. 4) takes place by the addition of a methyl group of S-adenosyl-1-methionine 
(SAM) to carbon five of a cytosine residue (5mC) at cytosine-phosphate-guanine dinucleotides 
(CpGs).22 This process is mediated by DNA methyltransferases (DNMTs), namely DNMT1/2/ 
3A/3B or 3L, and can be established in two 
different manners. After cell division hemi-
methylated CpGs attract DNMT1, the mainte-
nance methyltransferase, which methylates 
the newly replicated DNA strand. In contrast, 
DNMT3A and DNMT3B, de novo methyl-
transferases, can methylate completely un-
methylated DNA on both strands during 
development.23 DNMT2 methylates RNA 
instead of DNA and DNMT3L, which has no 
catalytic activity itself, assists the de novo 
methyltransferases by increasing their 
binding affinity to SAM.23,24 DNA de-
methylation (Fig. 4) is initiated by Ten-
Eleven Translocation (TET) enzymes 1-3, which demethylate stepwise 5mC into 5-hydroxyl-
methyl- (5hmC), 5-formyl- (5fC), and 5-carboxylcytosine (5caC). Finally unmodified cytosines 
are regenerated by thymine-DNA glycosylase (TDG) and base excision repair (BER) 
mechanisms.11,25 DNMTs and TET proteins are shown to be expressed throughout human 
spermatogenesis, with stage specific levels. DNMTs are increasingly present in earlier stages of 
spermatogenesis, while TETs are more likely to be found in later stages.25,26  
Figure 4: Methylation (Me) and demethylation cycle of a 
cytosine residue mediated by DNMT/TET enzymes and 
repair mechanisms (TDG/BER). 
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The establishment and regulation of DNA methylation patterns is essential for a normal cell 
function and plays distinct roles in transcriptional gene regulation, genomic imprinting, X-
chromosome inactivation and embryonic development.27,28  
Global DNA methylation levels in the human germline change dynamically in two waves to ensure 
correct embryonic development (Figure 5). The first wave of DNA demethylation starts shortly 
after fertilization, where the male genome is rapidly and actively demethylated, to generate a toti-
potent zygote with full development capacity.27 Then the maternal genome is passively and slower 
demethylated. Meanwhile the first wave methylation levels of imprinted genes are conserved, as 
these marks will be given to the next generation.29 Reaching the stage of blastocyst implantation, 
DNA methylation patterns become re-established by de novo methyltransferases in a cell lineage-
specific manner.  
The second wave of demethylation occurs in primordial germ cells (PGCs), where also the 
methylation status of imprinted genes is erased. Afterwards sex-specific de novo methylation starts, 
where the sperm-specific imprints will be re-established in prespermatogonia before birth and the 
oocyte-specific methylome will be completed after birth.29,30 It is worth noting, that there are many 
time windows during epigenetic reprogramming, in which errors in establishing the correct 
germline-specific DNA methylation patterns can arise and affect the new generation later in 
life.11,27  
In general, DNA methylation patterns in male germ cells are much lower compared to somatic 
cells, but are similar to those of embryonic stem cells.11,28,31 DNA methylation in mature human 
sperm is a direct reflection of the spermatogonial stem cell landscape.32  
Figure 5: Epigenetic reprogramming of the global DNA methylation patterns in the human germ line.29 
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1.3.2 Post-translational Histone modifications (PTHMs) in spermatozoa 
In humans, the histone-to-protamine exchange occurs during the last step of spermatogenesis and 
affects reportedly 85 % to 97 % of the genome.33,34 Initially regarded as remnants of an incomplete 
replacement, the remaining histones and their PTHMs of the N-terminal tails, mostly methylation 
(me), acetylation (ac) or phosphorylation (ph), are now considered to have essential roles for gene 
activation and repression in embryogenesis and beyond.22,27 Many studies revealed that retained 
histones, where less condensed paternal DNA is more accessible for transcription, are not randomly 
distributed and mark genes and chromosomal regions (e. g. HOX/miRNA clusters, bivalent histone 
modifications [H3K4me3/K27me3] or imprinted loci), and are important for male fertility and 
proper embryo development.30,35,36 Additionally, post-translational modifications (PTMs) of 
human sperm proteins, like AKAP, CABYR and PA200,37–39 are shown to be fundamental for the 
regulation of cellular processes required for human spermatogenesis and sperm function, including 
sperm compaction and maturation.40,41  
In 2016 a comprehensive analysis of histone PTHMs in mouse, human male germ cells and human 
spermatozoa was performed using nanoliquid chromatography–tandem mass spectrometry (nano-
LC-MS/MS).42 In mouse, a total of 61 PTHMs and in human 103 PTHMs were found on the four 
core histone H2A, H2B, H3 and H4. A strong conservation of PTHMs on histone H3 (17/20) and 
H4 (10/12) could be observed in mouse and human germ cells, but not for the other two histones 
H2A and H2B. In Figure 6 the PTHMs found on histones H3 and H4 are displayed for mouse and 
human sperm cells.  
Figure 6: The post-translational histone modifications in mouse and human sperm cells displayed as a scheme.42
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Among the conserved PTHMs in human and mouse sperm cells H3K9me1/2/3, H3K27me1/2/3 
and H4K20me1/2/3 can be found.42 Mono- or dimethylation of lysine residues of peptides on 
histones residues are associated both with open and active chromatin regions, whereas 
trimethylation represents a hallmark of constitutive heterochromatin and often appears at silenced 
genes.43–45  
In human sperm cells, among H3, H3K9me3 (27.9 %) was found to be the most abundant PTHM 
on peptide amino acids (aa) 9-17 followed by H3K27me1/H3K36me2 on peptide aa 27-40. 
Regarding H4 aa 4-17, H4K16ac (22.5 %) was the most common PTHM, while the remaining 
residues were unmodified (40.3 %). Among H4 peptide aa 20-23, high proportion of H4K20me2 
(80.9 %), H4K20me3 (9.8 %) and H4K20me1 (7.9 %) were found.42 Interestingly, the gain in 
H4K20me3 level from round to elongated spermatids was the highest.42 
The methylation of H4K20 has been identified as key player of the genomic integrity, having 
crucial roles in DNA damage repair, DNA replication and chromatin compaction.46 In particular, 
H4K20me3 is a proven repressor of repetitive DNA elements and transposons in somatic cells.47,48 
Methylation of H4K20 is mediated by specific histone methyltransferases, namely SET8 (alias 
KMT5A), SUV4-20 H1 (alias KMT5B) and SUV4-20 H2 (alias KMT5C), which each  mono-, di- 
and trimethylate H4K20 in a cell cycle specific 
manner.46 The regulation of these histone methyl-
transferases and the resulting H4K20 methylation states 
are not fully unraveled. Figure 7 shows in a scheme the 
currently known enzymes that induce H4K20 
methylation in human. SET8 specifically mono-
methylates H4K20 and demethylation of H4K20me1 is 
performed by PHF8, which is also responsible for 
H3K9me1/me2 and H3K27me2 demethylation.49,50 H4K20me2 is generated by SUV4-20 H1, 
which can also produce H4K20me3.51 The main portion of H4K20me3 is generated by SUV4-20 
H2, whereas both SUV4-20 H1 and SUV4-20 H2 prefer H4K20me1 as substrate.46 The exact 
erasure mechanisms of H4K20me2 and H4K20me3 in mammals are still unknown. Histone lysine 
demethylases closely related to PHF8 (H4K20me1 demethylase), such as PHF2 and JMJD2A have 
been suggested to target H4K20me2 and H4K20me3. The demethylase activity of PHF2, produced 
in bacterial cell extracts, was investigated in an in vitro histone demethylation assay, but no 
catalytic activity was recorded for H4K20me3.52 
Figure 7: Methylation and demethylation cycle 
of H4K20 by its histone methyltransferases. 
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In a comparative molecular dynamics simulations study the molecular recognition of H4K20me2 
and H4K20me3 by JMJD2A was investigated.53 In this simulation JMJD2A binds with high 
affinity to both PTHMs (H4K20me2 > H4K20me3). In another study the crystal structure of human 
JMJD2A alone and in complex with H4K20me3 was resolved, but no change in the conformation 
of JMJD2A could be observed in both structures.54 Further research on the regulation of H4K20 
methylation is necessary to understand, why especially these PTHMs are highly enriched and 
conserved in mouse and human sperm cells. H4K20 methylation in human sperm has not yet been 
analysed and genome-wide localized. In order to demonstrate that heterochromatin must also be 
correctly labelled with epigenetic markers in human sperm, the methylation state of H4K20 was 
investigated in this thesis. 
1.4 Long interspersed nuclear element 1: LINE-1 (L1) 
The human genome consists of about 45 % transposable elements (TE) with repetitive character 
(Fig. 8).55 TEs can be subdivided into two subclasses based on their transposition mechanism.  
Class I TEs, the retrotransposons, like long and short interspersed nuclear elements (LINEs, SINEs 
[alias ALUs]) and retrotransposons containing long terminal repeats (LTRs), need an RNA inter-
mediate for their transposition mechanism (“copy and paste”). In contrast, class II TEs, the DNA 
transposons, need an DNA intermediate for their transposition mechanism (“cut and paste”).56,57  
LINE-1 elements (L1) are the only active class I transposons, which account for up to 17.0 % of 
the human genome with a copy number of nearly 500.000.57,58 These elements, derived from an 
ancient retrovirus, are the evolutionary youngest class of TEs that emerged about five million years 
ago, when chimpanzees diverged to humans.59,60  
Figure 8: Scheme of the human genome consisting of 55 % non-transposable and 45 % 
transposable elements. Class I TEs: L1, ALU (SINEs), LTR. Class II TEs: DNA transposons.55
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Most L1 elements are inactive through their truncation at the 5` or 3`-untranslated region (UTR) 
and were considered long time as “junk” DNA since they apparently had no important function. 
Various studies have shown that 80-100 full-length copies of these elements are still active in the 
human genome, playing crucial roles in cell differentiation and generation of alternative 
transcription start sites.57,61,62  
1.4.1 L1 structure and its retrotransposition cycle 
Human L1 elements are around 6 kb in full length and consist of a 5`UTR, two open reading frames 
(ORF1, ORF2) and a 3`UTR ending in a poly(A) tail (Figure 9, top). ORF1 encodes a 40 kDa RNA 
binding protein with nucleic acid chaperone activity and ORF2 encodes a 150 kDa protein with 
reverse transcriptase (RT) and endonuclease activities. The complete L1 retrotransposition cycle 
can be described in six steps (Fig. 9, bottom).  
 
In the first step L1 RNA is transcribed by RNA polymerase II from the internal L1 promoter located 
at its 5`UTR and is exported from the nucleus into the cytoplasm of the cell in the second step. 
Then in the third step L1 RNA is translated into two ORF proteins, namely ORF1p and ORF2p. 
Both proteins will form in the fourth step a ribonucleoprotein (RNP) complex with L1 RNA in cis 
Figure 9: General structure of a L1 element (top) plus its six-step retrotransposition cycle (bottom).56
 
Introduction 
15 
 
preference or trans complementation with other RNAs (like mRNA or class I/II TEs RNA) is 
possible. In the fifth step these RNP complexes are transferred back into the nucleus, where they 
can integrate themselves in their final sixth step at new genomic locations through target primed 
reverse transcription (TPRT) leading to mutations.56,63 
L1 retrotransposition is reported in the germ line, human embryonic stem cells (hESCs) and in 
somatic cells.64–66 There, L1 mutations can influence its activity positively and negatively.65 On 
the one hand, L1 element activity in the early mouse embryo ensures precise global chromatin 
accessibility and genomic stability, since the highest levels of L1 transcripts were found in the 2-
cell mouse embryo and these level were significantly lowered in the 8-cell stage.62 On the other 
hand, a prolonged or shorted L1 activity leads to delays in chromatin reorganization and thus to 
impairments in the further development of the early mouse embryo.62 In epithelial cancers (like 
prostate and ovarian) tumorigenesis is promoted by L1 insertions at cancer-specific DNA hypo-
methylation sites, while in breast and bladder cancers insertions of L1 at cancer-specific genes 
reduced tumorigenesis.63,67 Also, higher L1 transcript levels are reported in testicular germ cells in 
men suffering from hypospermatogenesis.68 Hence, it is necessary that L1 elements are strictly 
regulated so that harmful effects are prevented. 
1.4.2 Association of remaining sperm nucleosomes with repetitive elements 
Initial studies of sperm nucleosomes and histones, respectively, remaining in sperm chromatin after 
histone-to-protamine exchange revealed, that 
these are enriched at developmental promoters, 
miRNA genes and some imprinted loci.27,30,36 
Additionally, our group and others have shown 
that nucleosomes are also remaining in gene-
poor regions and, at the genome-wide scale, they 
are rather depleted from gene-rich regions. As 
shown in Figure 10 the nucleosome-rich regions 
include frequently repetitive DNA elements like 
L1 and SINEs, and are also characteristic for 
introns, few promoter regions (e.g. that of RNA 
processing genes) and, genes important for pre-
implantation development.34,69  
Figure 10: Nucleosome retention patterns in 
mammalian sperm chromatin.34
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Further examinations of retained nucleosomes and PTHMs in human sperm cells and their genomic 
localization, respectively, are needed to understand the association of L1s and sperm nucleosomes 
and to clarify the partially contradicting observations reported in different papers. Moreover, 
epigenetic mechanisms regulating L1 in sperm and spermatogenesis are not well studied yet and 
need to be investigated further. Hence, in the present thesis, the epigenetic tagging of L1 and L1 
regulators, well known from studies on somatic cells, were analyzed. 
1.4.2.1 CpG methylation 
DNA hypermethylation of a gene promoter is associated with its suppression, as it inhibits the 
transcription machinery from binding to the promoter region (Fig. 11).70 In many cancer types, 
such as breast, brain and prostate, DNA hypermethyl-
ation in promoter regions of e.g. tumor suppressor 
genes is a frequently observed feature. For instance, 
hypermethylation of GHSR (growth hormone secret-
agogue receptor) can be used as an epigenetic marker 
in human to distinguish cancer (e.g. breast, lung, pros-
tate) from non-cancer samples.71 In contrast, DNA 
hypomethylation of a gene promoter is linked to gene activation, as the chromatin is more open to 
the transcriptional machinery.24,27 Loss of DNMT proteins leads to a strong demethylation of the 
whole genome and to severe implications. For example, knockout of Dnmt1 as well as DNMT3A/3B 
in mice induced aberrant paternal imprinting during spermatogenesis and embryonic lethality.28,72 
In human ejaculated spermatozoa high mRNA levels of DNMT1 and DNMT3A are reported but not 
of DNMT3B.26  
As already mentioned, L1 comprises about one fifth of the human genome and is proven to serve 
as surrogate measure for the global DNA methylation level due to this high number.73 DNA hyper-
methylation of L1 promoters is an epigenetic suppression mechanism of L1 retrotransposition that 
can often be observed in normal somatic tissues.74 Particularly DNA hypomethylation of L1 pro-
moters along with its increased expression are hallmarks in various cancer types and is linked to a 
number of diseases such as hemophilia A, schizophrenia and bipolar disorder.74–76 Aberrations in 
global DNA methylation and imprinting genes are associated with poor sperm quality and male 
infertility.31,77,78 For the causal diagnosis of idiopathic male infertility, the global DNA methylation 
state (5-mC, L1) and DNA methyltransferase activities (DNMT1, DNMT3A) were determined here. 
Figure 11: DNA hypermethylation of a gene 
promoter leads to its suppression. 
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1.4.2.2 Post-translational Histone modifications (PTHMs) as L1 regulators 
As noted, in human sperm cells the highest conservation of PTHMs was detected on H3 (31 
PTHMs) and H4 (14 PTHMs), using mass spectrometry.42 Moreover, on histone H4 peptide aa 20-
23 the most abundant PTHMs were H4K20me2 (80.9 %) and H4K20me3 (9.8 %).42 H4K20me2 
plays distinct roles for DNA replication, by marking places of origin for the Orc (origin of replica-
tion) complex and DNA double-strand break repair, by recruiting repair enzymes like 53BPI to 
damage sites.46,79   
H4K20me3 is described as heterochromatin marker, repressor of transcription when present at pro-
moters and silencer of repetitive DNA elements in somatic cells.47,48,80 In a study on human colo-
rectal cancer (CRC), reduced H4K20me3 levels were found in CRC patients compared to healthy 
controls, whereby H4K20me3 was localized in both cohorts at repetitive DNA elements like L1 
and SINE elements. In the same study, another heterochromatin marker, H3K9me3, was also         
localized at repetitive DNA elements, but in smaller amounts (60.6 %) compared to H4K20me3 
(74.8 %).81 It is postulated, that retrotransposons have regulatory functions for their host genome, 
by acting as a template for the transcription factor binding repertoire.82 Moreover, it is possible that 
retained histones in spermatozoa are transferred to the egg cell and participate in the establishment 
of gene expression in the early embryo, as highest L1 activity is reported in the 2-cell mouse em-
bryo and decreases with its further development.62,83 The knockdown of histone methyltransferases 
KMT5B and KMT5C led to a reduction of H4K20me3 and in particular to an upregulation of L1 
elements, which induced the death of mouse embryos at morula stage.84,85  
In regard of the high numbers of idiopathic infertile males, H4K20me2 and H4K20me3 and their 
histone methyltransferases (KMT5A, KMT5B and KMT5C) were investigated here in human 
sperm cells, to see if these factors were also associated with L1 regulation and have the potential 
to affect male fertility.  
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1.4.2.3 Transcription factors (TFs) of L1 
Transcription factors are proteins which bind alone or together with others to a specific DNA 
sequence in the promoter region of a gene and can either promote or inhibit its transcription. Gene 
promoters are typically located near the transcription start site (TSS) upstream of a gene (5`UTR). 
The 5`UTR is an essential component for the retrotransposition cycle of a L1 element. However, 
the 3`UTR, which contains a polypurine tract, is not critical for L1 retrotransposition.86,87        
Human L1 elements contain in their 5`UTR multiple promoter binding sites for transcription 
factors such as YY1, RUN3 and SOX (Fig. 12).86  
 
Figure 12: General structure of a L1 element, including transcription factor binding sites (YY1, RUN2, SOX).     
RT= reverse transcriptase. 
YY1 (Yin Yang 1) is a transcription factor binding on the antisense strand of the L1 5`UTR between 
position +13 and +21. Mutations in the YY1 binding site show weak effects on L1 retrotrans-
position, but this site is required for the precise initiation of L1 retrotransposition in cultured human 
cells.60,88 L1 elements lacking a YY1 binding site are predicted to shorten over time until they are 
incapable of retrotransposition.86 
The transcription factor RUN3 (runt-domain transcription factor 3) has three binding sites, one 
antisense (+526 to +508) and two in sense strand direction (+83 to +101 and +389 to +407), on 
human L1 5`UTR. SOX (SRY-related HMG box containing) has two binding sites on the sense 
strand on human L1 5`UTR (+472 to +477; +572 to +577).  Both SOX binding sites and only one 
RUN3 binding site (+83 and +101) induce in vitro L1 retrotransposition in cultured cells. On the 
one hand, mutations in these binding sites diminish L1 retrotransposition events. On the other hand, 
overexpression of RUN3 or SOX led to a nearly tenfold increase of L1 retrotransposition activity 
in human cervical carcinoma (HeLa) or human embryonic kidney cells (HEK), respectively.60,86,88  
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Recently SIRT6 (sirtuin 6), a histone methyltransferase and heterochromatin regulator, was 
discovered as a L1 suppressor in human dermal fibroblasts (HDF).89 SIRT6 binds to the 5`UTR of 
L1 elements and ribosylates the nuclear corepressor protein KAP1, which is then able to interact 
with the heterochromatin factor HP1α and packages L1 into transcriptionally inactive 
heterochromatin (Fig. 13).89  During aging and oxidative stress, SIRT6 disappears from L1 5`UTRs 
and relocalizes at DNA damage sites such as DNA double strand breaks, whereby L1 5`UTRs are 
loosened and L1 retrotransposition is reactivated.89  
 
 
 
 
 
 
 
 
 
 
Sirtuins are proven lifespan regulators in different organisms, such as yeast, nematodes and 
fruitflies through deacetylation of critical transcription factors.90,91 Premature aging and a shortened 
lifespan are observed in Sirt6 knockout mice, while overexpression of Sirt6 led to an extended 
lifespan exclusively in male mice.90 Moreover, SIRT6 gene promoter methylation increases with 
age in human lymphocytes, but no significant correlation to gender or longevity was observed in 
that study.91 According to the human protein atlas SIRT6 protein is highly expressed in human 
testis tissue, which allows the hypothesis that SIRT6 is also responsible for L1 regulation there.92 
Figure 13: Model of L1 suppression by SIRT6. In young cells SIRT6 is 
able to keep L1 elements in their silent state, but this capability decreases 
with increasing age.89
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A genome-wide screen in 2018 revealed more L1 regulators in two human cell lines, namely human 
chronic myeloid leukemia K562 and human embryonic stem cells (hESC).93 MORC2 
(microrchidia 2) and human silencing hub (HUSH) complex subunits MPP8 (M-Phase 
Phosphoprotein 8) and TASOR (Transgene Activation Suppressor Protein) are able to bind and 
repress young full-length L1 elements in euchromatic environment (Fig. 14). In neuronal cells, 
MORC2 and HUSH-complex interactions were demonstrated and in addition, the bundled 
localization of these components at H3K9me3 promotes the formation of heterochromatin and L1 
suppression.93,94 In mouse germ cells Morc1 is repressing retrotransposons and its knockout leads 
to loss of germ cells and infertility in males.95  
 
 
In this thesis, some L1 transcription factors known from somatic cells (YY1, SIRT6 and MORC2) 
were analyzed in human spermatozoa and testicular tissues, to uncover L1 regulatory mechanisms 
and to properly address possible causes and treatment options for the factor male idiopathic 
infertility.  
  
Figure 14: Model of L1 suppression by HUSH/MORC2 
complex. HUSH/MORC2 bind to young full-length L1s, 
promote H3K9me3 deposition and thus inhibit L1     
retrotransposition.93
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1.5 Aims of this work 
It is likely that epigenetic aberrations in sperm are responsible for idiopathic forms of male factor 
infertility and/or reflect this situation. Available studies focused mostly on aberrations of the 
methylome and some PTHMs characteristic for gene regions.  
The working hypothesis of this thesis was, that aberrations in sperm epigenome, specifically those 
leading to dysregulation of retrotransposons, are associated with idiopathic male infertility. L1 
dysregulation during human spermatogenesis and its incorrect epigenetic tagging in mature 
spermatozoa could lead to errors in pre-implantation development and thus contribute to the 
triggering of sub- and infertility in men. 
Epigenetic regulation of L1 in spermatogenesis and in mature sperm is largely unknown. In order 
to first identify and then investigate different factors of the sperm epigenome potentially controlling 
L1 regulation, the following components were analyzed in both motile and immotile spermatozoa 
of healthy males (donors/controls) and in motile spermatozoa of idiopathic infertile males 
(subfertile patients) used for ART. Also, human, mouse and bull testis tissues were utilized in order 
to get information about the expression pattern of some selected factors: 
➢ Analyzes of L1-mRNA and L1-methylation levels in mature motile versus immotile 
spermatozoa, to find out whether L1 is differentially regulated, using RT-qPCR, ELISA based 
assays and pyrosequencing;  
➢ Determination of global 5mC, 5hmC DNA and m6A RNA methylation and DNMT1/3A mRNA 
levels in mature human spermatozoa by ELISA and RT-qPCR, to see if differences exist 
between the cohorts; 
➢ Investigation of potential L1 regulating PTHMs, like H4K20me2 and H4K20me3, and HMTs, 
like KMT5A, KMT5B and KMT5C, in mammalian testis tissues and mature human 
spermatozoa, to analyze their abundance and regulation, utilizing immunohistochemistry 
(IHC), immunocytochemistry (ICC), RT-qPCR and western blot (WB); 
➢ Analyzes of L1 transcription factors known from somatic cells, YY1, MORC2 and SIRT6, to 
unravel L1 regulations in mature human spermatozoa and testis tissue, using IHC, RT-qPCR 
and pyrosequencing. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
AppliChem, Darmstadt     NaAc solution 3 mol/l (3 M, pH 5.2) 
Biorad, München     Acrylamide solution (30 %); APS;  
Biozym Scientific, Oldendorf   Agarose 
Merck, Darmstadt  Citric acid; Orange G; PFA; Tri-sodium citrate 
PeqLab, Erlangen     PeqGold TriFast 
Roth, Karlsruhe  Acetic acid; chloroform; DTT; Glycine; 
Glycogen; HCl; Milk dry, non-fat; NaCl; 
NaOH; SDS; Phenol/Chloroform/Isoamyl-
alcohol; Proteinase K; Roti®-Phenol; 
TEMED; Tris; Triton X-100 
Sigma-Aldrich, Steinheim  BSA; DEPC; EDTA; EtOH; H2O2; Isopropa-
nol; Lithium 3,5-diiodosalicylate; MeOH; β-
mercaptoethanol; PMSF; PBS; Protease         
inhibitor cocktail Tablets (S8820)   
VWR, Darmstadt  Xylol   
2.1.2 Reagents, buffers and kits 
2.1.2.1 DNA, RNA and protein extraction 
Thermo Scientific, Darmstadt   DNase I (50-375 U/µL, 20000 U), DNase I 10x 
buffer  
Somatic cell lysis buffer     0.1 % SDS, 0.5 % Triton X-100 in DEPC-H2O  
Proteinase K buffer  50 mM Tris-HCl pH 8.0, 50 mM EDTA, 0.5 % 
NP-40, 0.5 % SDS 
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2.1.2.2 CpG methylation and mRNA analysis 
2 % agarose gel      2 g Agarose in 100 mL 1 x TAE 
10x TAE buffer (pH 8.0)   2.5 mM Tris, 17.4 M acetic acid, 11 mM 
EDTA ad 1 L ddH2O 
Active Motif, La Hulpe, BG  Global DNA Methylation - L1 Kit (Cat. No. 
55017) 
Bioline, Luckenwalde  2x My Taq HS Mix 
Biotium, Fremont      GelRed Nucleic acid gel stain  
GE Healthcare, Freiburg    Streptavidin sepharose high performance 
Gentaur   MethylFlashTM Global DNA Methylation & 
Hydroxymethylation ELISA Easy Kit (Cat. 
No. P-1030/1032), EpiQuik RNA Methyla-
tion Quantification Kit (Cat. No. P-9005)  
Promega, Mannheim Recombinant RNasin® Ribonuclease Inhibitor 
(40 U/µL); dNTP mix (dATP/dCTP/cGTP/ 
dTTP), 10 mM 
Qiagen, Hilden  PyroMark binding / denaturation / annealing / 
wash buffers; PyroMark Gold Q24 reagents; 
Rotor-Gene SYBR Green PCR Master mix; 
L1/SIRT6 pyrosequencing kits (Cat. No. 
970012/978746) 
Thermo Scientific, Darmstadt  GeneRuler DNA Ladder Mix, RiboLock 
RNase Inhibitor (40 U/µL) 
Zymo Research, Freiburg    EZ DNA Methylation Kit 
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2.1.2.3 Immunohistochemistry 
10x Tris-HCl Puffer, pH 7.4  1 M Tris-HCl, 1 M NaCl ad 1 L ddH2O 
1x Tris-HCl-Puffer  1/10 volume 10 x Tris-HCl, 0.1 % Triton in 
ddH2O 
Citrate buffer, pH 6.0   18 mM citric acid monohydrate, 82 mM so-
dium citrate in ddH2O 
3 % H2O2 / Methanol      63 mL ice cold MeOH, 7 mL 30 % H2O2  
5 % BSA       3.5 g BSA in 70 mL 1x Tris-HCl buffer  
Dako, Glostrup, DK  AEC+ high sensitivity substrate chromogen, 
Faramount Mounting Medium 
Merck, Darmstadt  Mayer`s Haemalaun 
Waldeck GmbH und Co. KG, Münster  Haemalaun, acidic 
Vector, Peterborough, UK    Vectastain Elite ABC-Peroxidase Staining Kit 
2.1.2.4 Western blot 
10 % APS       50 mg APS in 500 μL ddH2O  
10 x SDS running buffer, pH 8.3   25 mM Tris, 192 mM glycine, 0.1 % SDS in 
ddH2O  
1 x PBS, pH 7.4      5 PBS Tablets in 1 L ddH2O  
1x PBST, pH 7.4      1 x PBS, 0.1 % Tween 20 in ddH2O 
BioRad, München  Laemmli buffer (4x); Extra Thick Blot Filter 
Paper, Precut, 7 x 8.4 cm  
Coomassie destaining solution   40 % MeOH, 10 % acetic acid in ddH2O 
Coomassie staining solution  0.1 % Coomassie Brilliant blue R250, 50 % 
MeOH, 10 % acetic acid in ddH2O  
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Laemmli loading buffer, 1 mL  900 μL Laemmli buffer, 100 μL β-Mercap-
toethanol  
LI-COR Biosciences, Bad Homburg  Odyssey Blocking Buffer TBS/PBS (1:3 in 
1xPBS, REVERT™ Total Protein Stain Kit 
Merck, Darmstadt  Immobilon-FL PVDF, 0.45 µm, 26,5 cm x 
3,75 m roll 
RIPA buffer 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 % 
Triton X-100, 0.1 % SDS, 0.5 % sodium deox-
ycholate, 1 mM PMSF, 1 mM EDTA, 4 mM 
sodium fluoride, 1 mM DTT, 1x Protease In-
hibitor Cocktail (1 Tablet/ 100 mL) 
Running gel buffer; pH, 8.8     1.5 M Tris in ddH2O 
Stacking gel buffer; pH 6.8     1.5 M Tris in ddH2O  
Transfer buffer, pH 8.0-8.5   48 mM Tris, 38 mM glycine, 20 % MeOH, 
0.0375 % SDS in ddH2O 
Tris-Urea buffer  8 M Urea, 2 % SDS, 50 mM Tris (pH 8.0), 
105 mM NaCl, 1 mM PMSF, 10 mM DTT, 1x 
Protease Inhibitor Cocktail (1 Tablet/ 100 mL) 
SERVA Electrophoresis, Heidelberg  Coomassie Brilliant blue, R250  
Thermo Scientific, Darmstadt  Page RulerTM prestained protein ladder 10-
180 kDa 
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2.1.3 Antibodies 
Abcam, Cambridge  Rabbit polyclonal primary antibodies: 
H4K20me3 (ab9053), 1:100 IHC/ICC, 1:500 
WB; H4K20me2 (ab9052), 1:100 IHC/ICC, 
1:500 WB; YY1 (ab109237), 1:200 IHC; 
SIRT6 (ab62739/ab176345), 1:2000/ 1:500 
WB, KMT5C (ab91224), 1:50 WB; GAPDH 
(ab9485), 1:2500 WB  
Dako, Glostrup, DK  Goat anti rabbit IgG biotynilated (E0432), 
1:200 IHC 
LI-COR Biosciences, Bad Homburg  IRDye® 800CW Goat anti-Rabbit IgG (H + 
L), 1:10000 WB; IRDye® 680LT Goat anti-
Rabbit IgG (H + L), 1:10000 WB 
2.1.4 Equipments 
Biometra, Göttingen     Gel documentation system, BioDocAnalyze 
Bioblock Scientific     Vibracell 75022, ultrasonic processor, 130 W 
Bio-Rad, München  Mini-PROTEAN Tetra Cell; Power PAC 200 
+ 300; Thermocycler T100 + C1000 Touch; 
Trans-Blot SD Semi-dry transfer cell 
BOSCH, Stuttgart      Fridge; Freezer Economic GSL 1202 + 3601 
BRAUN, Schwalbach am Taunus   Gourmet cooker 
Eppendorf, Germany     Thermo Mixer; Mastercycler; Pipettes; tubes 
Fisherbrand, Schwerte    Mini centrifuge 
Helmut Hund GmbH, Wetzlar    Microscope H 600 LL 
Heidolph, Schwabach    Shaker Reax 2000; Vortex mixer REAX 2000 
Heraeus, Hanau     Incubator Kelvitron T 
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Hettich, Frankenberg     Centrifuge (MIKRO 220R) 
IKA, Staufen  Shaker VIBRAX-VXR; Magnetic Stirrer 
(BLSH0007) 
LI-COR Biosciences, Bad Homburg   LI-COR Odyssey Fc 
LG, Ratingen      Microwave Untellowave 
Merck, Darmstadt      MilliQ direct water purification system 
Mettler Toledo, Giessen   Fine balance Mettler AE 240; pH meter 
(S20K) 
Nerbe plus, Winsen + Biozym, Oldendorf  Pipette tips 
Olympus, Tokio, JPN     Microscope BX43 
PeqLab, Erlangen  Gel chamber; NanoDrop ND-1000  
Qiagen, Hilden  Stainless steel beads (ball), 5 mm; Pyromark  
Q24 system and supplies; Rotor Gene Q PCR  
cycler; TissueLyzer LT 
R. Langenbrinck GmbH, Emmendingen  Cover plates; Glass plates superfrost  
Roth, Karlsruhe     Neubauer-improved counting chamber 
Störktronic, Stuttgart     Heating plate Präzitherm 28-1 
Thermo Scientific, Darmstadt  Centrifuge (Heraeus Fresco 21); HERA-
freeze™ HFU T Series -86°C Freezer; Invitro-
gen Power Ease® 500 Power Supply; Multi-
scan Go Photometer; Tube Revolver 
VLM, Bielefeld     Heating block LS 2 
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2.2 Methods 
2.2.1 Collection and preparation of human semen samples 
From the Division of Gynecological Endocrinology and Reproductive Medicine, Department of 
Gynecology and Obstetrics, Clinical Centre of the Ludwig-Maximilians-University Munich motile 
sperm samples of 48 subfertile men (patients) were obtained, who underwent an ART (assisted 
reproductive technology), like ICSI (intracytoplasmic sperm injection) or IVF (in vitro 
fertilization). In this study the term “subfertile men” is used to describe the condition, when a 
couple was unable to conceive a child naturally within one year without contraception. The use of 
an ART could improve the pregnancy rates of these couples.  
Semen samples from 112 healthy volunteers (donors) were collected at the Department of Urology, 
Pediatric Urology and Andrology of the Justus-Liebig-University Giessen. In sum 15 donors with 
asthenozoospermia (< 32 % mot. spermatozoa, n=10) and/or oligozoospermia (< 15 Mio/mL sperm 
cells, n=7) were excluded from this study. Every participant was informed and gave a written 
consent to this study, which was approved by the Ethics Commission of the Medical Faculty of the 
Justus-Liebig-University of Giessen (approval from 15.12.10 in the frame of the Clinical Research 
Unit KFO181/Period 2 ‘Mechanisms of male factor infertility’, confirmed on 17.12.14)  and is 
funded by a DFG grant to Schagdarsurengin U. (SCHA 1531/2-1). 
All semen samples were collected and analyzed according to the WHO guidelines of 2010. Freshly 
ejaculated semen samples from donors were obtained by masturbation after at least 3 days of sexual 
abstinence and collected into sterile containers. After liquidation at 37 °C for 15-30 min, semen 
samples were separated into motile and immotile sperm cell fractions, using the swim-up 
technique, for further individual analysis. Briefly, liquefied semen was placed on the bottom of a 
round tube containing 1.2 mL sperm wash medium (HTF-Medium/2 % HSA) and put at an 45° 
angle for 60 min at 37 °C. During this incubation motile (M) sperm cells “swim-up” into the wash 
medium, which can be aspirated afterwards, whereas immotile (I) sperm cells stay at the bottom of 
the tube. Sperm concentration and motility were determined for both fractions. Then sperm samples 
were centrifuged at 500 g for 10 min at 4 °C and washed twice with PBS. Afterwards sperm 
samples were frozen in liquid nitrogen and stored at -80 °C until further processing. Spermiogram 
parameters and ages of collected donors and patients, including the ages of the female partners of 
the patients, are summarized in Table 1. Further patient and donor data can be found in the 
supplement (Tables 16-21). 
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Table 1: Spermiogram parameters (median, range; p-values calculated by Mann-Whitney U-test: *p ≤ 0.05,          
**p ≤ 0.01) and ages of collected donors and patients, including female ICSI/IVF-partners. 
Spermiogram parameter Donors Patients 
Number 97 48 
Age (years) 29.0 (20.0-49.0) 39.0** (29.0-50.0) 
Partner Age (years) - 35.3 (27.0-44.0) 
Sperm concentration (Mio/mL) 63.6 (15.4-282) 17.7** (1.00-155) 
Total sperm count (Mio) 194 (30.8-930) 128** (5.12-491) 
Vitality (%) 86.0 (54.0-95.0) - 
Progressive motility (%) 61.0 (33.0-85.0) 39.5** (9.00-62.0) 
Total motility (%) 70.0 (42.0-89.0) 61.0** (25.0-83.0) 
 
2.2.2 Human cancer cell line cultures 
Cervix carcinoma cell line HeLa and prostate cancer cell lines (LNCaP, DU145 and PC3) were 
used as positive controls to test PCR primers and antibodies for investigations in human sperms. 
These cell lines were cultured in an appropriate culture media (Dulbecco’s modified Eagle’s 
medium and cell culture medium developed at the Roswell Park Memorial Institute supplemented 
with 10 % fetal calf serum and 1 % penicillin/streptomycin, Life Technologies GmbH)96 at 90 % 
confluency, 5 % CO2 and 37 °C.  Cell lines were washed twice with PBS and finally scraped in 
PBS. After centrifugation (5 min, 1500 g at 4 °C) the supernatants were removed and the cell 
pellets were either resolved in PBS buffer (for DNA/RNA extraction, see 2.2.3) or in RIPA buffer 
(for protein extraction). HeLa protein pellets, resuspended in 300 µL RIPA buffer supplemented 
with protease inhibitor cocktail, were left on ice for 30 min with vortexing each 5 min. Sonication 
was performed with ultrasonic processor Vibra Cell for three cycles, each 10 s (Amplitude 30 %, 
max. pulse), until pellets were completely solubilized. After centrifugation (5 min, 13000 rpm, 
4 °C) protein extracts were taken into a new tube, concentrations were determined (NanoDrop) and 
kept frozen at -80 °C. 
2.2.3 DNA & RNA extraction 
Motile and immotile sperm cell fractions, separated after swim-up procedure, were thawed on ice, 
4 Mio sperm cells were taken out and washed twice with PBS (in DEPC-H2O). Instantly motile 
sperm cells were equally divided for further DNA and RNA extraction. Immotile sperm cells were 
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treated for 15 min on ice with 250 µL somatic cell lysis buffer (0.1 % SDS, 0.5 % Triton X-100 in 
DEPC-H2O) prior division, to ensure the analysis of a pure spermatozoa population.
97,98  
RNA was isolated with the Trifast reagent, then separated from the DNA with chloroform and 
precipitated with alcohol. Initially semen samples were resuspended in 150 µL Trifast and lysed 
on TissueLyser LT for 5 min at 4 °C and 50 osc/sec. Foams were removed by short centrifugation 
(30 s, 13000 rpm, 4 °C), 350 µL Trifast (total 500 µL Trifast) and subsequently 100 µL chloroform 
were added and mixed thoroughly per Hand. After incubation for 5 min at RT samples were 
centrifuged at 4 °C and 13000 rpm for 10 min. The upper aqueous phase containing RNA was put 
into a new tube and precipitated overnight at -20 °C by addition of one volume isopropanol 
(500 µL) and 5 µL glycogen (20 mg/mL). Afterwards RNA was pelletized at 13000 rpm and 4 °C 
for 30 min, washed twice with 500 µL Ethanol (75 % in DEPC-H2O) and air-dried at RT. To 
exclude DNA contamination in following RT-qPCRs, RNA was subsequently DNase I digested. 
Therefore, RNA was dissolved in 16 µL DEPC-H2O, 2 µL of DNase I and 2 µL of DNase I 10x-
buffer were added and the mixture was incubated for 30 min at 37 °C. DNase I heat inactivation 
occurred at 65 °C for 10 min after 2 µL EDTA (50 mM) were added. RNA concentration was 
measured (NanoDrop) and samples were stored at -80 °C. 
DNA isolation started with Proteinase K digestion, followed by phenol/chloroform extraction and 
alcohol precipitation. Therefore, a semen sample was resuspended in 120 µL Proteinase K buffer, 
80 µL DTT (0.1 M) and lysed on TissueLyser LT for 5 min at 4 °C and 50 osc/sec. After short 
centrifugation (30 s, 13000 rpm, 4 °C) foams were removed and overnight protein digestion at 
56 °C was initiated by the addition of 10 µL Proteinase K (20 mg/mL in PBS). Next the aqueous 
phase was increased with 300 μL of Tris buffer (10 mM, pH 8.0) to facilitate handling. 500 µL of 
phenol/chloroform solution were added, well mixed per hand shaking and centrifuged for 10 min 
at 13000 rpm at RT. The DNA containing upper aqueous phase was supplemented with 500 µL 
chloroform, well mixed per hand shaking and centrifuged again for 10 min at 13000 rpm at RT. 
DNA was precipitated overnight at -20 °C through the addition of one volume isopropanol, 1/10 
volume NaAc solution (3 M, pH 5.2) and 5 µL glycogen (20 mg/mL) to the aqueous phase. 
Centrifugation at 13.000 rpm and 4 °C for 30 min pelletized DNA, which was washed twice with 
500 µL Ethanol (75 % in ddH2O) and air-dried at RT. DNA was resuspended in 30 µL Tris EDTA 
buffer (10 mM, pH 8.0), concentration was measured (NanoDrop) and samples were stored at             
-80 °C. 
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2.2.4 CpG methylation analysis 
For L1 methylation analysis DNA was either bisulfite treated prior pyrosequencing or directly used 
for ELISA. SIRT6 methylation was analyzed using pyrosequencing, and global 5-mC/5-hmC DNA 
and m6A RNA methylation levels were determined using ELISA. 
2.2.4.1 Bisulfite treatment and pyrosequencing 
Bisulfite treatment was done using the EZ DNA Methylation Kit (Zymo Research) according to 
the manufacturer`s protocol. 500 ng DNA were treated overnight at 50 °C with 100 µL CT 
Conversion reagent (reconstituted in 750 µL ddH2O and 210 µL M-Dilution Buffer). Then samples 
were cooled for 10 min on ice, mixed with 400 µL M-Binding-Buffer and transferred on a Zymo-
SpinTM IC Column. After centrifugation at 13000 rpm for 1 min, the flow-through was loaded onto 
the column a second time to increase DNA binding and centrifuged again. The column was washed 
with 100 µL M-Wash Buffer and treated with 200 µL M-Desulphonation Buffer at RT for 30 min 
to remove incomplete converted cytosines. Subsequent centrifugation at 13000 rpm for 1 min and 
washing with 200 µL M-Wash-Buffer (twice) was done. Bisulfite converted DNA was eluted in 
15 µL Tris buffer, concentration was measured (NanoDrop) and samples were stored at -80 °C.  
10-20 ng BS-DNA were used per pyrosequencing reaction. Pyrosequencing uses a real-time and 
sequence-based working method to quantify methylation level of CpGs from a gene region of 
interest using the pyrosequencing instrument and PyroMark Q24 Software. According to the 
manufacturer`s protocol, a PCR amplification of the desired gene region with the provided forward 
and reverse PCR primers of a PyroMark Q24 Kit (Qiagen, Table 2) was done. Then, PCR products 
were immobilized to streptavidin sepharose beads (GE Healthcare) and incubated in denaturation 
buffer to get single-stranded DNA, to which the provided sequencing primer anneals. Through 
sequencing by synthesis, a light emission proportional to the amount of the correctly incorporated 
nucleotide is measured. Light signals are displayed as peaks in a pyrogram and the methylation of 
the examined CpGs is indicated in percent. Bisulfite treated prostate cancer cell line DNA (LNCaP) 
was used as positive methylation control during pyrosequencing. 
Table 2: Pyrosequencing Kits used from Qiagen, including general information. 
Gene Cat. no. Sequence to analyze PCR product size (bp) Number of CpGs 
L1 970012 GCTCGTGTAGTCAGTCG 145 3 
SIRT6 978746 
AACATGTCGCCTGCGGCGT 
CAGCAAGAGGCGCATGCGC 
205 5 
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2.2.4.2 ELISA 
L1 methylation was also investigated using the Global DNA Methylation Assay-L1 Kit (ELISA, 
12 CpGs, Active Motif, Cat. No. 55017) according to the product manual instructions. Shortly, 
800 ng DNA were MseI digested, hybridized to the provided L1 probe and immobilized onto a 
streptavidin-coated plate. Methylated fragments were detected using a 5-Methylcytosine primary 
and a horseradish peroxidase secondary antibody. Global methylation was quantified by OD 
measurements at 450 nm and the generation of a DNA standard curve fit, by the methylated and 
non-methylated DNA standards provided.  
The DNA 5-mC/5-hmC levels were analyzed using the MethylFlashTM Global DNA Methylation/ 
Hydroxymethylation ELISA Easy Kits (Cat. No. P-1030/1032, Gentaur) and the m6A RNA 
methylation level was analyzed using the EpiQuik RNA Methylation Quantification Kit (Cat. No. 
P-9005, Gentaur) according to the product manuals instructions. Briefly, 100 ng DNA/RNA were 
bound to an assay plate and incubated with the respective primary antibody solution. A color 
developer solution was then added to measure the absorbance of 5-mC/5-hmC DNA and m6A 
RNA at an OD of 450 nm. The global DNA and RNA methylation levels were quantified by 
generating a standard curve fit using the methylated and non-methylated standards provided. 
2.2.5 RT-qPCR analysis  
Synthesis of cDNA was performed using DNase I digested RNA of human sperm and M-MLV 
reverse transcriptase (Promega) according to the manufacturer`s protocol with minor deviations or 
LunaScript RT SuperMix Kit. In the first case 300 ng of RNA were incubated with 200 units of the 
M-MLV reverse transcriptase with the provided 5x M-MLV reaction buffer. Additionally, 2 µL 
dNTP mix (10 mM, Promega), 2 µL random Hexamere (10 mM), 2 µL Poly dT primer mix 
(10 mM) and 20 units of RNase Inhibitor (0.5 µL of 40 U/µL) were added with DEPC-H2O to a 
final volume of 20 µL. For reverse transcription this mixture was incubated for 10 min/25 °C, 
60 min/42 °C and 5 min/ 85 °C. The resulting cDNAs were purified with the QIAquick Nucleotide 
Removal Kit (Qiagen) and stored at -80 °C until PCR analysis. In the other case 300 ng RNA were 
reverse transcribed with the ready-to-use LunaScript RT SuperMix, containing random hexamer 
and oligo-dT primers, dNTPs, Murine RNase Inhibitor, and Luna Reverse Transcriptase. 4 µL of 
LunaScript RT SuperMix (5x) were added to 300 ng RNA and the final volume was adjusted with 
DEPC-H2O to 20 µL. Reverse transcription was performed at 25 °C/2 min, 55 °C/10 min and 
95 °C/1 min. The resulting cDNAs synthesized with this kit needed no further purification steps 
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and were directly stored at -80 °C until PCR analysis. Specific qPCR primer sets were either 
designed with the Primer 3 online tool (v. 0.4.0) or taken from literature to analyze DNMT1, 
DNMT3A, L1, KMT5A/B/C, SIRT6, MORC2, GAPDH and ß-Actin (Table 3) mRNA levels in 
samples. Amplification of cDNA (~15 ng/reaction) was performed for 45 cycles (initial 
denaturation 95 °C/5 min, cycling: 95 °C/30 s, 60 °C/30 s, 72 °C/30 s, final elongation 72 °C/ 
3 min) on the CFX96 Touch Real-Time PCR Detection System (Biorad). All PCR reactions were 
performed in duplicates and relative values for all mRNA levels were calculated using cDNA from 
prostate cancer cell lines (LNCaP/DU145/PC3) as calibrator and positive control. Differences in 
mRNA levels between groups were identified using the double delta CT (∆∆CT) method. PCR 
product sizes were verified on a 2 % agarose gel.  
Table 3: Primer sets used for mRNA level quantification in motile and immotile sperm cells. 
Gene Primer sequences (5`-3`) 
PCR product  
size (bp) 
DNMT1 
FWD: GAACGGTGCTCATGCTTACAA 
REV: TCTCCATCGGACTTGCTCCT 
159 
DNMT3A 
FWD: CCTGCAGAAGCGGGTGAG 
REV: ATATGCGCAGGCTGCATC 
183 
L165 
FWD: GAATGATTTTGACGAGCTGAGAGAA 
REV: GTCCTCCCGTAGCTCAGAGTAATT 
67 
KMT5A 
FWD: GGGAACTGCCAAACCAAAC 
REV: TTCAATGGAAGCCTTGCTG 
127 
KMT5B 
FWD: AATTCCAGCTTCTTCCAACTC 
REV: GCATTCTTTTGCTCCAGCC 
147 
KMT5C 
FWD: AGATGAACGTCAGCCCTGTG 
REV: CCGCTGCCTCAGGAAAGTT 
80 
FWD: GCCCGCTACTTCCAGAGC 
REV: GGAGGTAGCGATAGACGTGG 
70 
FWD: AGGTGACATGCTTCTACGG 
REV: CTGGTTCGGAAAGCTCCTTC 
100 
SIRT699–101 
FWD: GAGGAGCTGGAGCGGAAGGTGTG 
REV: GGCCAGACCTCGCTCCTCCATGG 
156 
FWD: CTCCTCCGCTTCCTGGTC 
REV: CGTCTTACACTTGGCACATTCTT 
123 
FWD: CTGGTCAGCCAGAACGTGGA 
REV: CACGACTGTGTCTCGGACGTA 
135 
MORC2 
FWD: TCGGAAGCGGAGTGTC 
REV: CGTGCAGCCCTTTATCT 
191 
GAPDH25 
FWD: TGGAGAAGGCTGGGGCTCAT 
REV: GACCTTGGCCAGGGGTGCTA 
176 
ß-Actin 
FWD: CGAGAAGATGACCCAGATCA 
REV: ATAGCACAGCCTGGATAGCA 
74 
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2.2.6 Statistical analysis and Figure preparations 
Data calculations were performed with Microsoft Excel (Microsoft Corporation, Redmond, WA, 
USA) and the statistical significance was determined with the SPSS 24.0 software (IBM, Chicago, 
USA) by setting p<0.05 as significant and p<0.01 as highly significant. Mean and median values 
including ranges (lowest to highest) and standard deviations were calculated for all parameters of 
interest. Differences between variables within two groups (non-normally distribution) were 
analyzed using Mann-Whitney U test (two-tailed). Relationships between variables were calculated 
with Pearson`s and/or Spearman`s rank correlation. Correlation directions (positive [+], negative 
[-]) and strengths were assumed with the correlation coefficient r (range: 0.50-1.00 strong, 0.30.-
0.49 medium, 0.10-0.29 weak, 0.00-0.09 no correlation).102,103 ChemDrawBio Ultra 12.0 Software 
was used to design Figures manually. 
2.2.7 Protein extraction and western blot analysis of sperm nucleoproteins 
Swim-up semen samples (motile and immotile fractions) were defrozen on ice, at least 20 x 106 
sperm cells were taken and washed with PBS (in DEPC-H2O). Sperm cells were resuspended in 
Tris-Urea buffer (8 M Urea, 2 % SDS, 50 mM Tris (pH 8.0), 105 mM NaCl, 1 mM PMSF, 10 mM 
DTT, 1x Proteinase Inhibitor Cocktail) and incubated at RT for 30 min under frequent vortexing. 
Then sperm cells were sonicated with ultrasonic processor Vibra Cell for three cycles, each 10 s 
(Amplitude 30 %, max. pulse). Removal of cell debris was performed by centrifugation (10 min, 
13.000 rpm, RT) and whole protein extracts were taken into a new tube. Protein concentrations 
were measured (Nanodrop) and extracts were kept at -80 °C until further processing. 
25-50 µg protein were mixed with 4x Laemmli loading buffer and put on a SDS Gel. This consisted 
of a 15 % running gel (2.3 mL ddH2O, 5 mL acrylamide, 2.5 mL running gel buffer, 100 µL SDS 
[10 %], 100 µL APS [10 %], 4 µL TEMED) and a 4 % stacking gel (2.1 mL ddH2O, 500 µL 
acrylamide, 380 µL stacking gel buffer, 30 µL SDS [10 %], 30 µL APS [10 %], 3 µL TEMED). 
Protein separation was started at 100V for ~20 min, until the proteins reached the running gel and 
continued at 140 V for ~100 min until the proteins reached the bottom of the gel. Gels were 
equilibrated for 15 min in transfer buffer. In the meantime, a PVDF membrane (0.45 µM) was 
activated in 100 % for 5 min, washed for 2 min in ddH2O and equilibrated 5 min in transfer buffer. 
Semi-dry was used as protein transfer technique for 30 min at 150 mA and 25 V (max). After 
protein transfer the membranes were dried at 37 °C for 15 min to bind proteins irreversible.  
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Subsequent to renewed activation of the membrane the whole protein content, which was 
transferred onto the membrane, was analyzed with the REVERTTM Total Protein Stain Kit. Images 
of these stainings were documented with the Odyssey Fc system for later normalization. After that 
the membrane was blocked in Odyssey blocking buffer (1:3 in PBS) for 1 h at RT. Primary 
antibodies (H4K20me3 [ab9053], 1:500; H4K20me2 [ab9052], 1:500; GAPDH [ab9485], 1:2500; 
SIRT6 [ab62739/ab176345], 1:2000/1:500; KMT5C [ab91224], 1:100) diluted in Odyssey 
blocking buffer (1:3 in PBS, 0.1 % Tween-20) were added to the membrane and incubated 
overnight at 4 °C on a rotator (15 rpm). Hereafter the membranes were washed three times with 
PBST buffer for 5 min (20 rpm) and incubated for 1 h (15 rpm) with secondary antibody (IRDye® 
800CW/680LT Goat anti-Rabbit IgG, 1:10000) diluted in Odyssey blocking buffer (1:3 in PBS, 
0.1 % Tween-20, 0.01 % SDS). After three times washing in PBST buffer for 5 min (20 rpm), 
membranes were rinsed three times with PBS and fluorescence signals were detected with the 
Odyssey Fc system (2 min acquisition). 
2.2.8 IHC on human/bull/mouse testis tissues and ICC with human spermatozoa 
Immunohistochemical (IHC) stainings were performed to analyze H4K20me3 (ab9053), 
H4K20me2 (ab9053) and YY1 (ab109237) on human testis tissues, obtained for TESE (testicular 
sperm extraction) and on wildtype mouse/bull testis tissues, all exhibiting normal spermatogenesis. 
Immunocytochemical (ICC) stainings for H4K20me3 (ab9053), H4K20me2 (ab9053) and YY1 
(ab109237) were performed with human spermatozoa (motile fractions) from healthy donors. 
At the start formalin-fixed and paraffin-embedded human testis tissue samples on microscope 
slides (R. Langenbrinck) were deparaffinated stepwise in Xylol (3 x 10 min) and Ethanol 
(2 x 5 min in 100 % EtOH, 2 x 5 min in 96 % EtOH and 2 x 5 min in 70 % EtOH) and cooked for 
20 min in citrate buffer (18 mM citric acid monohydrate, 82 mM sodium citrate) to improve 
primary antibody binding. After cooling down for 30 min at RT, peroxidase activity was inhibited 
by blocking in ice cold hydrogen peroxide solution in methanol (3 % H2O2 in MeOH). Then the 
slides were washed three times for 5 min in Tris-HCl buffer (0.1 M Tris-HCl, 0.1 M NaCl) and 
blocked for 20 min in BSA solution (5 % in Tris-HCl) to prevent non-specific antibody binding. 
Primary antibodies (H4K20me3, ab9053, 1:100; H4K20me2, ab9053, 1:100; YY1, ab109237, 
1:200) diluted in BSA solution were dropped onto one side of the slides and incubated overnight 
at 4 °C. As negative control BSA solution without antibody was dropped onto the other side of 
each slide. The slides were washed three times for 5 min in Tris-HCl buffer and incubated at RT 
Materials and Methods 
36 
 
for 1 h with secondary antibody (goat anti-rabbit IgG, 1:200, Dako). After repeated washing in 
Tris-HCl buffer (3 x 5 min) slides were developed for 10-30 min with ABC-Peroxidase Staining 
Kit. Development was stopped through washing in ddH2O (3 x 5 min) and counterstaining was 
performed for 5 s in Mayer`s Haemalaun with final washing in dH2O (3 x 5 min). Slides were 
mounted with Dako Faramount and covered with glass plates followed by microscopic examination 
and documentation of the antibody staining pattern. 
ICC slides were prepared by scratching out at least one million sperm cells (motile swim-up 
fraction) onto a glass plate. After drying, sperm cells were decondensed for 10 min in DTT (10 mM 
in Tris-HCl buffer) and further 2 h in Lithium diiodo salicylate solution (10 mM LIS in 1 mM DTT 
Tris-HCl buffer). Then sperm cells were fixed with 4 % PFA (in PBS, pH 7.4) and blocked for 
15 min in BSA/Triton solution (0.1 % BSA, 2 % Triton X-100 in PBS). Primary and secondary 
antibody incubation, as well as ABC system, Dako reagents and documentation were performed as 
described above for human testis tissue. 
2.2.9 ChIP and ChIP-qPCR with human spermatozoa 
Chromatin Immunoprecipitation (ChIP) was performed with H4K20me3 (ab9053) and ChIP-IT 
High Sensitivity Kit (Active Motif, Cat. No. 53040) on 10-20 Mio motile and immotile human 
sperm cells of four healthy donors to analyze DNA loci, which are interacting with this histone 
modification. According to the manufacturer`s protocol, with following modifications, sperm cells 
were first fixed with formaldehyde, to cross-link protein/DNA complexes. Then sperm cells were 
sonicated, using ultrasonic processor Vibra Cell ten times for 30 s on and 30 s off at an 40 % 
amplitude (total 10 min), to generate the desired DNA fragmentation (200-1200 bp). After 
centrifugation (10 min, 13000 rpm, 4°C) 10 % of the supernatant were abstracted as input and 
another 10 % for a chromatin check on 2 % agarose gel. The remaining supernatant (80 %) of each 
sample was incubated with 8 µg H4K20me3 (ab9053) overnight at 4°C for immunoprecipitation. 
Antibody-bound protein/DNA complexes were captured with Protein G agarose beads and washed 
using the provided ChIP filtration columns. After elution of the complexes from these columns 
reverse cross-linking and Proteinase K digestion was performed, to separate protein/DNA 
complexes. Finally, DNA was purified using the provided DNA purification columns and 
concentration of double stranded DNA (dsDNA) was determined using Qubit 2.0 Fluorometer (Cat. 
No. Q328669). 
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Recently, our group (Ozturk et al., 2019 in preparation) identified through an MNase followed by 
genome-wide ChIP-sequencing of motile human sperm fractions (three healthy volunteers) the 
genome/gene loci, which are highly enriched with H4K20me3. Based on these results, ChIP-qPCR 
primer sets (Table 4) in promoter regions of five selected genes enriched for H4K20me3 were 
designed or chosen from literature.  
Table 4: Primer sets used for H4K20me3-ChIP-qPCR in motile and immotile human sperm cells. 
Gene Primer sequences (5`-3`) PCR product size (bp) 
CXCL8 
FWD: TGGCTGGCTTATCTTCACCA 
REV: AGTGGCAGGTGTTAGAACAAGA 
107 
TNSFS13B 
FWD: GCAGGAACTTTCAGCTGCTTTT 
REV: AGCCCACCCTTAAGTGTAGCAA 
90 
IFNW1 
FWD: TGGTTCTAAAGAGCTTATTTGCTGC 
REV: AGCCTCCATTTTTACCCTCCT 
110 
CST8 
FWD: TTTAGACCAAAGGCCGGAGG 
REV: TGCAGGGAGGTTACGCTTTG 
95 
L1-
ORF1104 
FWD: TAACCAATACAGAGAAGTGC 
REV: GATAATATCCTGCAGAGTGT 
298 
L1-
5`UTR65 
FWD: GAATGATTTTGACGAGCTGAGAGAA 
REV: GTCCTCCCGTAGCTCAGAGTAATT 
67 
An intra- and inter-individual comparison of H4K20me3 enrichments in motile and immotile sperm 
cells was performed. Therefore, relative binding of H4K20me3 was calculated using the ChIP-
qPCR signals (CTs generated with H4K20me3-precipitated DNA and respective input DNAs). 
Relative binding of H4K20me3 was calculated as enrichments over the input signals. 
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3. Results 
3.1 In fertile men, DNMT1 and DNMT3A mRNAs are stored at high levels in 
motile spermatozoa and are strongly correlated to each other 
Here, the gene expression levels of the DNA methyltransferase DNMT1 (maintenance) and 
DNMT3A (de novo) were measured in human spermatozoa. Total sperm RNA from motile human 
spermatozoa of 96 donors (donors` M) and 48 subfertile patients (patients` M) were extracted and 
reverse transcribed into cDNA. Specific qPCR primer sets for DNMT1 and DNMT3A (Table 3) 
were used to quantify and compare the mRNA levels in donors` and patients` M using RT-qPCR. 
Figure 15 displays the relative and logarithmic mRNA levels as box plots (dark blue: DNMT1, 
light blue: DNMT3A) for the cohorts after normalization to the housekeeping gene GAPDH (Table 
3).  
 
Figure 15: DNMT1/DNMT3A mRNA levels of donors` and patients` M (left: relative scale; right: log scale). Both 
transcript levels were significantly decreased in patients` M compared to donors` M (p=0.001/p<0.001, n=144/143). 
Both the DNMT1 and DNMT3A mRNA levels in patients` M were significantly decreased 
(p=0.001/p<0.001, n=144/143) compared to the healthy donors` M. More precisely, as shown in 
Table 5, the median DNMT1 (0.92±0.47) and DNMT3A (0.44±0.67) mRNA values in patients` M 
were reduced by 33 % and 77 %, respectively. 
Table 5: Descriptive statistics of relative DNMT1 and DNMT3A mRNA level. 
Descriptive Statistics 
Relative DNMT1 mRNA level (n=144) Relative DNMT3A mRNA level (n=143) 
Donors M (n=96) Patients M (n=48) Donors M (n=95) Patients M (n=48) 
Average 2.34 0.84 2.87 0.64 
Median 1.37 0.92 1.87 0.44 
Standard deviation 4.43 0.47 4.24 0.67 
Range 0.09-36.4 0.02-2.42 0.08-34.91 0.01-3.49 
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Through a correlation analysis (Figure 16), it could be determined in motile spermatozoa that both 
DNMT1 and DNMT3A mRNA levels correlated significantly (strong positive) to each other 
(p<0.001, r=0.671, n=143). DNMT1 and DNMT3A mRNA levels were not significantly correlated 
to clinical or spermiogram data of patients` and donors` M, such as age, sperm concentration, 
fertilization rate, pregnancy outcome, progressive and total motility. 
  
Figure 16: Significant positive correlation (p<0.001, r=0.671, n=143) between                                                         
DNMT1 and DNMT3A mRNA levels of donors`/patients` M (log scale). 
Taken together, these data show that decreased mRNA levels of DNMT1 and DNMT3A are 
characteristic for patients` motile sperm cells and can possibly influence their global DNA 
methylation status.  
3.2 Analysis of the global DNA/RNA methylation & L1 methylation states in 
motile and immotile human spermatozoa 
In order to analyze possible influences of decreased DNA methyltransferase levels detected in 
patients` M, global DNA methylation and L1 methylation were investigated in patients` M and 
donors` M as well as in immotile human spermatozoa of donors (donors` IM). In addition, 5-hmC 
and RNA methylation (m6A) were analyzed in the same samples. 
3.2.1 5-mC / 5-hmC DNA and m6A RNA methylation in motile human spermatozoa 
Total sperm DNA & RNA from 20 donors` M and 20 patients` M were extracted and their global 
methylation status was analyzed by ELISA (MethylFlashTM Global DNA Methylation ELISA 
Easy Kit, EpiQuik RNA Methylation Quantification Kit; Gentaur). Figure 17 shows the 5-mC 
DNA and m6A RNA methylation as box plots (green: donors` M, purple: patients` M).  
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5-hmC was analyzed using ELISA (MethylFlashTM Global DNA Hydroxymethylation ELISA 
Easy Kit, Gentaur) in 20 donors` M and 20 patients` M, and was absent (0.00 %) and thus not 
illustrated here. 
 
Figure 17: 5-mC DNA (left) and m6A RNA (right) methylation in donors` versus patients` M analyzed by ELISA. 
No significant differences in 5-mC DNA (p=0.935, n=40) and m6A RNA (p=0.516, n=40) methylation were found. 
5-mC levels in patients` and donors` M did not differ significantly (p=0.935, n=40) from each other 
and ranged from 0.12 to 10.1 %. The methylation levels of m6A RNA were much lower and ranged 
from 0.01 to 0.06 % in patients` and donors` M and did not, as well, differ significantly between 
the two groups (p=0.516, n=40).  In Table 6 the exact methylation values can be inspected. 
Table 6: Descriptive statistics of 5-mC and m6A analyzes. 
Descriptive Statistics 
5-mC global DNA methylation  
(Elisa/%, n=40) 
m6A RNA methylation  
(Elisa/%, n=40) 
Donors M (n=20) Patients M (n=20) Donors M (n=20) Patients M (n=20) 
Average 4.52 3.97 0.02 0.02 
Median 3.97 2.67 0.01 0.01 
Standard deviation 3.68 3.00 0.01 0.01 
Range 0.12-9.63 0.55-10.06 0.01-0.06 0.01-0.05 
5mC DNA and m6A RNA methylation levels were not significantly correlated to clinical or 
spermiogram data of patients` and donors` M. Also, no significant correlation between DNA 
methyltransferases (DNMT1 and DNMT3A) and global 5-mC DNA or m6A RNA methylation were 
found here in the cohorts.  
The global DNA Methylation ELISA Easy Kit based findings showed here, that there are no 
differences in global DNA methylation levels between the motile sperm cells from healthy donors 
and subfertile patients. Also, RNA methylation levels were comparable in these two groups.  
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L1 is a retrotransposon that makes up to 17.0 % of the human genome and it was shown, that this 
element can serve as a surrogate measure for the global DNA methylation level.73 For this reason, 
the L1 methylation status in human spermatozoa was additionally investigated using two different 
methods, ELISA and pyrosequencing. 
3.2.2 ELISA analyzes reveal that motile spermatozoa from healthy men possess higher L1 
methylation in comparison to that in subfertile men 
Using ELISA for L1 methylation analysis (Global DNA Methylation - L1 Kit, Cat. No. 55017) 
total sperm DNAs extracted from 79 donors` M, 78 donors` IM and 48 patients` M were evaluated. 
In Figure 18 (left) the L1 methylation levels of the cohorts (green: donors` M, orange: donors` IM, 
purple: patients` M) are shown as box plots.  
For L1 methylation analysis using pyrosequencing (L1 pyrosequencing kit, Cat. No. 970012; levels 
shown in Figure 18, right) total sperm DNAs from 33 donors` M, 38 donors` IM and 48 patients` 
M were extracted and bisulfite treated (EZ DNA Methylation Kit).  
 
Figure 18: L1 methylation of donors` M/IM and patients` M analyzed by ELISA (left) and pyrosequencing (right). 
No difference in L1 methylation is measurable using pyrosequencing. Using ELISA, L1 methylation is significantly 
decreased in patients` M compared to donors` M (p=0.001, n=127) and donors` IM (p<0.001, n=126). Between 
donors` M and IM no difference in L1 methylation is measurable (p=0.168, n=157). 
Evaluating the pyrosequencing results (Figure 18, right) no significant differences were found 
between the cohorts (all p>0.05). Median L1 methylation of donors` M (52.0±6.22), donors` IM 
(51.5±7.06) and patients` M (52.3±4.67) of the three CpGs investigated by pyrosequencing are 
almost identical (Table 7).  
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By using the ELISA kit (Figure 18, left), L1 methylation was found significantly decreased in 
patients` M compared to donors` M (p=0.001, n=127) and donors` IM (p<0.001, n=126). No 
significant difference in L1 methylation was found between donors` M and IM (p=0.168, n=157). 
This different result is probably due to the higher number of analyzed CpGs (n=12) and a different 
L1 region considered. Evaluation of median values (Table 7) showed, that L1 methylation was 
reduced in patients` M (44.3±12.5) by 7.7 % compared to donors` M (48.0±18.8) and by 21 % 
compared to donors` IM (56.3±13.5).  
Table 7: Descriptive statistics of L1 methylation analyzes. 
Descriptive 
Statistics 
L1 methylation (Elisa/%; n=205) L1 methylation (Pyro./%; n=118) 
Donors M 
(n=79) 
Donors IM 
(n=78) 
Patients M 
(n=48) 
Donors M 
(n=33) 
Donors IM 
(n=38) 
Patients M 
(n=47) 
Average 52.25 58.07 47.19 50.54 50.33 51.11 
Median 47.96 56.32 44.29 52.00 51.50 52.33 
Standard 
deviation 
18.79 13.52 12.53 6.22 7.06 4.67 
Range 23.55-100 33.73-100 26.53-89.73 28.67-58.50 27.33-73.33 36.50-57.00 
L1 methylation levels, analyzed by pyrosequencing and ELISA, were not significantly correlated 
to clinical and spermiogram data of patients` and donors` M. A significant correlation of L1 
methylation levels to other genes (DNMT1 and DNMT3A, Figure 19), 5-mC DNA and m6A RNA 
methylation was not found here.  
 
Figure 19: No significant correlation between L1 methylation and DNMT1 (p=0.082, r=-0.188, n=87; left) or 
DNMT3A (p=0.330, r=-0.106, n=87; right) mRNA levels of donors` and patients` M. 
Overall, differences in global methylation could be detected in patients` M using L1 ELISA. As 
next, L1 mRNA levels were investigated in motile and immotile human spermatozoa, in order to 
examine if there are any differences. 
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3.2.3 Immotile spermatozoa possess high levels of L1 mRNA 
Total sperm RNAs from 58 donors` M, 50 donors` IM and 33 patients` M were extracted and 
reverse transcribed into cDNA. A specific PCR primer set for L1 (Table 3) was used to quantify 
and compare the mRNA levels in donors` M and IM, and patients` M using RT-qPCR. Figure 20 
displays the relative and logarithmic L1 mRNA levels as box plots (green: donors` M, orange: 
donors` IM, purple: patients` M) for the cohorts after normalization to the housekeeping gene β-
Actin (Table 3).  
 
Figure 20: L1 mRNA level of donors` M/IM and patients` M analyzed by RT-qPCR (left: relative scale 1:20; right: 
log scale). L1 mRNA levels were at highest in donors` immotile sperms and are significantly increased compared to 
donors` (p<0.001, n=108) and patients` motile sperm fractions (p=0.013, n=83).  
It was obvious, that L1 mRNA levels were significantly increased in donors` IM compared to 
donor`s (p<0.001, n=108) and patients` M (p=0.013, n=83). Table 8 demonstrates that in donors` 
motile sperm the L1 mRNA levels were at lowest (0.19±3.08) and gradually increased in patients` 
motile sperm (1.33±5.61) and were at highest level in immotile sperm cells (4.59±38.5). This 
corresponds to 96 % and 71 % lower L1 mRNA levels in donors` and patients` M, respectively. 
These observations provide a strong indication, that L1 is dysregulated (upregulated) in immotile 
sperms as well as in motile sperm of subfertile men. 
Table 8: Descriptive statistics of relative L1 mRNA level. 
Descriptive Statistics 
Relative L1 mRNA level (n=141) 
Donors M (n=58) Donors IM (n=50) Patients M (n=33) 
Average 1.60 21.51 3.69 
Median 0.19 4.59 1.33 
Standard deviation 3.08 38.50 5.61 
Range 0.00-13.49 0.01-168.04 0.00-26.06 
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It is well-known, that L1 in somatic cells are suppressed by DNA hypermethylation.61,74,105 In 
agreement with this, a significant negative correlation between L1-mRNA and -methylation levels 
was found here in motile human spermatozoa (p<0.001, r=0.3681, n=91; Figure 21, left).  
In addition, a highly significant positive correlation between the fertilization rate and L1 
methylation was found, exclusively in the patient subgroup showing a positive pregnancy 
(p=0.009, r=0.555, n=21; Figure 21, right). 
 
Figure 21: Significant negative correlation (p=0.008, r=-0.368, n=91) between L1 methylation and mRNA levels in 
donors` and patients` M (left). Significant positive correlation (p=0.009, r=0.555, n=21) between L1 methylation and 
fertilization rate in patients` M with a positive pregnancy (right). 
L1 mRNA levels were not significantly correlated to other clinical and spermiogram data of 
patients` and donors` M such as age, sperm concentration, fertilization rate, pregnancy outcome, 
progressive and total motility. Also, no significant correlations of L1 expression to expression of 
other genes (DNMT1 and DNMT3A) were found. In donors` M, 5-mC DNA and L1 methylation, 
analyzed by ELISA, were positively correlated to each other, but their correlation coefficient was 
very low (p=0.045, r=0.154, n=20). 
All these findings suggest, that a targeted regulation of L1 elements is important for male fertility 
and ART outcome. For this reason, different epigenetic regulators of L1, well known from studies 
on somatic cells, were studied in human sperm cells and, moreover in healthy human testis tissues, 
in order to evaluate those factors relevant for L1 regulation in human spermatogenesis and in 
mature sperm. 
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3.3 SIRT6 methylation and expression analyzes 
Sirtuin 6 (SIRT6) is a histone deacetylase, which packages L1 elements into transcriptionally 
repressive heterochromatin in human dermal fibroblasts but fails with stress and age by for e. g. 
SIRT6 promoter methylation and reduced expression.89  
Here, for SIRT6 methylation analysis using pyrosequencing (SIRT6 pyrosequencing kit, Cat. No. 
978746) total sperm DNA from 32 donors` M, 35 donors` IM and 47 patients` M were extracted 
and bisulfite treated (EZ DNA Methylation Kit). In Figure 22 the evaluated SIRT6 methylation 
levels in the cohorts are displayed (green: donors` M, orange: donors` IM, purple: patients` M). 
 
Figure 22: SIRT6 methylation in donors` M and IM and patients` M was analyzed by pyrosequencing. SIRT6 
methylation was significantly increased in patients` M compared to donors` M and IM (p=0.003/p=0.013; 
n=79/n=82; respectively). Between donors` M and IM no difference was measured (p=0.563, n=67). 
Patients’ motile sperm possessed significantly increased SIRT6 methylation (Table 9) in 
comparison to controls’ motile (p=0.013, n=79) as well as immotile sperm (p=0.003, n=82). There 
was no difference in SIRT6 methylation between donors` M and IM (p=0.563, n=67).  
Table 9: Descriptive statistics of SIRT6 methylation analyzed by pyrosequencing. 
Descriptive Statistics 
SIRT6 methylation (Elisa/%, n=114) 
Donors M (n=32) Donors IM (n=35) Patients M (n=47) 
Average 1.00 0.97 1.34 
Median 1.00 1.00 1.00 
Standard deviation 0.21 0.23 0.69 
Range 0.80-1.40 0.60-1.80 0.60-3.80 
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In literature91 it is described, that SIRT6 methylation in lymphocytes increases with age. To check 
the situation in human sperm cells, SIRT6 methylation was analyzed in correlation to age in the 
available samples (Figure 23). For all groups, no significant correlation between SIRT6 methylation 
and age could be detected. Thus, it can be concluded that in sperm there is no age effect on SIRT6 
methylation. 
 
Figure 23: No significant correlation between SIRT6 methylation and age in patients` M (p=0.097, n=47)                 
and donors` M (p=0.704, n=32) was found. 
It is tempting to speculate, if increased SIRT6 methylation in patients` M decreased L1 packaging 
into silent heterochromatin and thus, led to L1 activation. Therefore, a correlation analysis between 
SIRT6 methylation and L1 mRNA level of patients` and donors` M was performed (Figure 24). No 
significant correlation was found, but the correlation directions were different between the cohorts. 
 
Figure 24: SIRT6 methylation and L1 mRNA level were not significantly correlated in patients` M (p=0.638,          
r=-0.085, n=33) and donors` M (p=0.524, r=-0.117, n=32). 
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SIRT6 mRNA and protein levels in human spermatozoa were analyzed as a next step, to see if these 
are connected with L1 regulation. Three different qPCR primer sets for SIRT6 were taken from 
literature99–101 (Table 3) to analyze SIRT6 mRNA level in human spermatozoa. In five donors` M 
and LNCaP (human prostate cancer cell line used as positive control) the primer sets mentioned 
above were tested. In Figure 25 the agarose gels of the obtained PCR products for SIRT6 analysis 
are shown. 
 
Figure 25: SIRT6 mRNA analysis in donors` M using primers selected from published studies. SIRT6: 156 bp; 
Radak et al., 2011.99 SIRT6: 123 bp; Wang et al., 2014.100 SIRT6: 135 bp; Nagai et al., 2015.101 All three qPCR 
primer sets worked well in positive controls (LNCaP, prostate cancer cell line). No PCR product bands could be 
amplified using indicated primer pairs in all five motile sperm samples. 
The right PCR products were detected only in LNCaP cells, whereas in motile sperm samples 
SIRT6 mRNA was absent. In the next step SIRT6 protein levels in motile human spermatozoa were 
analyzed by western blot using two different primary antibodies, to see if any SIRT6 mRNA was 
translated during spermatogenesis and stored in mature sperm. 
SIRT6 protein levels in donors` M could not be analyzed with western blot because of the weak 
performance of the used antibodies (Figure 26). Two primary antibodies against SIRT6 (ab62739 
-no longer available at abcam, checked on February 5, 2019- and ab176345) were tested. Since no 
LNCaP protein extracts were available, those from HeLa were used as a positive control instead.  
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Ab62739 showed unspecific bands in the positive control HeLa (Figure 26, left, green band at 39 
kDa), whereas ab176345 performed better (Figure 26, right, green band at 39 kDa). No SIRT6 was 
detected in all sperm samples.  
 
Figure 26: Western blot analysis using two SIRT6 primary antibodies on donors` M and HeLa cells (positive 
control). On the left picture ab62739 (SIRT6, 39 kDa, 1:2000, unspecific green bands in HeLa) and on the right 
picture ab176345 (SIRT6, 39 kDa, 1:500, green band in HeLa) was used as primary antibody against SIRT6. No 
bands in human sperm samples were detected using both antibodies (Ej. 3: whole ejaculate; DM: motile sperms; DI: 
immotile sperms). 
To sum up, SIRT6 methylation was increased in patients in comparison to fertile controls. No 
correlation between SIRT6 methylation and age was found in human sperm. Regarding SIRT6 
expression, neither SIRT6-mRNA nor -protein could be detected in human sperm. The latter 
suggests, that SIRT6 is probably not expressed, at least during the last stages of human 
spermatogenesis. Also, neither significant correlations of SIRT6 methylation to clinical and 
spermiogram data of patients` and donors` M nor to methylation (5-mC, m6A and L1) and mRNA 
(DNMT1, DNMT3A and L1) data previously obtained were found here. 
 
 
 
 
 
 
Results 
49 
 
3.4 Analyzes on MORC2 mRNA in human sperm 
MORC2  (microrchidia 2) is a chromatin regulator and suppresses L1 elements by silencing its 
transcription in human chronic myeloid leukemia K562 and human embryonic stem cells (hESC).93 
Total sperm RNA from 32 donors` M, 24 donors` IM and 46 patients` M were extracted and reverse 
transcribed into cDNA. For MORC2 mRNA levels analysis a specific PCR primer set was designed 
(Table 3) and used to quantify and compare the levels in donors` M and IM and patients` M using 
RT-qPCR. Figure 27 displays the relative and logarithmic MORC2 mRNA levels as box plots 
(green: donors` M, orange: donors` IM, purple: patients` M) for the cohorts after normalization to 
the housekeeping gene β-Actin (Table 3). 
 
Figure 27: MORC2 mRNA measured in donors` M and IM and patients` M. In healthy donors` M, MORC2 mRNA 
levels were significantly increased compared to patients` M (p<0.001, n=78) and donors` IM (p<0.001, n=56). 
Relative MORC2 mRNA levels were significantly higher in donors` M compared to patients` M 
(p<0.001, n=78) and donors` IM (p<0.001, n=56). The relative MORC2 mRNA was in 4 donors` 
M, 20 donors` IM and 26 patients` M not detectable and therefore set as zero. The logarithmic scale 
could not be used here as the log (0) is not defined. Table 10 summarizes the average and median 
relative values observed for MORC2 mRNA. 
Table 10: Descriptive statistics of relative MORC2 mRNA level. 
Descriptive 
Statistics 
Relative MORC2 mRNA level, 
inclusive zero values (n=102) 
Relative MORC2 mRNA level, 
exclusive zero values (n=52) 
Donors M 
(n=32) 
Donors IM 
(n=24) 
Patients M 
(n=46) 
Donors M 
(n=28) 
Donors IM 
(n=4) 
Patients M 
(n=20) 
Average 0.95 0.09 0.19 1.09 0.55 0.44 
Median 0.16 0.00 0.00 0.34 0.47 0.25 
Standard deviation 1.76 0.26 0.45 1.84 0.41 0.61 
Range 0.00-8.82 0.00-1.12 0.00-2.72 0.01-8.82 0.16-1.12 0.01-2.72 
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To conclude, 28/32 in donors` M (87.5 %) and only 20/46 (43.5 %) in patients` M and 4/24 donors` 
IM (16.7 %) had detectable levels of MORC2 mRNA. Healthy donors’ motile sperm fraction had 
stored significantly higher levels of MORC2 mRNA. No significant correlation of MORC2 
expression to L1 expression (Figure 28) and clinical and spermiogram data of patients` and donors` 
M were found here. 
 
Figure 28: No significant correlation between MORC2 and LINE-1 mRNA levels in patients` M and donors` M 
(p=0.690, r=-0.51, n=63) was found. 
3.5 YY1 expression analysis in human testis tissue 
Human L1 elements contain a YY1 (Yin Yang 1) binding site at their 5`UTR, located on the 
antisense strand between position +13 and +21, and YY1 is known to regulate the human L1 
transcription initiation.60,88 Here, human testis tissue samples exhibiting normal spermatogenesis 
(obtained from patients with non-obstructive azoospermia for testicular sperm extraction) were 
investigated for YY1 expression (ab109237, 1:200).  
Figure 29 shows that YY1 is exclusively expressed in Sertoli cells and no YY1 signal can be found 
in any spermatogenetic cell of the seminiferous epithelial cycle (I-V). Therefore, further 
experiments of YY1 in human spermatozoa were not performed. 
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Figure 29: A-C show exemplary tubules with different stages of the seminiferous epithelial cycle (I-V), where YY1 
(ab109237, 1:200) is only detectable in Sertoli cells. C represents the negative staining of serial section A. 
Magnification x40, Bar 50 µm. Sertoli cells = Ser; Spermatogonia = SG; Spermatocytes of the preleptotene stage = 
PL and pachytene stage = P; Round spermatids = RS; Maturing spermatids = MS. D shows a scheme106 of the 
seminiferous epithelial cycle of man; modified from Clermont, 1963.107      
3.6 Histone modifications & regulators associated with L1 
Previously our group34 showed that nucleosomes after protamine exchange are located in repetitive 
DNA elements, like L1 and SINEs. L1 elements were shown to be activated shortly after 
fertilization in the early mouse embryo and regulate global chromatin accessibility there.62 The 
methylation status of histone 4 lysine 20 (H4K20me) has been identified as key player of the 
genomic integrity, playing distinct roles for DNA damage repair, DNA replication and chromatin 
compaction.46 In 2016 a comprehensive study identified histone isoforms and post-translational 
modifications (PTHM) existing in mouse and human male germ cells.42 On the H4 tail peptide 
encompassing amino acids 20-23, H4K20me2 was the most abundant PTHM (80.9 %) besides 
H4K20me3 (9.8 %) and H4K20me1 (7.9 %). The heterochromatin marker H4K20me3, and 
H4K20me2 and their regulators (histone methyltransferases KMT5A, KMT5B and KMT5C) were 
analyzed next, to see if they are associated with L1 regulation in spermatozoa. 
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3.6.1 IHC analyzes of H4K20me2 in human, mouse and bull testis samples 
Healthy human testis tissues obtained for TESE, wildtype mouse and healthy bull testis tissues, all 
exhibiting normal spermatogenesis, were analyzed for H4K20me2 expression, using immunohisto-
chemistry (IHC).  
Figure 30 shows that H4K20me2 (ab9052, 1:100) is detectable in spermatogonia of stage I until 
step 4 elongating spermatids in man. The highest staining intensity for H4K20me2 can be observed 
in spermatogonia type B, then weaker in primary spermatocytes and again higher in elongating 
spermatids. In pachytene spermatocytes (III-V) and maturing spermatids (I/II/V) no H4K20me2 
was present.  
 
Figure 30: H4K20me2 is detectable in human SG of stage I until step 4 ES in man. In P (III-V) and MS (I/II/V) no 
H4K20me2 was present. A-C show exemplary tubules with different stages of the seminiferous epithelial cycle (I-
V). C represents the negative staining of serial section A. Magnification x40, Bar 50 µm. Spermatogonia = SG; 
Spermatocytes of the preleptotene-/leptotene stage = PL/L and pachytene stage = P; Round spermatids = RS; 
Maturing spermatids = MS; Elongating Spermatids = ES. D shows a scheme106 of the staining intensities of 
H4K20me2 in the seminiferous epithelial cycle of man; modified from Clermont, 1963.107              
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In mouse (Figure 31) high expression of H4K20me2 (ab9052, 1:100) could be detected in 
spermatogonia (stage II-VI), and less in preleptotene-/leptotene spermatocytes (VII-X), pachytene 
spermatocytes (stage VII-XI), round spermatids (stage I-VIII) and elongating spermatids (stage IX-
XI). In maturing spermatids (stage I-VIII) no H4K20me2 was sighted.  
 
Figure 31: H4K20me2 is detectable in mouse SG (stage II-VI), PL/L (VII-X), RS (stage I-VIII), P (stage VII-XI) and 
ES (stage IX-XI) in mouse. Only in MS (stage I-VIII) no H4K20me2 was present. A-D show exemplary tubules with 
different stages of the seminiferous epithelial cycle. D represents the negative staining of a serial section A. 
Magnification x40, Bar 50 µm. Spermatogonia = SG; Spermatocytes of the preleptotene-/leptotene stage = PL/L and 
pachytene stage = P; Round spermatids = RS; Maturing spermatids = MS; Elongating Spermatids = ES. E shows a 
scheme108 of the staining intensities of H4K20me2 in the 12 spermatogenetic stages of mouse; modified from 
Russell, 1990.109       
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Figure 32 presents the expression of H4K20me2 (ab9052, 1:100) in bull testis, which can be seen 
in spermatogonia (stage I-VI), preleptotene-/leptotene spermatocytes (VIII/IX), pachytene 
spermatocytes (stages II-IV), round spermatids (I-VII) and in elongating spermatids (stage VIII-
X). Here, expression patterns of H4K20me2 were at highest in round and elongating spermatids. 
In pachytene spermatocytes (stages V-IX) and maturing spermatids (stage I-VI, XI-XIII) no 
H4K20me2 was detectable. 
 
Figure 32: H4K20me2 is detectable in bull SG (stage I-VI), PL/L (VIII/IX), P (stages II-IV), RS (I-VII) and in ES 
(stage VIII-X) in bull. In maturing spermatids (stage I-VI, XI-XIII) no H4K20me2 was present. A-E show exem-
plary tubules with different stages of the seminiferous epithelial cycle (I-XIII). E represents the negative staining of 
serial section B. Magnification x20, Bar 50 µm. Spermatogonia = SG; Spermatocytes of the preleptotene-/leptotene 
stage = PL/L and pachytene stage = P; Round spermatids = RS; Maturing spermatids = MS; Elongating Spermatids = 
ES. F shows a scheme110 of the staining intensities of H4K20me2 in the 14 spermatogenetic stages of bull. 
In summary, H4K20me2 is ubiquitously expressed in human, mouse and bull testis and is highly 
abundant in spermatogonia, primary spermatocytes and round spermatids. In all three species no 
H4K20me2 expression could be detected in elongated/maturing spermatids. This is probably due 
to the mild decondensation step used here in this method, where sperm heads remain mostly intact. 
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To analyze if H4K20me2 is present in elongated/ maturing spermatids, immunocytochemical 
stainings and western blots were performed in motile human spermatozoa. 
3.6.2 ICC staining & Western blot of H4K20me2 on human spermatozoa 
Motile human sperm cells (donors` M), obtained by the swim-up method, were analyzed for 
H4K20me2 using immunocytochemistry (ICC) and western blot. Compared to the method used so 
far (IHC), ICC has an additional 2 h decondensation step to really crack the compact motile sperm 
heads for a staining. Figure 33 A-D shows ICC staining of two exemplary donors` M using 
H4K20me2 antibody (ab9052, 1:100), and in E western blot of two donors` M plus a whole 
ejaculate sample (Ej. 3) and HeLa as positive control are presented (ab9052, 1:500). 
 
Figure 33: In two donors` M H4K20me2 could be detected (A: D52M, B: negative control of A, C: D58M, D: 
negative control of C). Magnification x40, Bar 50 µm. E: Left: whole protein extract after transfer to the membrane; 
Right: Western blot with H4K20me3 (ab9053, 1:500) and H4K20me2 (ab9053, 1:500) in total protein extracts 
(25µg/lane) of two donors` M, one whole ejaculate and HeLa cells (positive control). In all samples H4K20me3 
(green bands, 13/15 kDa, lane 1-4) protein levels are 5.1-38.3-times higher than H4K20me2 (green bands, 
13/15 kDa, lane 5-8) level. 
When using ICC, the H4K20me2 retention in donors` M is clearly detectable (Figure 33, A and C, 
red staining). Western blot analyzes showed that the retention of H4K20me2 in motile sperm is 
5.1-38.3-times lower compared to H4K20me3, after normalization to the whole protein content 
(Figure 33 E, right: green numbers under blot represent the enrichment factor).  
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Taken together, IHC, ICC and WB analyzes showed that H4K20me2 is present in all stages of 
human spermatogenesis as well as in human motile spermatozoa. In contrast to literature42, the 
amount of H4K20me2 in mature sperm was considerably lower than that of H4K20me3. 
3.6.3 IHC staining of H4K20me3 in human, mouse and bull testis samples 
Healthy human testis tissues obtained for TESE, wildtype mouse and healthy bull testis tissues, all 
exhibiting normal spermatogenesis, were analyzed for H4K20me3, using IHC.  
Figure 34 shows that H4K20me3 (ab9053, 1:100) is detectable in spermatogonia of stage I until 
step 4 elongating spermatids in man. The highest staining intensity for H4K20me3 can be observed 
in round spermatids, and gets weaker in primary spermatocytes and elongating spermatids. In 
pachytene spermatocytes (III-V) and maturing spermatids (I/II/V) no H4K20me3 was detectable.  
 
Figure 34: H4K20me3 is detectable in human SG of stage I until step 4 ES in man. In P (III-V) and MS (I/II/V) no 
H4K20me3 was present. A-C show exemplary tubules with different stages of the seminiferous epithelial cycle (I-
V). C represents the negative staining of serial section A. Magnification x40, Bar 50 µm. Spermatogonia = SG; 
Spermatocytes of the preleptotene stage = PL, leptotene stage = L and pachytene stage = P; Round spermatids = RS; 
Maturing spermatids = MS; Elongating Spermatids = ES. D shows a scheme106 of the staining intensities of 
H4K20me3 in the seminiferous epithelial cycle of man; modified from Clermont, 1963.107              
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In mouse (Figure 35) expression of H4K20me3 (ab9053, 1:100) can be detected at high levels in 
spermatogonia (stage II-VI), lesser in preleptotene-/leptotene spermatocytes (VII-X), pachytene 
spermatocytes (stage VII-XI), round spermatids (stage I-VIII), and again highly in elongating 
spermatids (stage IX-XI). In maturing spermatids (stage I-VIII) no H4K20me3 was detected.  
 
Figure 35:  H4K20me3 is detectable in mouse SG (stage II-VI), PL/L (VII-X), RS (stage VII/VIII) and ES (stage IX-
XI) in mouse. In P and MS (stage I-VIII) no H4K20me3 was present. A-D show exemplary tubules with different 
stages of the seminiferous epithelial cycle. D represents the negative staining of a serial section A. Magnification 
x40, Bar 50 µm. Spermatogonia = SG; Spermatocytes of the preleptotene stage = PL, leptotene stage = L and 
pachytene stage = P; Round spermatids = RS; Maturing spermatids = MS; Elongating Spermatids = ES. E shows a 
scheme108 of the staining intensities of H4K20me3 in the 12 spermatogenetic stages of mouse; modified from 
Russell, 1990.109       
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Figure 36 presents the expression of H4K20me3 (ab9053, 1:100) in bull testis, which can be seen 
in spermatogonia (stage I-VI), preleptotene-/leptotene spermatocytes (VIII/IX), pachytene 
spermatocytes (stages II-IV), round spermatids (I-VII) and in elongating spermatids (stage VIII-
X). Here, expression patterns of H4K20me3 were at highest in round and elongating spermatids. 
In pachytene spermatocytes (stages V-IX) and maturing spermatids (stage I-VI, XI-XIII) no 
H4K20me3 was detectable. 
 
Figure 36: H4K20me3 is detectable in bull P (stages V-IX), RS (V-VII) and ES (stage VIII-X) in bull. In SG (stages 
I-VII) and MS (stage I-VI) no H4K20me3 was present. A-E show five exemplary tubules with different stages of the 
seminiferous epithelial cycle (I-XIII). E represents the negative staining of serial section B. Magnification x20, Bar 
50 µm. Spermatogonia = SG; Spermatocytes of the preleptotene-/leptotene stage = PL/L and pachytene stage = P; 
Round spermatids = RS; Maturing spermatids = MS; Elongating Spermatids = ES. F shows a scheme110 of the 
staining intensities of H4K20me2 in the 14 spermatogenetic stages of bull. 
In summary, H4K20me3 is ubiquitously expressed in human, mouse and bull testis tissues and is 
most abundant in round and elongating spermatids. In comparison to H4K20me2, the expression 
peak of H4K20me3 is one to two stages later. In all three species no H4K20me3 expression can be 
detected in maturing spermatids. This is probably due to the mild decondensation step used here in 
this method, where sperm heads remain mostly intact. Thus, H4K20me3 was further analyzed in 
mature motile human spermatozoa using ICC and WB. 
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3.6.4 ICC staining & Western blot of H4K20me3 on human spermatozoa 
Motile human sperm cells (donors` M), obtained by the swim-up method, were analyzed for 
H4K20me3 expression using ICC and WB. As mentioned before, ICC has an additional 2 h 
decondensation step, which is helpful to crack the motile sperm heads for a staining. Figure 37 A-
D shows ICC staining of two exemplary samples (donors` M) using H4K20me3 antibody (ab9053, 
1:100), and Figure 37 E shows western blot analyzes on 20 donors` M and 20 donors` IM (ab9053, 
1:500) in order to compare the retention rates within each donor (green numbers under blots are 
evaluated enrichment scores). 
 
Figure 37: ICC and Western blot staining with H4K20me3 antibody in 20 donors` M and M, respectively. In two 
donors` M H4K20me3 was well detectable (A: D52M, B: negative ctrl of A, C: D58M, D: negative control of C). 
Magnification x40, Bar 50 µm. E Western blots with H4K20me3 in total protein extracts (25µg/lane) of 20 donors` 
M and same 20 donors` IM. Under each blot the signal intensity, normalized to the whole protein content for each 
donor, is noted in green. 16 of 20 donors showed higher amounts of H4K20me3 (13/15 kDa) in their immotile 
fractions (1.1-7.7-times more, see Table 11). 
By using ICC, the H4K20me3 retention could be observed in mature spermatozoa (Figure 37, A 
and C, red staining), which was more intense compared to H4K20me2 signals (Figure 33).  
 
Results 
60 
 
Using western blot and blot quantification, it could be found that the retention of H4K20me3 in 
donors` immotile sperm was up to 7.7-times higher compared to motile ones (normalization to the 
whole protein content, Figure 37 E, see also Table 11). This means in 80 % (16/20) of the 
investigated samples H4K20me3 was enriched in donors` IM, which refers to the lower 
compactness of immotile human sperm heads. 
Table 11: H4K20me3 analysis by western blot. The signal intensities of H4K20me3 for 20 donors` M (DM) and 20 
donors` IM (DI) were calculated after normalization to their whole protein content. The enrichment factor was 
calculated by dividing the DI through the DM signal. 
Donor-ID DM signal DI signal Enrichment factor (DI/DM) 
43 0.86 1.60 1.87 
92 0.68 3.47 5.10 
35 6.74 10.55 1.57 
61 2.43 4.10 1.69 
57 1.14 3.42 3.00 
93 3.94 1.43 0.36 
47 0.07 0.19 2.71 
54 0.19 1.46 7.68 
31 0.48 0.52 1.08 
52 0.17 0.43 2.53 
76 1.91 1.63 0.85 
95 0.90 0.33 0.37 
96 0.40 1.23 3.08 
97 0.05 0.16 3.20 
94 0.61 2.69 4.41 
101 0.49 1.48 3.02 
56 0.86 1.39 1.62 
103 0.34 0.26 0.76 
100 0.80 3.30 4.13 
102 1.12 1.31 1.17 
Taken together, these findings suggest that H4K20me3 is expressed in all spermatogenic stages, 
and is preserved in mature motile spermatozoa. Interestingly, immotile spermatozoa possessed 
often higher amounts of H4K20me3 probably reflecting an incomplete histone-to-protamine 
exchange and herewith a restriction in motility.   
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3.6.5 Analysis of histone methyltransferases KMT5A, KMT5B and KMT5C regulating 
H4K20 
KMT5A, KMT5B and KMT5C, also known as SET8, SUV4-20H1 and SUV4-20H2, are histone 
methyltransferases for H4K20.46 KMT5A is responsible for monomethylation (H4K20me1), 
KMT5C for trimethylation (H4K20me3) and KMT5B for both di-/trimethylation (H4K20me2/ 
H4K20me3). In order to analyze, whether KMT5s are dysregulated in subfertile men and immotile 
spermatozoa total sperm RNAs from 21 donors` M, 14 donors` IM and 31 patients` M were 
extracted and reverse transcribed into cDNA. For KMT5A and KMT5B mRNA levels analyzes 
specific qPCR primer sets (Table 3) were designed and used to compare their levels in donors` M 
and IM, and patients` M using RT-qPCR. Figure 38 illustrates the relative and logarithmic KMT5A 
and KMT5B mRNA levels as box plots (green: donors` M, orange: donors` IM, purple: patients` 
M) for the cohorts after normalization to the housekeeping gene β-Actin (Table 3). 
Figure 38: KMT5A and KMT5B mRNA levels in donors` M and IM, and patients` M (left: KMT5A; right: KMT5B; 
log scale 1:1, respectively). KMT5A mRNA levels were significantly increased in donors` IM compared to donors` 
M (p=0.001, n=35) and patients` M (p=0.043, n=45). In patients` M, KMT5A mRNA level were also significantly 
increased compared to donors` M (p=0.017, n=52). KMT5B mRNA levels were significantly decreased in donors` M 
compared to donors` IM (p=0.002, n=34) and patients` M (p=0.025, n=51). KMT5B mRNA level were increased in 
donors` IM compared to patients` M, but without significance (p=0.056, n=45). 
Both KMT5A and KMT5B were significantly lower in donors` M compared to donors` IM 
(p=0.001/0.002, n=35/34, respectively) and patients` M (p=0.017/ 0.025, n=52/51, respectively). 
In Table 12 the exact values for KMT5A and KMT5B mRNA levels of the cohorts are listed. KMT5A 
mRNA levels were 96 % lower in donors` M (0.02±0.34) and 77 % lower in patients` M 
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(0.11±0.36) compared to immotile sperms (0.47±3.00). KMT5B mRNA levels were 88 % lower in 
donors` M (0.02±0.23) and 59 % lower in patients` M (0.07±0.17) compared to immotile sperms 
(0.17±4.80). 
Table 12: Descriptive statistics of relative KMT5A and KMT5B mRNA level. 
Descriptive 
Statistics 
Relative KMT5A mRNA level (n=66) Relative KMT5B mRNA level (n=65) 
Donors M 
(n=21) 
Donors IM 
(n=14) 
Patients M 
(n=31) 
Donors M 
(n=20) 
Donors IM 
(n=14) 
Patients M 
(n=31) 
Average 0.12 1.87 0.25 0.07 2.91 0.12 
Median 0.02 0.47 0.11 0.02 0.17 0.07 
Standard deviation 0.34 3.00 0.36 0.23 4.80 0.17 
Range 0.00-1.57 0.01-9.73 0.00-1.75 0.00-1.06 0.00-14.25 0.00-0.91 
Next, the correlation between gene expression of KMT5s and L1 methylation was examined. No 
significant correlation of KMT5A or KMT5B mRNA to L1 methylation level in patients` M and 
donors` M was found (p=0.617/0.982, r=-0.072/0.003, n=51/50; respectively; Figure 39). Further-
more, no significant correlations between KMT5A and KMT5B mRNA levels with clinical and 
spermiogram data of patients` and donors` M were found. 
 
Figure 39: KMT5A (p=0.617, r=-0.072, n=51) and KMT5B (p=0.982, r=0.003, n=50) mRNA levels were not 
significantly correlated to L1 methylation in patients` M and donors` M. 
For KMT5C mRNA analysis three qPCR primer sets (Table 3) were designed. Figure 40 shows 
agarose gels of the PCR products generated with these qPCR primer sets in motile human sperm 
cells. With none of the designed primers KMT5C mRNA could be analyzed optimally, as only in 
few motile sperm samples (DM09, DM24, DM16, and DM25) the expected product sizes were 
amplified besides larger amounts of other PCR products. However, the primer sets worked well for 
positive controls (LNCaP, DU145 and PC3 cell lines) and showed the expected PCR products. 
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Figure 40: KMT5C mRNA analysis in donors` M and prostate cancer cell lines (LNCaP, PC3, DU145 used as 
positive controls). Three different qPCR primer sets (Table 3) for KMT5C mRNA analysis worked well in positive 
controls and showed the right PCR products (80/70/100 bp). Very weak or wrong product bands were observed in 
seven tested human sperm samples (DM = motile sperms). 
According to the human protein atlas all three KMT5s are expressed in human testis tissue, showing 
higher values for KMT5A and KMT5B, and lowest for KMT5C.111–113 To prove whether KMT5C 
protein, the main mediator of H4K20me3 in somatic cells46, is present in motile spermatozoa, a 
western blot experiment was performed as next. KMT5A and KMT5B proteins were not 
investigated here, as these two histone methyltransferases primarily mediate H4K20me1 and 
H4K20me2, respectively. Figure 41 shows the results of KMT5C protein analysis (ab91224, 52 
kDa, 1:50) in the positive control (HeLa) and in 12 donors` M and 12 donors` IM (50 µg protein 
loaded). KMT5C protein was not detectable in human sperm. 
 
Figure 41: Western blot analysis using KMT5C primary antibody (ab91224, 1:50, expected size 52 kDa) on 12 
donors` M and IM, and HeLa cells (positive control). None or wrong bands were visible in human sperm samples. In 
the positive control the right protein band (52 kDa) was detected besides two other protein bands. 
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To summarize the analysis of the histone methyltransferases of H4K20, both KMT5A and KMT5B 
mRNA levels were detectable in motile and immotile human spermatozoa. Thereby, significantly 
higher KMT5A and KMT5B mRNA levels were found in patients` motile and donors` immotile 
sperm cells compared to donors` motile. However, neither KMT5C-mRNA nor -protein could be 
detected in human spermatozoa. 
3.7 ChIP-qPCR confirming H4K20me3 binding in gene regions evaluated by 
ChIP-sequencing 
Chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) was performed on motile and 
immotile sperm fractions of four healthy donors with H4K20me3 antibody (ab9053) and ChIP-IT 
High Sensitivity Kit (Active Motif, Cat. No. 53040) for intra- and inter-individual comparison of 
H4K20me3 enrichment. Based on recently generated ChIP-sequencing data from our group 
(Ozturk et al., 2019 in preparation), several genome/gene loci associating with H4K20me3 were 
found and, ChIP-qPCR primer sets were designed or taken from literature for some selected regions 
(Table 4). Promoter regions from five genes, namely CXCL8, TNSFS13B, IFNW1, CST8, and L1 
associated regions were analyzed. Two primer sets for L1 analyzes were designed, one covering 
the ORF1 (L1-OFR) and another covering the 5`UTR region (L1-5`UTR). Figure 42 shows 
exemplary for one donor sample (motile and immotile fractions) the ChIP-qPCR products 
amplified with all primer sets used here.  
 
Figure 42: ChIP-qPCR products in motile and immotile sperm fractions of healthy donor number 106, obtained with 
the respective primer sets after ChIP with H4K20me3 antibody (ab9053). Gene names and expected PCR product 
sizes are shown on top. All primer sets amplify the right PCR products in human spermatozoa.  
All ChIP-qPCR primers showed the expected PCR products in motile as well as immotile sperm 
cells. The relative binding of H4K20me3 was calculated using the ChIP-qPCR signals (CTs 
generated with H4K20me3-precipitated DNA and respective input DNAs). Then, relative binding 
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of H4K20me3 (80 % sample) was calculated as enrichments over the input signals (10 % sample; 
Table 13). The remaining 10 % of the samples were taken for a chromatin check. 
Table 13: Relative enrichments of CXCL8, TNSFS13B, IFNW1, CST8, L1-ORF and L1-5`UTR in motile and 
immotile sperm fractions from four healthy men (2^-delta CT).  
Sample ID CXCL8 TNSFS13B IFNW1 CST8 L1-ORF L1-5`UTR 
Donor M 98-H4K20me3 0,00 0,02 0,02 0,02 0,02 0,01 
Donor I 98-H4K20me3 0,23 0,26 0,27 0,26 0,25 0,21 
Donor M 106-H4K20me3 0,03 0,49 0,42 0,43 0,82 0,38 
Donor I 106-H4K20me3 0,55 0,56 0,33 0,40 1,59 0,65 
Donor M 107-H4K20me3 0,01 0,10 0,10 0,18 0,21 0,14 
Donor I 107-H4K20me3 0,12 0,13 0,13 0,13 0,18 0,11 
Donor M 113-H4K20me3 0,00 0,05 0,04 0,06 0,07 0,04 
Donor I 113-H4K20me3 0,05 0,06 0,06 0,07 0,08 0,06 
Figure 43 shows the box plots from ChIP-qPCR analyzes on motile and immotile sperm fractions 
from four healthy donors. Each sample was precipitated with H4K20me3 antibody and qPCRs for 
CXCL8, TNSFS13B, IFNW1, CST8, L1-ORF and L1-5`UTR were done in duplicates. 
 
Figure 43: Relative enrichment of H4K20me3 over the input in CXCL8, TNSFS13B, IFNW1, CST8, L1-ORF and L1-
5`UTR. The DNA of each gene could be found in motile and immotile sperm fractions. Binding of H4K20me3 in      
-CXCL8 promoter was significantly higher among immotile sperms in comparison to motile ones (p=0.021). 
All selected gene regions showed binding to H4K20me3 in varying degrees. Remarkably, 
H4K20me3 was significantly enriched at CXCL8 in immotile sperm fractions compared to the 
motile ones (p=0.021, n=8). For the remaining four genes (TNSFS13B, IFNW1, CST8 and L1) 
H4K20me3 was found at similar levels in motile and immotile sperms (p>0.05). In comparison to 
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L1-5`UTR an increased binding of H4K20me3 in L1-ORF was found in motile as well as in 
immotile sperms. 
Tables 14 and 15 show the average values of H4K20me3 enrichment in five selected genes in 
human sperm samples (motile and immotile fractions). H4K20me3 was in average 24-times more 
enriched at CXCL8 in immotile sperms in comparison to motile sperms. Interestingly, H4K20me3 
was 1.9-times more enriched in L1-ORF than in L1-5’UTR in both motile and immotile sperms. 
Table 14: Average values of H4K20me3 enrichment in motile sperm cells of healthy donors. 
Descriptive Statistics 
H4K20me3 enrichment (ChIP-qPCR) 
Donors M (n=4) 
CXCL8 TNSFS13B IFNW1 CST8 L1-ORF L1-5`UTR 
Average 0.01 0.17 0.15 0.17 0.28 0.14 
Median 0.01 0.08 0.07 0.12 0.14 0.09 
Standard deviation 0.01 0.22 0.19 0.18 0.37 0.17 
Range 0.00-0.03 0.02-0.49 0.02-0.42 0.02-0.43 0.02-0.82 0.01-0.38 
Table 15: Average values of H4K20me3 enrichment in immotile sperm cells of healthy donors. 
Descriptive Statistics 
H4K20me3 enrichment (ChIP-qPCR) 
Donors IM (n=4) 
CXCL8 TNSFS13B IFNW1 CST8 L1-ORF L1-5`UTR 
Average 0.24 0.25 0.20 0.22 0.53 0.26 
Median 0.18 0.20 0.20 0.20 0.22 0.16 
Standard deviation 0.22 0.22 0.12 0.15 0.71 0.27 
Range 0.05-0.55 0.06-0.56 0.06-0.33 0.07-0.40 0.08-1.59 0.06-0.65 
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4. Discussion 
Considering that more than one third of infertile men suffer from idiopathic infertility, more 
investigations are needed to uncover the causes of this type of infertility, so that differential 
diagnosis and potential treatment strategies can be developed. Aberrations in the sperm epigenome 
represent one of the possible causes for idiopathic male factor infertility/subfertility as it was 
frequently documented in literature.31,36,72,114,115 Moreover, the sperm epigenome was found to be 
sensitive to environmental factors, diet and also to systemic diseases like obesity9–11 - factors, 
which are handled as risk factors for male fertility.  
During human spermiogenesis a histone-to-protamine exchange occurs after which around 3 % to 
15 % of the histones still remain.33,34,116 These histones and, respectively, their specific post-
translational modification and genome-wide localization represent one of the main features of the 
sperm epigenome. Genome-wide studies using ChIP-seq revealed that histones stay in genes, which 
have a relevance for spermatogenesis and for development.116–122 Our group and others have 
revealed that, viewed at the genome-wide scale, the majority of sperm histones and nucleosomes 
are located in gene-poor regions and are enriched in repetitive DNA elements like L1 and 
SINEs.34,69 Also, independent studies have shown that epigenetic information in sperm chromatin 
was transferred to next generations and can regulate gene expression there.123–125 
L1 elements are the only active retrotransposons and account for up to 17 % of the human 
genome.57 L1 activity can impair genomic integrity by random insertion and lead to mutations and 
cause diseases like hemophilia A, colon cancer and X-linked Duchenne muscular distrophy.56,126,127 
In somatic cells, L1 is known to be regulated by CpG methylation, transcription factors and specific 
PTHMs, e. g. H4K20me3. The situation in mammalian sperm is still unknown.  
In this thesis, epigenetic factors and regulators of L1 elements, known from studies on somatic 
cells, were investigated in human sperm cells to gain new insights about their suppression 
mechanisms and influences on spermatogenesis. In particular, motile spermatozoa of subfertile 
patients and of healthy fertile donors (healthy controls), as well as immotile spermatozoa from 
healthy donors (available only here) were studied. In addition, PTHMs were analyzed in testicular 
tissue samples from man, mouse and bull. These results should contribute to a better understanding 
of L1 regulation in spermatogenesis and mature sperm and their impact on male fertility. 
 
Discussion 
68 
 
4.1 Spermatozoa of subfertile patients possessed decreased DNMT1 and 
DNMT3A mRNA levels  
The best analyzed epigenetic factor, in sperm, is DNA methylation. Sperm cells have a unique and 
tailored DNA methylation pattern to ensure fertility and a proper embryo development.27,128 
Aberrations in global DNA methylation and imprinting genes are associated with poor sperm 
quality and male infertility.31,77,78,128,129 DNA methylation is regulated by DNMTs, namely 
DNMT1/2/3A/3B or DNMT3L. During all stages of human and mouse spermatogenesis activities 
of DNMT1 and DNMT3A were found. Especially in spermatogonia type A, primary spermatocytes 
and round spermatids high DNMT1/3A expression was measured, while almost no activity was 
found in elongating spermatids.26 In mice, knockout of Dnmt3a leads to decreased spermatogenesis 
through the maturation arrest at spermatogonia stage and mice embryos lacking Dnmt3a die after 
only one month.23,26 Mutations and knockout of Dnmt1 in mice cause global hypomethylation, 
retrotransposons reactivation and embryonic lethality at around day E9.23,27 
Here, DNMT1 and DNMT3A mRNA levels were measured in controls` and patients` motile 
spermatozoa. Both DNMT1 and DNMT3A were significantly decreased in patients` M compared 
to controls` M and showed a significant positive correlation to each other. Lower global sperm 
DNA methylation was demonstrated in idiopathic infertile males, oligozoospermic men and low 
motility sperm samples.21,130,131 Based on these findings and the results obtained here it can be 
presumed, that spermatozoa of subfertile patients are hypomethylated due to reduced DNMT 
levels. The lack of DNMTs in general could impair the progress and efficiency of the 
spermatogenic cycle in subfertile patients, as total sperm concentration and motility of this cohort 
was significantly reduced compared to those of healthy controls. Moreover, decreased DNMT1 and 
DNMT3A mRNA levels could represent one reason for the subfertility of 26 of the 48 patients here, 
as they did not achieve a pregnancy through ART. But, the residual 22 subfertile patients were able 
to achieve a pregnancy despite low DNMT1 and DNMT/3A mRNA levels. These observations 
emphasize the complex nature of molecular reasons of idiopathic male infertility. Another DNMT, 
namely DNMT3L, was shown to assist de novo methyltransferases like DNMT3A and DNMT3B, 
and Dnmt3l knockout mice developed azoospermia and infertility.132,133 Therefore, further studies 
should involve DNMT3L in order to elucidate the role of DNA methylation on fertilizing capacity 
of human sperm. 
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4.2 Global DNA and RNA methylation status in human spermatozoa 
The global DNA methylation in the human germline is strictly organized and occurs in two waves. 
Immediately after fertilization the first wave of active demethylation starts in the paternal 
pronucleus and is followed by passive demethylation of the female genome.27,29 Reaching 
blastocyst stage, DNA methylation patterns become re-established until the second wave of 
demethylation occurs in PGCs. Finally, sex-specific de novo methylation starts to re-establish the 
sperm-/oocyte-specific methylomes.29,30 Aberrant DNA methylation patterns in the sperm 
epigenome can negatively impact transcriptional gene regulation, genomic imprinting and 
embryonic development.11,27,29 Moreover, idiopathic male infertility was associated with aberrant 
DNA methylation of imprinted loci.130 This emphasizes the importance of the precise regulation of 
DNA methylation and demethylation patterns by its enzymes (DNMTs and TET1-3). Here, global 
DNA (5-mC, 5-hmC) and RNA (m6A) methylation levels were analyzed in spermatozoa of 
controls` and patients` motile spermatozoa to see if there are differences between the cohorts and 
if these influence the sperm quality. As L1 methylation was shown to serve as surrogate measure 
for global DNA methylation73,  the methylation level of L1 was also determined here. 
4.2.1 Motile spermatozoa of healthy controls and subfertile patients did not differ in global 
DNA and RNA methylation levels 
Mature human spermatozoa are transcriptionally inactive cells and most of their CpGs are highly 
methylated (90-96%).22,27 Sperm hypermethylation is often observed in regions outside of gene 
promoters, more precisely in intergenic sequences and gene bodies, whereas sperm hypo-
methylation is found at gene promoters, particularly of genes with developmental relevance.31,132 
In mouse and human, 5-hmC is highly abundant in neuronal tissues like the brain or spinal cord 
and ranges from 0.3-0.7 % and is lowest in liver and testis tissue ranging from 0.03-0.06 %.134 
Despite their transcriptional inactive state, mature human sperm cells carry a huge amount of 
RNAs, like mRNAs and non-coding RNAs, which in addition to DNMTs and TET enzymes also 
have the ability to mediate DNA methylation, as already proven in plants.135,136 The most abundant 
RNA modification in eukaryotes is m6A (<80 %), which is involved in microRNA (miRNA) 
biogenesis and mRNA regulation.137,138 In sperm RNA from asthenozoospermic patients, m6A 
content was significantly increased compared to healthy controls and was negatively correlated to 
sperm progressive motility.139  
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Measuring global 5-mC, 5-hmC DNA and m6A RNA methylation levels in motile spermatozoa of 
controls` and patients` no significant differences in 5-mC were found. 5-mC levels ranged from 
0.12 to 10.1 %, whereby the average value in patients` was 3.97 % and in controls` 4.52 %. 5-hmC 
could not be detected in human sperm and m6A was almost identical between the groups (0.02 %).  
Wang et al. evaluated the global 5-mC DNA methylation status in 24 human semen samples, by 
UPLC-MS/MS (ultra-performance liquid chromatography/tandem mass spectrometry)140, which 
ranged from 3.79 % to 4.65 %, highly similar to the results obtained here. It is worth to note, that 
higher methylation (4.25 %) was observed in semen samples, where abnormal and dead sperm cells 
were removed by density gradient centrifugation. This reflects the findings obtained here, that 5-
mC level in motile spermatozoa of healthy controls and subfertile patients, both purified with the 
swim-up technique, were ranging from 3.97-4.52 %. Guz et al. showed additionally that 5-mC 
DNA methylation levels in Percoll gradient purified spermatozoa of 91 men, measured by UPLC-
MS/MS, range around 3.82 % ± 0.08 % and 5-hmC level are ranging around 0.80 % ± 0.17 %.141 
However, Jenkins et al. reported that 5-hmC DNA methylation levels in 30 human spermatozoa 
samples range from 0.00 % to 0.03 %,142 which is comparable to the findings here. In that study 
the same ELISA kit was used for 5-hmC quantification as here, but the used DNA was higher 
concentrated and originated not only from motile but also from immotile sperm cells. The different 
sperm cell populations and higher amount of utilized DNA might be the reasons, why Jenkins et 
al. were able to measure at least 0.03 % 5-hmC in contrast to here (0.00 %).  
To conclude, the results for global methylation in motile human spermatozoa obtained here are 
comparable to values reported in previous studies. 5-hmC methylation was not detectable here, 
apparently due to the low abundance of this DNA base in mature motile human spermatozoa and 
may be due to its detection limit using ELISA. No differences in global m6A RNA methylation 
level in the cohorts were analyzed here. This may be due to the fact that small differences between 
m6a RNA methylation levels in human sperm are not quantifiable by ELISA. Mass spectrometry 
could reveal such differences. The analysis of alternative RNA forms, like miRNAs and mRNAs, 
in mature human spermatozoa could be even more insightful. For example, in mice the injection 
of sperm-derived small non-coding RNAs into zygotes led a transmission of paternally acquired 
phenotypes to the offspring.143 Also the analysis of m6A regulators in human sperm could be very 
insightful, as knockout of Mettl3 (a catalysator of m6A formation), Alkbh5 (an m6A eraser) and 
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Ythdc1 (an m6A reader), inhibited the spermatogenesis and, moreover, led to male infertility and 
also blocked oocyte development in mice.144–146 
4.2.2 Lowest L1 methylation was detectable in motile spermatozoa of subfertile patients 
using ELISA and L1 mRNA was highest in immotile spermatozoa of healthy controls 
DNA hypermethylation of L1 promoters was shown to be one suppression mechanism of L1 
retrotransposition in somatic tissues.74,147,148 In this thesis,  L1 methylation levels were determined 
in healthy controls` and patients` motile spermatozoa as well as in immotile sperm of healthy 
controls using two methods, pyrosequencing and ELISA.  
Using pyrosequencing, no significant differences in L1 methylation were found in the cohorts. L1 
methylation levels in patients` and controls` motile spermatozoa were ranging from 51.1 % to 
50.5 %, respectively. Immotile spermatozoa of controls` showed L1 methylation levels around 
50.3 %. The use of ELISA technique (5-mC antibody against gDNA of interest, hybridized to a 
biotinylated L1 consensus probe) for L1 methylation analysis revealed highly significant 
differences between the cohorts, showing highest values in immotile spermatozoa of controls` 
(58.1 %) and lower values in patients` and controls` motile spermatozoa (47.2 % and 52.3 %, 
respectively).  
The difference to pyrosequencing is the detection and analysis of 12 CpG sites (instead of 3 CpGs 
in pyrosequencing) and analysis of another L1 genomic region. Notably, L1 methylation levels in 
controls` motile and immotile spermatozoa were significantly increased compared to patients` 
motile spermatozoa. Moreover, analyzing the patient subgroup showing a positive pregnancy after 
ICSI, a significant correlation of L1 methylation and fertilization rates was revealed. This suggests, 
that high L1 methylation and, respectively, L1 suppression in sperm favors the proper fertilization 
and leads to embryo development and pregnancy. In contrast, in the patient subgroup showing a 
negative pregnancy, the correlation of fertilization rates and L1 methylation was reversed and not 
significant, which implies that L1 methylation needs to be strictly regulated to ensure fertilization. 
Furthermore, this fact could indicate that L1 activation in spermatogenesis leads to substandard 
sperm, due to its hypomethylation, and thus to failures in developmental program. 
Various studies analyzed global sperm DNA methylation patterns, but found no differences in the 
methylation of L1 between fertile and infertile patients.31,78,149 However, Heyn et al. reported that 
L1 elements were hypomethylated in infertile patients,150 and Pacheco et al. showed that most 
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CpGs (80 %) in low motility human sperm samples were also hypomethylated.131 Furthermore, 
Hajj et al. demonstrated, that methylation of repetitive elements was significantly lower in sperm 
of infertile males compared to controls.151 In accordance with these reports, significantly decreased 
L1 methylation levels were found here in motile spermatozoa of subfertile patients.  
L1 activation was shown in different tissues and diseases to cause mutations, genomic instability 
and cancer.60,62,67 In order to see whether L1 mRNA levels in sperm differ between the cohorts and 
between the motile and immotile sperm, and if L1 mRNA is correlated to L1 methylation, RT-
qPCR was performed here using a published primer set from Muñoz-Lopez et al.65 (Table 3). 
Highest L1 mRNA levels were found in immotile spermatozoa of controls and motile spermatozoa 
of patients, which were both significantly increased in comparison to controls` motile spermatozoa. 
A correlation analysis between L1-methylation and -mRNA in motile human spermatozoa showed, 
that these are significantly negative correlated. This indicates that L1 hypermethylation is 
associated with L1 inactivation in mature human spermatozoa and herewith confirms observations 
made in somatic cells.61,74,105  
In terms of male germ cells and embryogenesis, Cheng et al. detected significantly increased L1 
transcripts in patients with hypospermatogenesis.152 He et al. studied L1-methylation and -mRNA 
levels in human placentas from different gestational ages and found a significant decrease of L1 
methylation and increase of L1 mRNA levels in third trimester placentas, showing evidence for a 
strict L1 regulation.74 Belancio et al. analyzed somatic expression patterns of L1 in human tissues 
and found the highest L1 expression in the testis and lower in the prostate.64 However, no  
significant correlations to clinical or semen parameters like age, sperm concentration, fertilization 
rate, pregnancy outcome, progressive and total motility were found for patients` as well as controls` 
motile spermatozoa.  
In spermatogonia P-element-induced wimpy testis (Piwi) proteins were reported to repress L1 
elements, whereby mutations in Piwi-interacting RNA (piRNA) pathways in mice were shown to 
induce L1 retrotransposition and result in defective sperm.153,154 In human cryptorchidism, 
characterized by the absence of one or both testicles from the scrotum, impaired expression of Piwi 
pathway genes, like PIWIL2 and PIWIL4, was related to derepression of L1 retrotransposons.155 
Moreover, in infertile men, suffering from spermatogenic failure and Sertoli cell-only syndrome, 
inactivation of PIWIL2 and its processing factor TDRD1 was associated with hypomethylation of 
L1 elements and reduced spermatogenesis.150  
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Possibly, in the subfertile patients` cohort analyzed in this thesis, Piwi pathways were dysregulated, 
which could explain the decreased L1-methylation and increased L1-mRNA levels measured here 
in comparison to healthy controls` motile spermatozoa. Recently, Giebler et al. have shown, that 
PIWIL1 and PIWIL2 mRNA expression can be measured in ejaculated spermatozoa of men and, 
that expression levels of these two genes were negatively associated with sperm count and 
progressive motility.156 The measurement of PIWIL1 and PIWIL2 mRNA levels in subfertile 
patients` spermatozoa could provide information, if these genes were correlated with L1 expression 
in mature spermatozoa and contribute to male fertility and pregnancy outcome after ART. 
Taken together all these findings suggest, that L1 methylation is a critical factor for male fertility 
and can possibly be used as diagnostic marker. Future studies should consider L1 methylation in 
subfertile patients, as this could provide information about their fertilization rates by using ARTs. 
Moreover, L1 dysregulation was traceable here in sperm of subfertile men and in immotile sperm 
of healthy controls, although it remains unclear how and why L1 became dysregulated. This 
implies, that L1 regulation is an important factor in spermatogenesis, and to shed more light on this 
issue, some selected L1 regulators known from somatic cells were analyzed in the current work, 
and these results are discussed below. 
4.3 SIRT6 was hypermethylated in motile spermatozoa of subfertile patients 
SIRT6 was shown to package L1 elements into transcriptionally repressive heterochromatin in 
human dermal fibroblasts (HDF) but fails with stress and age.89 SIRT6 modulation in mice 
dramatically influences aging and DNA repair processes.90,91 Moreover, SIRT6 protein was 
detectable in the mouse nucleus of transitional spermatids and in the acrosome of mature 
spermatozoa, which implies a role for SIRT6 in spermiogenesis, the final step of spermato-
genesis.157  
SIRT6 promoter methylation increases with age in human lymphocytes and SIRT6 mRNA levels 
in the brain of pigs decrease with age.91,158 These findings indicate, that SIRT6 is epigenetically 
regulated by methylation. In this work, SIRT6 promoter methylation, mRNA and protein levels in 
spermatozoa of healthy controls and subfertile patients were analyzed, to determine, whether 
SIRT6 is differentially regulated in these and possibly associated with L1 regulation. 
Significantly elevated SIRT6 methylation was observed in patients` motile spermatozoa compared 
to controls` motile and immotile spermatozoa. No significant correlations between SIRT6 
methylation, L1-methylation or -mRNA were found in the cohorts investigated here.  
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In sperm SIRT6 methylation was not affected by age, which contradicts literature observations, but 
can be explained by the different cell types (human lymphocytes and human dermal fibroblasts), 
which were analyzed there.89,91 SIRT6 hypermethylation found in sperm of subfertile patients could 
indicate that lower amounts of SIRT6 mRNA and protein are present and thus packaging of L1 into 
its silent heterochromatin state is decreased.  
Using three different qPCR primer sets from literature99–101 with proven functionality in positive 
controls SIRT6 mRNA was analyzed in the cohorts. However, in none of the sperm samples SIRT6 
mRNA could be detected. Also, SIRT6 protein levels could not be detected in mature spermatozoa 
of healthy controls. However, two antibodies used here showed also poor performances in Western 
blot (ab176345 and ab62739, Abcam). According to the human protein atlas SIRT6 is highly 
present in human testis.92 The antibody used there (HPA071776, Sigma) or mass spectrometric 
analyzes could further help to reveal if SIRT6 protein is abundant in human spermatozoa and 
regulates L1.  
4.4 Increased MORC2 mRNA levels in motile spermatozoa of healthy controls 
MORC2 is widely expressed in human tissues, showing highest abundance in brain, placenta and 
testis.159 Mutations of MORC2 are known to cause diseases, like spinal muscular atrophy and the 
Charcot-Marie-Tooth disease.160,161 In euchromatic environment, MORC2 together with the 
HUSH-complex was shown to bind and repress full-length L1 elements, whereby single or double 
knockout of MORC2 and/or HUSH-complex in human chronic myeloid leukemia cells (K562) led 
to an upregulated expression of L1s.93  
Here, MORC2 mRNA levels were analyzed in spermatozoa of healthy controls and subfertile 
patients to see if MORC2 mRNA levels were connected to L1 regulation in human spermatozoa 
and possibly influence sperm quality. Relative MORC2 mRNA level were detectable in 20/46 
(43.5 %) patients` motile spermatozoa, 28/32 (87.5 %) controls` motile and 4/24 (16.7 %) controls` 
immotile spermatozoa. Especially in motile spermatozoa of controls MORC2 mRNA was enriched. 
Thereby it was striking, that in most immotile sperm samples of controls and motile sperm samples 
of patients no MORC2 mRNA was present.  
On the one hand, MORC2 might only repress L1 elements in euchromatic environment, as shown 
in hESC and K562 cells,93 and not in heterochromatic environment, as in mature human 
spermatozoa. On the other hand, MORC2 regulation might be disturbed in controls` immotile and 
patients` motile spermatozoa, as all measured values in this two cohorts were close to zero.  
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In addition, no correlations of MORC2 expression to L1-mRNA, -methylation and clinical or 
semen parameters like age, sperm concentration, fertilization rate, pregnancy outcome, progressive 
and total motility were found in patients` as well as controls` spermatozoa. 
In mice two paralogues of Morc2 are present, namely Morc2a and Morc2b. Particular Morc2b was 
found to be essential for meiotic progression and fertility in both sexes.162 By extending the control 
and patient cohorts here and using alternative analytical methods (e.g. Western blot and IHC), 
MORC2 protein could be investigated in human spermatozoa and testis tissue. In addition, 
exploring the roles of HUSH complex subunits MPP8 and TASOR in mature human spermatozoa 
could be helpful, as these mediate L1 repression in euchromatic environment together with 
MORC2.93  
4.5 No YY1 expression in male germ cells 
Human L1 elements were shown to possess a YY1 binding site at their 5`UTR and this site is 
required for accurate human L1 transcription initiation.60,88 YY1 expression was examined in 
embryos and adult testes of mice and was found in Sertoli cells of 14.5 days old embryos and 
spermatogonia, spermatocytes and spermatids of 12-week-old adult mice.163 Loss of YY1 in mouse 
spermatocytes was shown to induce global heterochromatin instability and DNA double-strand 
breaks.164 
Here, YY1 expression was analyzed by IHC in healthy human testis tissues exhibiting normal 
spermatogenesis, obtained for TESE, to see if YY1 is expressed in human spermatogonial cells and 
potentially influences L1 regulation in mature spermatozoa. YY1 expression was exclusively found 
in Sertoli cells and not in any male germ cell of the seminiferous epithelial cycle.  
As mentioned above, YY1 expression was identified in embryos and adult testes of mice.163 Using 
IHC, YY1 expression was analyzed in 14.5 days old embryos and found in the nuclei of 86 % of 
Sertoli cells and in 38 % of gonocytes. In adult mouse testis, YY1 expression was found in Sertoli 
cells, spermatogonia, spermatocytes and spermatids but not in spermatozoa. Knockouts of YY1 in 
mice greatly slow down embryonic development and lead to its death around peri-implantation 
phase.165 These findings agree with the results obtained here from human testis, that YY1 was 
strongly expressed in Sertoli cells and not in mature spermatozoa using the same method, antibody 
(ab109237) and antibody dilution (1:200). This shows that IHC was a good method to analyze YY1 
expression in human testis tissue and that its appearance is specific to Sertoli cells.  
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The role of YY1 in human Sertoli cells and its influence on male fertility and embryo development 
should be further investigated. Since Sertoli cells provide sperm cells with nutrients during 
spermatogenesis, YY1 expression in these could ensure repression of L1 elements throughout 
spermatogenesis. Moreover, analysis of other transcription factors located on human L1 5`UTR, 
like RUN3 and SOX could be interesting, as studies in human cell lines showed, that these factors 
are also implicated in L1 repression.60,86,88 Thus, these transcription factors could also have 
important roles for L1 regulation during human spermatogenesis and potentially influence male 
fertility.  
4.6 H4K20me2 and H4K20me3 were present during human, bull and mouse 
spermatogenesis and in mature human spermatozoa, besides KMT5A and 
KMT5B, histone methyltransferases of H4K20  
Our group and Carone et al. have previously shown that after histone-to-protamine exchange 
certain histones and nucleosomes, respectively, are retained in repetitive DNA elements, like L1 
and SINEs and are potentially implicated in embryonic developmental processes.34,69 H4K20me2 
and H4K20me3 are two PTHMs, which are highly abundant in human spermatozoa (80.9 % and 
9.8 %) on the H4 tail peptide encompassing aa 20-23.42 H4K20me3 is a known repressor of L1 
elements in somatic cells and H4K20me2 plays distinct roles for DNA damage repair 
signaling.47,48,79 The exact establishment of H4K20 methylation states by methyltransferases 
KMT5A, KMT5B and KMT5C, and their erasure mechanisms are not fully understood. Studies 
focusing on the regulation of H4K20me2 and H4K20me3 retention patterns and their specific 
localization in mature spermatozoa were needed to understand their biological relevance for male 
fertility and embryonic development.  
Therefore, H4K20me2 and H4K20me3 expression patterns were analyzed in the current study in 
healthy human testis tissue obtained for TESE, wildtype mouse and healthy bull testis tissue all 
exhibiting normal spermatogenesis. First, with IHC a general overview of their expression patterns 
was obtained. Second, protein abundances of H4K20me2 and H4K20me3 in mature motile and 
immotile human spermatozoa were analyzed by ICC and third, protein quantities of these PTHMs 
were determined by western blot for inter- and intra-individual retention pattern analysis. Further, 
recently identified genes/gene loci by our group to be enriched with H4K20me3 in human 
spermatozoa through ChIP-sequencing (Ozturk et al., 2019 in preparation), were analyzed by 
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ChIP-qPCR in four sperm samples of healthy volunteers (motile and immotile fractions) to prove 
their interactions to verify ChIP-sequencing results. Finally, mRNA levels of the respective histone 
methyltransferases (HMTs) of H4K20 (KMT5A, KMT5B and KMT5C) were analyzed in the 
cohorts by RT-qPCR.  
4.6.1 H4K20me2 and H4K20me3 were present during human, bull and mouse spermato-
genesis and were retained in mature human spermatozoa 
In human, mouse and bull testis tissues H4K20me2 expression was at highest detectable in 
spermatogonia and, in round and elongating spermatids and weaker in primary spermatocytes. The 
expression patterns of H4K20me3 were similar to those of H4K20me2 in human, mouse and bull 
testis tissues, but showed its highest levels in round spermatids and elongating spermatids, 
confirming previous results achieved with LC/MS-MS (Luense et al., 2016)42. Neither H4K20me2 
nor H4K20me3 were detectable in human pachytene spermatocytes, but that of mouse and bull. 
Using ICC, H4K20me2 and H4K20me3 presence was proven in mature human spermatozoa, 
whereby higher staining intensities for H4K20me3 were obtained.  
The expression patterns of this two PTHM allow interpretations for their functions in 
spermatogenetic processes. Since H4K20me2 plays different roles in the open and active chromatin 
regions for signaling DNA damage repair and DNA replication, its presence during 
spermatogenesis can be assumed in highly replicative stages in euchromatic environment. This was 
proven here by the fact that H4K20me2 was most abundant in spermatogonia and decreasingly in 
spermatocytes.46,79 In round and elongating spermatids, cell division no longer occurs but DNA 
damage can still arise during cell differentiation. That is why a decreasing H4K20me2 expression 
can be assumed and was found here in three different mammalian species. H4K20me3 is a hallmark 
of constitutive heterochromatin and is associated with transcriptional inactivation.43–45 High 
expression of H4K20me3 was found in late spermatogenetic phases, where cell divisions have 
stopped and chromatin gets condensed in its heterochromatic state. Indeed, highest H4K20me3 
expression was found in round spermatids and elongating spermatids and further its retention was 
proven in mature spermatozoa by ICC. These results were in accordance with investigations in 
mouse spermatogenesis, where H4K20me3 was the PTHM which showed the highest enrichment 
in the transition from round spermatids to elongating spermatids.42  
To summarize, the localization of H4K20me2 and H4K20me3 here can be interpreted conclusively 
with respect to their literature properties in three mammalian species. Further localization and 
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interactions studies with other proteins, for instance involved in DNA damage repair (e. g. 53BPI) 
or heterochromatin formation (H3K9me3), are necessary to support the assumed roles of these 
PTHMs here.  
4.6.2 H4K20me3 was highly abundant in mature spermatozoa and was localized in L1 
elements 
Levels of H4K20me2 and H4K20me3 were analyzed by western blot (WB) in healthy controls` 
motile and immotile spermatozoa. Western blot in controls` motile spermatozoa showed that 
H4K20me2 protein levels (Signal intensities: 0.05-0.23) were much lower than those of 
H4K20me3 (Signal intensities: 1.16-2.05). In 80 % of the cases (16/20) H4K20me3 was 1.1-7.7-
times enriched in the immotile sperm fraction of controls in comparison to their motile fraction, 
suggesting a disturbed retention mechanism of H4K20me3 in immotile spermatozoa. The use of 
another H4K20me2 specific antibody should verify if H4K20me2 levels are indeed lower than 
H4K20me3, as Luense et al. revealed, by analyzing eight normozoospermic human semen samples 
using Nano-LC-MS/MS, that H4K20me2 levels were around times higher than H4K20me3.42  
The differences in histone retention patterns obtained here compared to those described in literature 
can be explained by different methods used and by analysis of differently composed samples. In 
the current work, motile and immotile sperm cells of normozoospermic healthy controls, fulfilling 
the WHO criteria, were separated by the swim-up technique prior western blot analysis. In the 
study of Luense et al., semen samples also fulfilled the WHO criteria, but no swim-up was 
performed, so that a mixture of motile and immotile sperm cells was examined.42 
A study in 2018 of 31 sperm samples from men with abnormal and normal sperm parameters 
showed striking differences in the abundance of H4K20 and H3K9 methylation states.40 Especially 
asthenoteratozoospermic samples (abnormal motility, forward progression and morphology) show 
a significant increase in H4K20me1, H3K9me1 and decrease in H4K20me2, H3K9me2/me3 
methylation. Moreover, H3K9me3 and H4K20me3 are postulated to be transmitted by the 
spermatozoon into the zygote and regulate constitutive heterochromatin formation there.124  
Our group identified through an MNase followed by genome-wide ChIP-sequencing (Ozturk et al., 
2019 in preparation) the distribution pattern of H4K20me3 in fertile human sperm. Evaluated 
H4K20me3 binding sites were analyzed and confirmed in the current work by ChIP-qPCR in four 
human sperm samples (motile and immotile sperm fractions). H4K20me3 was found at CXCL8, 
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TNSFS13B, IFNW1, CST8 and L1 associated regions in mature spermatozoa of healthy controls. 
Two primer sets for L1 analyzes were designed, one covering the ORF1 (L1-OFR) and another 
covering the 5`UTR region (L1-5`UTR). In comparison to L1-5`UTR an increased binding of 
H4K20me3 in motile as well as in immotile sperms was found in L1-ORF. This can be explained 
by the higher proportion of truncated L1 elements in the human genome than of full-length L1 
elements.57  
Other studies have already shown that H4K20me3 is associated with L1 elements in different cells 
and tumor tissues, like CRCs (colorectal cancer cells), ES (embryonic stem cells), proliferating and 
senescent human cells.81,166,167 Here, for the first time an association between L1 elements and 
H4K20me3 could be proven in human spermatozoa through two methods, ChIP-sequencing and 
ChIP-qPCR. These results suggest that H4K20me3 is involved in L1 element regulation in human 
sperm cells. As a negative control, a ChIP-qPCR primer set covering a gene region known to be 
not associated with H4K20me3, was not included here, results should be considered with caution. 
But since normalization was performed on the respective sample inputs and the H4K20me3-
antibody (ab9053, abcam), used in both ChIP experiments, was already validated during ChIP- 
sequencing, it can be assumed that specific results were obtained with ChIP-qPCR. 
To sum up, H4K20me2 and H4K20me3 were retained in human spermatozoa after protamine ex-
change. Five gene loci recently identified by our group through ChIP-sequencing (Ozturk et al., 
2019 in preparation), were also found in ChIP-qPCR to be associated with H4K20me3 in human 
sperm. This proves the reliability of the ChIP-sequencing and -qPCR results. Moreover, a connec-
tion between L1 elements and H4K20me3 could be proven here in mature spermatozoa using ChIP 
methods. Future research should focus more in detail on the genes identified here to be associated 
with H4K20me3, a repressive heterochromatin marker. With respect to male fertility the biological 
relevance of these genes should be analyzed, especially the one of the CXCL8, which showed sig-
nificantly higher H4K20me3 binding among immotile sperms in comparison to motile ones. 
4.6.5 KMT5A and KMT5B were present in human spermatozoa, but not KMT5C 
In mammalian cells, KMT5A, KMT5B and KMT5C are histone methyltransferases (HMTs) 
responsible for the cell cycle dependent mono-/di- and tri-methylation of H4K20, repectively.46 
KMT5B can generate both H4K20me2 and H4K20me3, with a higher preference for H4K20me1 
as substrate.51  
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In mice, knockout of Kmt5a is associated with mitotic defects and inhibits chromatin 
condensation.47,168 Double knockout of Kmt5b/Kmt5c leads to an almost complete removal of 
H4K20me2 and H4K20me3 in mice and induces growth retardation and perinatal death.85,168 
Studies of H4K20 HMTs in human sperm and their possible influences on male fertility and 
embryonic development are missing. Therefore, KMT5A, KMT5B and KMT5C mRNA levels were 
analyzed in spermatozoa of healthy controls and subfertile patients to see if these are present and 
possibly connected to above analyzed factors in human spermatozoa. 
Controls` immotile and patients` motile spermatozoa showed a significant increase of KMT5A and 
KMT5B mRNA levels in comparison to controls` motile spermatozoa. Interestingly, significantly 
increased H4K20me3 protein levels were also detected in controls` immotile spermatozoa 
(patients` immotile were not available for WB studies). No significant correlation of KMT5A and 
KMT5B expressions to L1 methylation or clinical and spermiogram parameters of patients` and 
controls` motile spermatozoa were found. KMT5C mRNA and protein levels were not detectable 
in mature human spermatozoa samples evaluated here. Thus, KMT5A and KMT5B seem to be the 
key players in the establishment of H4K20 methylation states in human sperm and should be 
investigated in future studies. As KMT5B mediates tri-methylation of H4K20 besides di-
methylation, this HMT might establish these two states in a cell cycle specific manner in human 
spermatozoa, as already postulated by Jørgensen et al. in proliferating cells.46 
Aberrant histone retention in sperm of infertile men, showing decreased semen parameters, 
asthenoteratozoospermic patients and sperm used for ARTs were reported.36,40,169 In mouse 
embryos, combined or single knockout of Kmt5b and Kmt5c led to the loss of H4K20me2 and 
H4K20me3 and resulted in genomic instability, developmental arrest and perinatal death.47,85 In 
the current work, spermatozoa of patients` motile and controls` immotile showed both decreased 
semen parameters as well as increased HMT levels (KMT5A and KMT5B) compared to motile 
controls. Additionally, increased H4K20me3 protein levels were found in controls` immotile 
spermatozoa. All these observations provide a strong indication, that histone retention mechanisms 
were disturbed in immotile sperms as well as in motile sperm of subfertile men. To understand the 
exact roles of the HMTs identified here in human spermatozoa, functional studies are required. 
Possibly, with the results of such studies, male sub- and infertility treatments can be improved. 
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5. Limitations 
Several potential limitations of this thesis should be taken into account. Patients` spermatozoa were 
limited by their availability and their sperm concentration, so experiments were first established in 
controls` spermatozoa to save material for many examinations. Further studies on a larger patient 
and control cohort, ideally with high sperm concentrations, would be helpful to strengthen the 
results obtained here.  
Mature human spermatozoa are transcriptionally inactive cells, but still carry e. g. mRNAs, which 
were regarded as remnants of spermatogenesis.22,170 So, mRNA studies could provide evidences of 
transcriptional levels of selected genes during mammalian spermatogenesis. Since the functions of 
RNAs in mature spermatozoa are still not clear, the results obtained here about mRNA levels by 
RT-qPCR should be considered with caution. To ensure that only mRNAs were measured in this 
study and no gDNA contaminations were present, which could have led to misinterpretations of 
the results, all RNA samples were treated with DNase I prior cDNA synthesis and RT-qPCR. In 
addition, during PCR primer design, care was taken to design exon-spanning primers. 
A further limitation in this thesis was, that the global DNA methylation state in human spermatozoa 
was examined by selected CpG island regions (determined by commercially available ELISA kits 
and Pyrosequencing sets), which represent only a small subset of all CpG sites. Genome-wide DNA 
methylation studies, like the ones of Pacheco et al.131, Hajj et al.151 and Sujit et al.171, could expand 
the results achieved here. 
Studies on L1 transcription factors and other regulators are limited to methylation, mRNA and/or 
protein analyzes in mature spermatozoa and testis tissues. As cell lines representing male germ 
cells are not available, further functional insights could be obtained from studies on stem cell or 
cancer cell cultures. So, the exact function of these factors in human spermatozoa remain unknown 
and need to be further investigated. 
Protein extraction from controls` immotile and patients` motile spermatozoa worked better and 
gave more yield in comparison to the compact motile spermatozoa of the controls. Hence, protein 
extractions from controls` motile spermatozoa might not be sufficient to reflect their whole protein 
pattern. To always compare same protein amounts of different samples, protein concentrations 
were previously adjusted by nanodrop measurements. In addition, obtained Western blot signals 
were normalized to the total protein content transferred onto the membranes.   
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6. Summary 
Previously we have shown in human sperm, that the majority of retained nucleosomes are enriched 
in repetitive DNA elements like L1 and SINEs. L1 is the only active retrotransposon and occupies 
about 17 % of the human genome. L1 activity can induce mutagenesis, genomic instability and 
tumor progression. Mechanisms specifically targeting L1 suppression in spermatozoa are still 
unknown. In somatic cells, L1 is known to be regulated by CpG methylation and, respectively 
DNA methyltransferases (DNMT1 and DNMT3A), specific transcription factors (YY1, SIRT6 and 
MORC2) and selected histone marks, predominantly H4K20me3. Recently, our group identified 
by genome-wide ChIP-sequencing, that H4K20me3 is highly enriched in L1 elements of human 
spermatozoa (Ozturk et al., 2019 in preparation). H4K20me3 together with H4K20me2 were 
shown to be the most abundant histone modifications in human spermatozoa (80.9 %, 9.8 %; 
respectively), whereby H4K20me3 was the one, which had the highest enrichment in transition 
from round to elongating spermatids. H4K20 methylation is mediated by specific histone 
methyltransferases, namely KMT5A, KMT5B and KMT5C.  
The aim of this thesis was to gain insights about the epigenetic regulation of L1 in spermatozoa 
and to reveal its impact on male subfertility. Therefore, the methylation and mRNA of L1 were 
analyzed in spermatozoa of fertile men and compared to those in subfertile patients, who underwent 
ART with their female partners. As female partners were inconspicuous, a male factor infertility/ 
subfertility was presumed. Moreover, based on insights from studies on somatic cells, known 
epigenetic modifiers and regulators of L1 were also analyzed in both groups. In order to have a cell 
model for inappropriate spermatogenesis and defective sperm, respectively, immotile spermatozoa 
obtained from semen of healthy donors were also included in this study (immotile sperm fraction 
was not available from patients). A description of the study design and main results are presented 
below:   
Ejaculates from 97 healthy donors (motile and immotile sperm fractions), fulfilling normal sperm 
parameters according to WHO and 48 subfertile patients (motile sperm fraction), who underwent 
an ART, like ICSI or IVF, were collected and analyzed separately.  
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➢ Spermatozoa of subfertile patients possessed significantly decreased DNMT1 and DNMT3A 
mRNA levels in comparison to healthy donors; 
➢ Global DNA and RNA methylation levels did not differ in motile spermatozoa of healthy 
donors and subfertile patients; 
➢ Significantly decreased L1 methylation was detectable in motile spermatozoa of subfertile 
patients in comparison to healthy donors` motile and immotile spermatozoa. Among patients` 
and donors` motile spermatozoa, L1-mRNA and -methylation were significantly negative 
correlated. Moreover, in the patient subgroup showing a positive pregnancy after ICSI, a 
significant correlation of L1 methylation and fertilization rate was revealed. Interestingly, 
immotile spermatozoa of healthy donors possessed significantly increased L1 mRNA levels; 
➢ SIRT6, a transcription factor which was shown to be epigenetically downregulated in aging 
human dermal fibroblasts was observed in human sperm cells. SIRT6 promotor hyper-
methylation was found in spermatozoa of subfertile patients. In sperm cells SIRT6 methylation 
was not affected by age. Another L1 transcription factor, MORC2, was found at lowest at 
mRNA level in immotile spermatozoa of healthy donors. In contrast, the L1 transcription factor 
YY1 was exclusively found in human Sertoli cells, but not in male germ cells; 
➢ Repressors of L1, H4K20me2 and H4K20me3, were found to be ubiquitously expressed in 
human, mouse and bull testis tissues, whereby H4K20me2 signals were more intense in earlier 
spermatogenetic stages (spermatogonia/spermatocytes) and H4K20me3 in later stages (round/ 
elongating spermatids). In mature spermatozoa of healthy donors, H4K20me2 and H4K20me3 
were retained in both motile and immotile ones. Comparison of H4K20me3 signals revealed 
their higher abundance in immotile spermatozoa. Genome-wide H4K20me3 binding sites, 
recently revealed by ChIP-sequencing in motile human spermatozoa, could be confirmed here 
for some selected genes (L1, CXCL8, TNSFS13B, IFNW1 and CST8);  
➢ The mRNAs of H4K20 methyltransferases, KMT5A and KMT5B, were found in motile and 
immotile human spermatozoa. In contrast, KMT5C-mRNA and -protein were undetectable in 
human spermatozoa. 
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This is one of the pioneer studies aiming to understand the epigenetic regulation of 
retrotransposable elements in human spermatogenesis and mature sperm cells, and to clarify if this 
impacts the capacity of sperm and the male fertility. It was obvious that motile and immotile 
spermatozoa from healthy men have huge differences in terms of L1 methylation and L1 mRNA 
levels, but also in terms of L1 regulation. Interestingly, motile spermatozoa from subfertile patients 
showed for some factors tendencies towards immotile sperms of healthy men. Moreover, a 
significant negative correlation of L1 mRNA and L1 methylation found among all motile 
spermatozoa, and the significant positive correlation of L1 methylation with fertilization rates after 
ART emphasizes the impact of a proper L1 regulation in male fertility issues.  
Future work is required to investigate the exact regulation mechanisms of retrotransposons in 
human spermatogenesis, address the impact of L1 dysregulation for sperm quality and post-
fertilization events, and clarify how these all could help in praxis and benefit men with idiopathic 
infertility.  
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7. Zusammenfassung 
Zuvor haben wir im menschlichen Spermium gezeigt, dass die Mehrheit der verbleibenden Nukleo-
somen an repetitiven DNA-Elementen wie L1 und SINEs angereicht ist. L1 ist das einzig aktive 
Retrotransposon und nimmt etwa 17 % des menschlichen Genoms ein. L1-Aktivitäten können zur 
Mutagenese, genomischen Instabilität und Tumorprogression beitragen. Mechanismen, die speziell 
auf die L1-Suppression bei Spermien abzielen, sind noch unbekannt. In somatischen Zellen ist 
bekannt, dass L1 durch CpG-Methylierung und jeweils durch DNA Methyltranferasen (DNMT1 
und DNMT3A), spezifische Transkriptionsfaktoren (YY1, SIRT6, MORC2) und bestimmte 
Histonmarkierungen, insbesondere H4K20me3 reguliert wird. Vor kurzem hat unsere Gruppe 
durch genomweite ChIP-Sequenzierung identifiziert, dass H4K20me3 in L1-Elementen von 
menschlichen Spermien hoch angereichert vorliegt. (Ozturk et al., 2019 in Vorbereitung). 
H4K20me3 zusammen mit H4K20me2 sind die am häufigsten vorkommenden 
Histonmodifikationen in menschlichen Spermien (80.9 %, 9.8 %; jeweils), wobei H4K20me3 
diejenige war, welche die höchste Anreicherung im Übergang von runden zu elongierenden 
Spermien aufwies. Die H4K20-Methylierung wird durch spezifische Histonmethyltransferasen 
vermittelt, nämlich KMT5A, KMT5B und KMT5C.  
Das Ziel dieser Arbeit war es, Erkenntnisse über die epigenetische Regulation von L1 in Spermien 
zu gewinnen und dessen Auswirkungen auf die männliche Subfertilität aufzuzeigen. Daher wurden 
die Methylierung und mRNA von L1 in Spermien von fertilen Männern (gesunde Spender) 
analysiert und mit denen von subfertilen Patienten verglichen, die mit ihren weiblichen Partnern 
eine ART durchgeführt haben. Da die weiblichen Partner unauffällig waren, wurde von einem 
männlicher Faktor Unfruchtbarkeit/Subfertilität angenommen. Darüber hinaus wurden auf der 
Grundlage von Erkenntnissen aus Studien in somatischen Zellen in beiden Kohorten auch bekannte 
epigenetische Modifikatoren und Regulatoren von L1 analysiert. Um ein Zellmodell für eine 
unzureichende Spermatogenese bzw. defektes Sperma zu haben, wurden auch immotile Spermien 
aus Samen gesunder Spender in diese Studie einbezogen (immotile Spermienfraktion war von 
Patienten nicht verfügbar). Eine Beschreibung des Studiendesigns und die wichtigsten Ergebnisse 
werden im Folgenden dargestellt:   
Ejakulate von 97 gesunden Donoren (motile und immotile Spermienfraktionen), die normale 
Spermienparameter nach WHO erfüllten und 48 subfertilen Patienten (motile Spermienfraktion),  
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die sich einer ART wie ICSI oder IVF unterzogen haben, wurden gesammelt und separat analysiert.  
➢ Die Spermien subfertiler Patienten besaßen im Vergleich zu gesunden Spendern signifikant 
niedrigere DNMT1- und DNMT3A-mRNA-Spiegel; 
➢ Die globalen DNA- und RNA-Methylierungswerte unterschieden sich nicht in motilen 
Spermien von gesunden Spendern und subfertilen Patienten; 
➢ Im Vergleich zu den motilen und immotilen Spermien gesunder Spender war eine signifikant 
verminderte L1-Methylierung bei motilen Spermien subfertiler Patienten nachweisbar. Bei den 
motilen Spermien von Patienten und Spendern waren L1-mRNA und -Methylierung signifikant 
negativ korreliert. Darüber hinaus wurde in der Patientenuntergruppe, die eine positive 
Schwangerschaft nach ICSI zeigte, eine signifikante Korrelation von L1-Methylierung und 
Befruchtungsrate festgestellt. Interessanterweise besaßen immotile Spermien von gesunden 
Spendern signifikant erhöhte L1-mRNA-Spiegel; 
➢ SIRT6, ein Transkriptionsfaktor, der sich als epigenetisch herunterreguliert bei alternden 
menschlichen dermalen Fibroblasten erwiesen hat, wurde in menschlichen Samenzellen unter-
sucht. SIRT6-Promotor-Hypermethylierung wurde in Spermien von subfertilen Patienten ge-
funden. In Spermien wurde die SIRT6-Methylierung durch das Alter nicht beeinflusst. Ein 
weiterer L1-Transkriptionsfaktor, MORC2, wurde auf dem niedrigsten mRNA-Spiegel in 
immotilen Spermien gesunder Spender gefunden. Im Gegensatz dazu wurde der L1-
Transkriptionsfaktor YY1 ausschließlich in menschlichen Sertoli-Zellen gefunden, nicht aber in 
männlichen Keimzellen; 
➢ L1-Repressoren, H4K20me2 und H4K20me3, waren im Hodengewebe von Menschen, Maus 
und Bulle allgegenwärtig exprimiert, wobei die H4K20me2-Signale in früheren spermatogene-
tischen Phasen (Spermatogonien/Spermatozyten) ausgeprägter waren und die von H4K20me3 
in späteren Phasen (runde/elongierende Spermatozoen). Sowohl in motilen als auch in 
immotilen Spermien gesunder Spender wurden H4K20me2 und H4K20me3 einbehalten. Der 
Vergleich der H4K20me3-Signale zeigte eine höhere Anreicherung in immotilen Spermien. 
Genomweite H4K20me3-Bindungsstellen, die kürzlich durch ChIP-Sequenzierung in 
beweglichen menschlichen Spermien entdeckt wurden, konnten hier für einige ausgewählte 
Gene bestätigt werden (L1, CXCL8, TNSFS13B, IFNW1 und CST8);  
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➢ Die mRNAs der H4K20-Methyltransferasen KMT5A und KMT5B wurden in motilen und 
immotilen menschlichen Spermien gefunden. Im Gegensatz dazu waren KMT5C-mRNA und  
-Protein in menschlichen Spermien nicht detektierbar. 
Dies ist eine der Pionierstudien, die darauf abzielt, die epigenetische Regulation retrotransposabler 
Elemente in der menschlichen Spermatogenese und in reifen Samenzellen zu verstehen und zu 
klären, ob diese Auswirkungen auf die Spermienkapazität und die männliche Fruchtbarkeit haben. 
Es war offensichtlich, dass motile und immotile Spermien von gesunden Männern große Unter-
schiede in Bezug auf L1-Methylierung und L1-mRNA-Spiegel, aber auch in Bezug auf L1-
Regulation aufweisen. Interessanterweise zeigten motile Spermien von subfertilen Patienten für 
einige Faktoren Tendenzen zu immotilen Spermien gesunder Männer. Darüber hinaus verdeutlicht 
die signifikant negative Korrelation von L1-mRNA und L1-Methylierung, die unter allen motilen 
Spermien gefunden wurde, und die signifikant positive Korrelation von L1-Methylierung und 
Befruchtungsrate nach ART die Auswirkungen einer korrekten L1-Regulierung bei männlichen 
Fruchtbarkeitsproblemen.  
Zukünftige Arbeiten sind erforderlich, um die genauen Regulationsmechanismen von Retrotrans-
posons in der menschlichen Spermatogenese, den Einfluss der L1-Dysregulation auf die Spermien-
qualität und die Ereignisse nach der Befruchtung zu untersuchen, und um zu klären, wie dies alles 
in der Praxis helfen und Männern mit idiopathischer Unfruchtbarkeit nützen könnte. 
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9. Supplementary Information 
Whole protein stainings after protein transfer with the REVERT™ Total Protein Stain Kit were 
performed, for checking transfer efficiency and later normalization of western blots. The stainings 
for later H4K20me3 protein level analysis of 20 donors` M/IM are shown here in Figure 44 (cor-
responding western blots with H4K20me3 displayed in Figure 37 E).   
 
Figure 44: Whole protein stainings after protein transfer of 20 donors M/IM. The signal intensity for H4K20me3 in 
western blots (Fig. 37 E) was normalized to its whole protein content. 
The normalization to the whole protein content of each sample is a much more stable method than 
normalization to individual house-keeping genes. In addition, uneven sample loads are eliminated 
with this normalization method and lead to an even more accurate comparison of protein signals 
between samples. 
In the following Tables (16-21) methylation and mRNA values of all tested targets in the three 
cohorts (patients` M, donors` M/IM) are summarized. 
 
 
Supplementary Information 
100 
 
Table 16: Summary of all values from methylation and mRNA analyzes in donors` M. 
Type ID 
Fertiliza-
tion rate 
Outcome 
5mC 
DNA 
meth. 
m6A 
RNA 
meth. 
L1 meth. 
pyroseq. 
L1 meth. 
ELISA 
L1 
mRNA 
Donor M DFG-US-01 unknown unknown           
Donor M DFG-US-04 unknown unknown           
Donor M DFG-US-05 unknown unknown           
Donor M DFG-US-06 unknown unknown           
Donor M DFG-US-07 unknown unknown           
Donor M DFG-US-08 unknown unknown           
Donor M DFG-US-09 unknown unknown       47,87   
Donor M DFG-US-11 unknown unknown           
Donor M DFG-US-12 unknown unknown           
Donor M DFG-US-13 unknown unknown           
Donor M DFG-US-14 unknown unknown           
Donor M DFG-US-15 unknown unknown           
Donor M DFG-US-16 unknown unknown           
Donor M DFG-US-17 unknown unknown           
Donor M DFG-US-18 unknown unknown           
Donor M DFG-US-19 unknown unknown           
Donor M DFG-US-20 unknown unknown           
Donor M DFG-US-21 unknown unknown           
Donor M DFG-US-22 unknown unknown           
Donor M DFG-US-23 unknown unknown           
Donor M DFG-US-24 unknown unknown       49,37   
Donor M DFG-US-25 unknown unknown       50,78   
Donor M DFG-US-26 unknown unknown       44,92   
Donor M DFG-US-28 unknown unknown           
Donor M DFG-US-31 unknown unknown     56,00 36,23 4,69 
Donor M DFG-US-33 unknown unknown     53,33 71,38 10,86 
Donor M DFG-US-34 unknown unknown     53,67 38,18 0,63 
Donor M DFG-US-35 unknown unknown     55,00 48,00 6,43 
Donor M DFG-US-36 unknown unknown     52,00 38,33 0,33 
Donor M DFG-US-37 unknown unknown     50,17 50,64 0,41 
Donor M DFG-US-38 unknown unknown 7,19 0,018 54,17 30,96 3,66 
Donor M DFG-US-39 unknown unknown     58,50 52,23 0,96 
Donor M DFG-US-40 unknown unknown 8,95 0,062 48,67 28,25 9,94 
Donor M DFG-US-41 unknown unknown     52,33 47,33 1,75 
Donor M DFG-US-42 unknown unknown 8,04 0,028 51,00 31,96 0,64 
Donor M DFG-US-43 unknown unknown 7,89 0,011 51,83 100,00 0,04 
Donor M DFG-US-45 unknown unknown 7,42 0,009 54,67 52,89 0,20 
Donor M DFG-US-46 unknown unknown     49,50 33,44 0,09 
Donor M DFG-US-47 unknown unknown 9,63 0,009 50,00 100,00 0,58 
Donor M DFG-US-48 unknown unknown 8,47 0,016 41,50 55,51 0,01 
Donor M DFG-US-50 unknown unknown     45,67 52,14 0,04 
Donor M DFG-US-51 unknown unknown 1,88 0,010 44,33 44,35 0,67 
Donor M DFG-US-52 unknown unknown 0,54 0,010 38,00 42,59 0,37 
Donor M DFG-US-53 unknown unknown 6,00 0,009 49,00 55,78 0,82 
Donor M DFG-US-54 unknown unknown 0,12 0,015 57,67 43,51 4,80 
Donor M DFG-US-55 unknown unknown     56,00 46,88 0,04 
Donor M DFG-US-56 unknown unknown 0,59 0,028 41,67 36,30 0,37 
Donor M DFG-US-57 unknown unknown 0,59 0,036 51,67 38,73 0,04 
Donor M DFG-US-58 unknown unknown 0,74 0,010 54,67 43,29 0,79 
Donor M DFG-US-59 unknown unknown           
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Type ID 
Log (L1 
mRNA) 
DNMT1 
mRNA 
Log 
(DNMT1 
mRNA) 
DNMT3A 
mRNA 
Log 
(DNMT3A 
mRNA) 
SIRT6 
meth.  
pyroseq. 
MORC2 
mRNA 
Donor M DFG-US-01   16,73 2,82         
Donor M DFG-US-04   17,75 2,88 34,91 3,55     
Donor M DFG-US-05   4,04 1,40 10,80 2,38     
Donor M DFG-US-06   1,99 0,69 11,60 2,45     
Donor M DFG-US-07   3,92 1,37 7,72 2,04     
Donor M DFG-US-08   3,06 1,12 4,08 1,41     
Donor M DFG-US-09   4,46 1,50 2,81 1,03     
Donor M DFG-US-11   1,11 0,10 1,19 0,17     
Donor M DFG-US-12   1,41 0,35 1,18 0,16     
Donor M DFG-US-13   0,86 -0,15 3,07 1,12     
Donor M DFG-US-14   6,00 1,79 4,83 1,58     
Donor M DFG-US-15   2,79 1,03 4,37 1,47     
Donor M DFG-US-16   3,24 1,17 8,77 2,17     
Donor M DFG-US-17   36,40 3,59 3,46 1,24     
Donor M DFG-US-18   1,27 0,24 0,83 -0,19     
Donor M DFG-US-19   1,06 0,06 1,81 0,59     
Donor M DFG-US-20   7,42 2,00 4,26 1,45     
Donor M DFG-US-21   3,04 1,11 3,07 1,12     
Donor M DFG-US-22   0,91 -0,09 2,02 0,71     
Donor M DFG-US-23   4,93 1,60 9,53 2,25     
Donor M DFG-US-24   2,26 0,82 2,02 0,71     
Donor M DFG-US-25   1,54 0,43 0,83 -0,18     
Donor M DFG-US-26   0,39 -0,95 0,41 -0,90     
Donor M DFG-US-28   1,48 0,39 1,71 0,54     
Donor M DFG-US-31 1,55 1,13 0,12 0,63 -0,46 1,00 9,37 
Donor M DFG-US-33 2,39 0,81 -0,21 0,47 -0,74 0,80 0,00 
Donor M DFG-US-34 -0,46 0,67 -0,40 0,60 -0,51 1,00 0,27 
Donor M DFG-US-35 1,86 1,48 0,39 1,09 0,09 0,80 2,36 
Donor M DFG-US-36 -1,10 0,75 -0,28 1,01 0,01 0,80 0,19 
Donor M DFG-US-37 -0,89 0,35 -1,04 1,09 0,09 -1,00 0,14 
Donor M DFG-US-38 1,30 1,82 0,60 1,25 0,22 1,00 0,40 
Donor M DFG-US-39 -0,04 0,91 -0,10 5,09 1,63 0,80 1,41 
Donor M DFG-US-40 2,30 0,99 -0,01 1,85 0,61 0,80 6,83 
Donor M DFG-US-41 0,56 0,89 -0,11 4,11 1,41 -1,00 0,16 
Donor M DFG-US-42 -0,45 0,61 -0,50 3,73 1,32 0,80 0,23 
Donor M DFG-US-43 -3,31 0,39 -0,95 0,25 -1,40 1,00 0,48 
Donor M DFG-US-45 -1,60 0,47 -0,75 1,33 0,29 1,00 0,00 
Donor M DFG-US-46 -2,46 2,22 0,80 13,66 2,61 0,80 0,00 
Donor M DFG-US-47 -0,55 0,54 -0,61 0,40 -0,93 1,00 0,00 
Donor M DFG-US-48 -4,51 0,34 -1,07 0,15 -1,87 1,00   
Donor M DFG-US-50 -3,26 0,47 -0,75 0,36 -1,02 1,00 0,04 
Donor M DFG-US-51 -0,40 0,47 -0,75 0,24 -1,41 1,40 6,12 
Donor M DFG-US-52 -1,01 1,11 0,11 0,35 -1,04 1,20 3,30 
Donor M DFG-US-53 -0,19 2,54 0,93 1,03 0,03 1,00 25,50 
Donor M DFG-US-54 1,57 1,81 0,59 2,52 0,92 1,00 1,48 
Donor M DFG-US-55 -3,22 0,71 -0,34 0,19 -1,67 -1,00 0,31 
Donor M DFG-US-56 -1,01 3,38 1,22 11,53 2,45 1,40 11,02 
Donor M DFG-US-57 -3,21 0,40 -0,91 0,29 -1,24 0,80 0,11 
Donor M DFG-US-58 -0,23 0,30 -1,21 0,18 -1,72 1,20 0,42 
Donor M DFG-US-59   9,13 2,21 3,61 1,28 -1,00 3,80 
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Type ID 
Log 
(MORC2 
mRNA) 
KMT5A 
mRNA 
Log 
(KMT5A 
mRNA) 
KMT5B 
mRNA 
Log 
(KMT5B 
mRNA) 
Donor M DFG-US-01           
Donor M DFG-US-04           
Donor M DFG-US-05           
Donor M DFG-US-06           
Donor M DFG-US-07           
Donor M DFG-US-08           
Donor M DFG-US-09           
Donor M DFG-US-11           
Donor M DFG-US-12           
Donor M DFG-US-13           
Donor M DFG-US-14           
Donor M DFG-US-15           
Donor M DFG-US-16           
Donor M DFG-US-17           
Donor M DFG-US-18           
Donor M DFG-US-19           
Donor M DFG-US-20           
Donor M DFG-US-21           
Donor M DFG-US-22           
Donor M DFG-US-23           
Donor M DFG-US-24           
Donor M DFG-US-25           
Donor M DFG-US-26           
Donor M DFG-US-28           
Donor M DFG-US-31 2,24 0,72 -0,14 1,16 0,15 
Donor M DFG-US-33   0,41 -0,38 0,42 -0,88 
Donor M DFG-US-34 -1,30 0,07 -1,14 0,12 -2,12 
Donor M DFG-US-35 0,86 1,62 0,21 1,03 0,03 
Donor M DFG-US-36 -1,64 0,03 -1,47 0,02 -3,72 
Donor M DFG-US-37 -1,98 0,24 -0,62 0,31 -1,16 
Donor M DFG-US-38 -0,92         
Donor M DFG-US-39 0,34 1,00 0,00 0,87 -0,14 
Donor M DFG-US-40 1,92 15,73 1,20 21,11 3,05 
Donor M DFG-US-41 -1,86         
Donor M DFG-US-42 -1,45 0,26 -0,59 0,24 -1,43 
Donor M DFG-US-43 -0,74         
Donor M DFG-US-45   0,05 -1,30 0,03 -3,58 
Donor M DFG-US-46   0,02 -1,78 0,02 -4,05 
Donor M DFG-US-47   0,06 -1,23     
Donor M DFG-US-48           
Donor M DFG-US-50 -3,27         
Donor M DFG-US-51 1,81 0,31 -0,51 0,29 -1,25 
Donor M DFG-US-52 1,19 0,17 -0,76 0,31 -1,16 
Donor M DFG-US-53 3,24 0,38 -0,42 0,62 -0,47 
Donor M DFG-US-54 0,39         
Donor M DFG-US-55 -1,18 0,01 -1,97 0,02 -3,86 
Donor M DFG-US-56 2,40 0,11 -0,94 0,09 -2,39 
Donor M DFG-US-57 -2,17         
Donor M DFG-US-58 -0,86         
Donor M DFG-US-59 1,34 0,17 -0,76 0,22 -1,51 
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Type ID 
Fertiliza-
tion rate 
Outcome 
5mC 
DNA 
meth. 
m6A 
RNA 
meth. 
L1 meth. 
pyroseq. 
L1 meth. 
ELISA 
L1 
mRNA 
Donor M DFG-US-60 unknown unknown 1,34 0,009 54,67 36,32 8,74 
Donor M DFG-US-61 unknown unknown 1,94 0,009 28,67 41,28 6,79 
Donor M DFG-US-62 unknown unknown 8,46 0,012 54,00 42,63 0,11 
Donor M DFG-US-63 unknown unknown 8,10 0,010 50,00 44,46 13,49 
Donor M DFG-US-64 unknown unknown 1,27 0,009 46,33 38,43 0,47 
Donor M DFG-US-65 unknown unknown       41,67 3,12 
Donor M DFG-US-66 unknown unknown     53,67 28,22 6,93 
Donor M DFG-US-68 unknown unknown 1,25 0,011 57,33 41,39 1,51 
Donor M DFG-US-69 unknown unknown     52,00 46,44 0,56 
Donor M DFG-US-70 unknown unknown     -2,00 30,41 0,19 
Donor M DFG-US-75 unknown unknown       39,58 0,01 
Donor M DFG-US-76 unknown unknown       41,71 0,01 
Donor M DFG-US-78 unknown unknown       47,06 0,13 
Donor M DFG-US-79 unknown unknown       36,74 0,00 
Donor M DFG-US-80 unknown unknown       54,47 0,21 
Donor M DFG-US-81 unknown unknown       40,01 0,04 
Donor M DFG-US-82 unknown unknown       78,05 0,00 
Donor M DFG-US-83 unknown unknown       100,00 0,00 
Donor M DFG-US-84 unknown unknown       95,36 0,04 
Donor M DFG-US-85 unknown unknown       78,26 0,01 
Donor M DFG-US-86 unknown unknown       93,07 0,00 
Donor M DFG-US-87 unknown unknown       50,73 0,00 
Donor M DFG-US-88 unknown unknown       100,00 0,04 
Donor M DFG-US-90 unknown unknown       80,48 0,11 
Donor M DFG-US-91 unknown unknown       84,65 0,00 
Donor M DFG-US-92 unknown unknown       47,96 0,02 
Donor M DFG-US-93 unknown unknown       76,10 0,09 
Donor M DFG-US-95 unknown unknown       67,14 0,84 
Donor M DFG-US-96 unknown unknown       60,69 0,01 
Donor M DFG-US-97 unknown unknown       54,61   
Donor M DFG-US-98 unknown unknown       54,80 0,14 
Donor M DFG-US-100 unknown unknown       83,83 0,03 
Donor M DFG-US-101 unknown unknown       57,22   
Donor M DFG-US-102 unknown unknown       57,01   
Donor M DFG-US-103 unknown unknown       60,38   
Donor M DFG-US-105 unknown unknown       49,99   
Donor M DFG-US-106 unknown unknown       57,89   
Donor M DFG-US-107 unknown unknown       55,94   
Donor M DFG-US-108 unknown unknown       37,06   
Donor M DFG-US-109 unknown unknown       29,84   
Donor M DFG-US-110 unknown unknown       47,30   
Donor M DFG-US-111 unknown unknown       32,43   
Donor M DFG-US-112 unknown unknown       27,06   
Donor M DFG-US-113 unknown unknown       52,95   
Donor M DFG-US-114 unknown unknown       61,90   
Donor M DFG-US-115 unknown unknown       58,24   
 
 
Supplementary Information 
104 
 
Type ID 
Log (L1 
mRNA) 
DNMT1 
mRNA 
Log 
(DNMT1 
mRNA) 
DNMT3A 
mRNA 
Log 
(DNMT3A 
mRNA) 
SIRT6 
meth.  
pyroseq. 
MORC2 
mRNA 
Donor M DFG-US-60 2,17 0,46 -0,78 0,23 -1,46 0,80 2,51 
Donor M DFG-US-61 1,91 1,07 0,07 0,71 -0,34 0,80 2,14 
Donor M DFG-US-62 -2,24 0,73 -0,32 0,52 -0,65 1,00   
Donor M DFG-US-63 2,60 1,89 0,64 1,87 0,63 0,80 0,12 
Donor M DFG-US-64 -0,75 0,89 -0,12 0,28 -1,27 0,80 0,26 
Donor M DFG-US-65 1,14 2,20 0,79 3,88 1,36 1,40 1,11 
Donor M DFG-US-66 1,94 0,77 -0,26 0,28 -1,26 1,20 7,07 
Donor M DFG-US-68 0,41 0,52 -0,66 0,08 -2,52 1,30 0,84 
Donor M DFG-US-69 -0,58 1,96 0,68 2,60 0,95 0,80   
Donor M DFG-US-70 -1,64 0,78 -0,25 0,44 -0,81 1,40   
Donor M DFG-US-75 -4,28             
Donor M DFG-US-76 -4,84             
Donor M DFG-US-78 -2,02             
Donor M DFG-US-79 -5,36             
Donor M DFG-US-80 -1,56             
Donor M DFG-US-81 -3,25             
Donor M DFG-US-82 -6,82             
Donor M DFG-US-83 -6,50             
Donor M DFG-US-84 -3,28             
Donor M DFG-US-85 -4,30             
Donor M DFG-US-86 -8,38             
Donor M DFG-US-87 -6,64             
Donor M DFG-US-88 -3,20             
Donor M DFG-US-90 -2,24             
Donor M DFG-US-91 -6,01             
Donor M DFG-US-92 -4,05             
Donor M DFG-US-93 -2,44             
Donor M DFG-US-95 -0,18             
Donor M DFG-US-96 -4,38             
Donor M DFG-US-97               
Donor M DFG-US-98 -1,94             
Donor M DFG-US-100 -3,46             
Donor M DFG-US-101               
Donor M DFG-US-102               
Donor M DFG-US-103               
Donor M DFG-US-105               
Donor M DFG-US-106               
Donor M DFG-US-107               
Donor M DFG-US-108               
Donor M DFG-US-109               
Donor M DFG-US-110               
Donor M DFG-US-111               
Donor M DFG-US-112               
Donor M DFG-US-113               
Donor M DFG-US-114               
Donor M DFG-US-115               
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Type ID 
Log 
(MORC2 
mRNA) 
KMT5A 
mRNA 
Log 
(KMT5A 
mRNA) 
KMT5B 
mRNA 
Log 
(KMT5B 
mRNA) 
Donor M DFG-US-60 0,92 1,49 0,17 1,07 0,07 
Donor M DFG-US-61 0,76         
Donor M DFG-US-62           
Donor M DFG-US-63 -2,16 2,58 0,41 1,12 0,11 
Donor M DFG-US-64 -1,34 0,16 -0,78 0,14 -1,99 
Donor M DFG-US-65 0,11         
Donor M DFG-US-66 1,96         
Donor M DFG-US-68 -0,18         
Table 17: Summary of the values of further DNMT1/3A mRNA analyzes to enlarge the cohort of donors` M. 
Type ID 
DNMT1 
mRNA 
Log 
(DNMT1 
mRNA) 
DNMT3A 
mRNA 
Log 
(DNMT3A 
mRNA) 
Donor M ZP5G-01 2,25 0,81 3,23 1,17 
Donor M ZP5G-02 1,91 0,65 2,73 1,00 
Donor M ZP5G-03 1,74 0,55 2,35 0,85 
Donor M ZP5G-04 1,92 0,65 1,59 0,46 
Donor M ZP5G-05 1,81 0,60 3,70 1,31 
Donor M ZP5G-07 2,00 0,69 1,83 0,61 
Donor M ZP5G-09 1,58 0,46 1,78 0,58 
Donor M ZP5G-10 1,38 0,32 3,23 1,17 
Donor M ZP5G-11 2,32 0,84 4,01 1,39 
Donor M ZP5G-13 2,41 0,88 2,63 0,97 
Donor M ZP5G-14 2,35 0,86 2,64 0,97 
Donor M ZP5G-15 2,19 0,78 3,23 1,17 
Donor M ZP5G-16 2,35 0,85 2,57 0,95 
Donor M ZP5G-18 1,96 0,67 2,29 0,83 
Donor M ZP5G-19 2,13 0,76 1,93 0,66 
Donor M ZP5G-20 1,36 0,31 2,63 0,97 
Donor M ZP5G-22 1,78 0,58 2,72 1,00 
Donor M ZP5G-23 1,34 0,29 2,37 0,86 
Donor M ZP5G-24 4,13 1,42 2,85 1,05 
Donor M ZP5G-25 1,03 0,03 1,79 0,58 
Donor M ZP5G-26 1,93 0,66 2,32 0,84 
Donor M ZP5G-27 0,29 -1,23 1,60 0,47 
Donor M ZP5G-28 0,44 -0,83 0,32 -1,14 
Donor M ZP5G-30 0,55 -0,59 1,49 0,40 
Donor M ZP5G-31 0,14 -2,00 0,81 -0,20 
Donor M ZP5G-32 0,13 -2,06 0,64 -0,44 
Donor M ZP5G-34 1,66 0,51 3,82 1,34 
Donor M ZP5G-35 0,09 -2,42 0,60 -0,51 
Donor M ZP5G-37 0,15 -1,87 2,04 0,71 
Donor M ZP5G-38 0,47 -0,76 1,01 0,01 
Donor M ZP5G-40 1,39 0,33 3,09 1,13 
Donor M ZP5G-41 0,43 -0,84 1,21 0,19 
Donor M ZP5G-42 0,16 -1,86 2,39 0,87 
Donor M ZP5G-43 0,62 -0,48 0,84 -0,17 
Donor M ZP5G-45 0,85 -0,16 1,46 0,38 
Donor M ZP5G-46 0,86 -0,15 3,50 1,25 
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Table 18: Summary of all values from methylation and mRNA analyzes in patients` M. 
Type ID 
Fertiliza-
tion rate 
Outcome 
5mC 
DNA 
meth. 
m6A 
RNA 
meth. 
L1 meth. 
pyroseq. 
L1 meth. 
ELISA 
L1 
mRNA 
Patient M P01 0,60 negative     53,67 50,40 0,19 
Patient M P02 0,67 positive     55,00 26,53 0,22 
Patient M P03 0,60 negative 4,24 0,011 53,00 89,73 0,20 
Patient M P04 0,70 positive     44,00 54,34 1,22 
Patient M P05 0,69 negative 8,40 0,009 55,33 47,92 5,15 
Patient M P06 0,50 negative     36,50 89,60 0,51 
Patient M P07 0,78 positive     51,67 36,55 0,71 
Patient M P08 0,89 positive 2,37 0,012 47,00 53,79 1,24 
Patient M P09 1,00 negative 10,06 0,049 53,00 45,01 1,33 
Patient M P10 0,60 negative     39,83 35,99 0,82 
Patient M P11 0,50 negative     52,33 49,37 0,26 
Patient M P12 0,67 positive     52,33 44,33 1,47 
Patient M P13 0,76 negative 7,67 0,009 54,33 57,56 0,01 
Patient M P14 0,60 negative     51,33 40,11   
Patient M P15 0,80 positive 8,34 0,046 52,33 51,59 0,20 
Patient M P16 0,67 positive     50,00 49,03   
Patient M P17 0,50 negative     55,33 75,30 0,60 
Patient M P18 0,86 positive 5,48 0,033 52,67 49,43 1,79 
Patient M P19 0,80 positive 7,50 0,023 51,67 66,86 5,23 
Patient M P20 0,71 positive 5,90 0,010 55,83 56,76 1,29 
Patient M P21 0,58 positive 1,41 0,011 53,00 36,59 26,06 
Patient M P22 unknown negative     41,00 36,95   
Patient M P23 0,22 negative     47,67 33,66   
Patient M P24 1,00 positive 0,71 0,010 50,67 62,22 0,00 
Patient M P25 1,00 negative 2,76 0,011 52,00 53,19 2,03 
Patient M P26 0,83 negative     52,67 38,96 18,38 
Patient M P27 0,75 negative 2,62 0,010 54,67 46,12 2,01 
Patient M P28 0,58 positive     50,00 39,08   
Patient M P29 0,57 negative     55,33 43,19   
Patient M P30 0,56 positive 0,55 0,009 49,00 48,48 0,63 
Patient M P31 unknown negative     52,00 38,71   
Patient M P32 0,38 negative     56,33 45,34   
Patient M P33 0,83 positive 0,90 0,010 40,67 43,30 3,30 
Patient M P34 0,86 negative     56,67 37,34 8,42 
Patient M P35 0,56 positive 2,52 0,009 49,33 43,86 5,93 
Patient M P36 0,79 negative     42,83 41,66   
Patient M P37 0,57 positive     54,00 45,44 0,26 
Patient M P38 0,69 positive     53,67 46,16 3,79 
Patient M P39 0,50 positive     55,00 39,30   
Patient M P40 1,00 negative 1,57 0,010 53,67 49,19 9,18 
Patient M P41 0,67 negative     57,00 39,81   
Patient M P42 0,55 negative     54,67 41,87   
Patient M P43 0,80 negative 1,65 0,010 49,00 44,25 5,32 
Patient M P44 0,77 positive 2,13 0,009 50,67 41,57 3,75 
Patient M P45 unknown positive       42,75   
Patient M P46 0,64 negative     49,33 39,19   
Patient M P47 0,79 negative     52,00 33,38   
Patient M P48 0,53 negative 2,71 0,009 52,00 43,46 10,28 
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Type ID 
Log (L1 
mRNA) 
DNMT1 
mRNA 
Log 
(DNMT1 
mRNA) 
DNMT3A 
mRNA 
Log 
(DNMT3A 
mRNA) 
SIRT6 
meth.  
pyroseq. 
MORC2 
mRNA 
Patient M P01 -1,67 0,21 -1,56 0,32 -1,15 1,80 0,42 
Patient M P02 -1,52 0,96 -0,04 0,51 -0,67 2,20 0,08 
Patient M P03 -1,63 1,21 0,19 0,14 -1,96 0,60 0,20 
Patient M P04 0,20 0,57 -0,56 0,93 -0,08 1,00 1,52 
Patient M P05 1,64 0,21 -1,56 0,37 -0,98 0,80   
Patient M P06 -0,67 1,64 0,49 2,73 1,00 1,00 1,07 
Patient M P07 -0,34 1,89 0,64 0,84 -0,17 1,40   
Patient M P08 0,21 0,20 -1,60 0,20 -1,63 1,20 0,18 
Patient M P09 0,29 0,31 -1,18 1,61 0,47 1,60   
Patient M P10 -0,20 2,42 0,88 3,49 1,25 1,00 0,47 
Patient M P11 -1,33 0,66 -0,42 2,51 0,92 1,00 0,28 
Patient M P12 0,38 0,55 -0,59 0,85 -0,16 0,80   
Patient M P13 -4,42 0,32 -1,13 0,11 -2,19 1,40   
Patient M P14   0,02 -4,04 0,01 -4,67 1,00 0,07 
Patient M P15 -1,60 0,04 -3,13 0,12 -2,11 1,20 0,98 
Patient M P16   0,38 -0,97 0,50 -0,70 1,20 2,05 
Patient M P17 -0,51 0,07 -2,66 0,27 -1,31 0,80 0,22 
Patient M P18 0,58 0,05 -2,94 0,34 -1,09 0,80   
Patient M P19 1,65 0,60 -0,52 1,00 0,00 1,00 0,44 
Patient M P20 0,25 0,65 -0,43 1,72 0,54 1,00   
Patient M P21 3,26 0,93 -0,07 0,33 -1,12 0,80   
Patient M P22   1,18 0,16 0,50 -0,68 1,40 1,90 
Patient M P23   1,04 0,04 0,48 -0,74 2,00   
Patient M P24 -5,75 1,11 0,10 0,49 -0,72 1,60 7,85 
Patient M P25 0,71 0,88 -0,13 0,48 -0,74 1,00   
Patient M P26 2,91 1,10 0,09 0,48 -0,74 1,00   
Patient M P27 0,70 1,08 0,08 0,58 -0,55 2,20   
Patient M P28   1,32 0,28 0,49 -0,72 1,00   
Patient M P29   1,08 0,08 0,43 -0,84 0,80   
Patient M P30 -0,46 0,73 -0,32 0,44 -0,82 1,60   
Patient M P31   0,89 -0,12 0,48 -0,74 0,80 1,66 
Patient M P32   0,99 -0,01 0,38 -0,96 0,80   
Patient M P33 1,19 0,91 -0,09 0,44 -0,82 2,20   
Patient M P34 2,13 1,02 0,02 0,40 -0,91 1,00   
Patient M P35 1,78 0,76 -0,27 0,41 -0,89 3,20   
Patient M P36   0,99 -0,01 0,43 -0,84 0,80   
Patient M P37 -1,33 0,96 -0,04 0,44 -0,82 1,40 0,02 
Patient M P38 1,33 1,04 0,03 0,48 -0,74 3,80   
Patient M P39   0,95 -0,05 0,43 -0,84 1,30 2,73 
Patient M P40 2,22 0,77 -0,26 0,43 -0,84 1,00   
Patient M P41   0,92 -0,08 0,49 -0,72 0,80   
Patient M P42   0,73 -0,32 0,39 -0,94 1,00   
Patient M P43 1,67 1,05 0,05 0,55 -0,60 1,20 1,99 
Patient M P44 1,32 1,00 0,00 0,41 -0,89 1,60   
Patient M P45   0,89 -0,12 0,43 -0,84 1,20   
Patient M P46   0,92 -0,08 0,37 -0,98   1,02 
Patient M P47   1,18 0,16 0,37 -0,98 1,40   
Patient M P48 2,33 1,07 0,07 0,45 -0,80 3,20   
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Type ID 
Log 
(MORC2 
mRNA) 
KMT5A 
mRNA 
Log 
(KMT5A 
mRNA) 
KMT5B 
mRNA 
Log 
(KMT5B 
mRNA) 
Patient M P01 -0,87 0,06 -1,20 0,08 -2,57 
Patient M P02 -2,48         
Patient M P03 -1,63 0,02 -1,81 0,05 -3,08 
Patient M P04 0,42         
Patient M P05   1,00 0,00 3,31 1,20 
Patient M P06 0,06         
Patient M P07   0,06 -1,24 0,18 -1,72 
Patient M P08 -1,71         
Patient M P09   1,11 0,05 1,00 0,00 
Patient M P10 -0,76 0,31 -0,51 0,10 -2,33 
Patient M P11 -1,27 0,03 -1,57 0,01 -4,30 
Patient M P12   0,34 -0,47 0,36 -1,02 
Patient M P13           
Patient M P14 -2,60 0,00 -2,37 0,00 -6,15 
Patient M P15 -0,02 0,09 -1,04 0,25 -1,40 
Patient M P16 0,72 0,75 -0,12 1,27 0,24 
Patient M P17 -1,52 0,21 -0,69 0,11 -2,19 
Patient M P18   1,59 0,20 3,38 1,22 
Patient M P19 -0,82 2,87 0,46 3,94 1,37 
Patient M P20           
Patient M P21           
Patient M P22 0,64 1,03 0,01 2,57 0,94 
Patient M P23   0,49 -0,31 0,38 -0,96 
Patient M P24 2,06 0,22 -0,67 0,15 -1,91 
Patient M P25   17,45 1,24 18,13 2,90 
Patient M P26   3,29 0,52 2,53 0,93 
Patient M P27   3,06 0,49 2,20 0,79 
Patient M P28   4,94 0,69 6,70 1,90 
Patient M P29   5,39 0,73 3,39 1,22 
Patient M P30   0,38 -0,42 0,26 -1,37 
Patient M P31 0,50         
Patient M P32           
Patient M P33           
Patient M P34   1,69 0,23 1,44 0,36 
Patient M P35   5,62 0,75 4,21 1,44 
Patient M P36           
Patient M P37 -3,93 5,08 0,71 3,11 1,13 
Patient M P38   8,46 0,93 3,48 1,25 
Patient M P39 1,00         
Patient M P40   5,84 0,77 4,47 1,50 
Patient M P41           
Patient M P42           
Patient M P43 0,69 1,69 0,23 1,59 0,46 
Patient M P44   3,67 0,56 2,64 0,97 
Patient M P45           
Patient M P46 0,02         
Patient M P47           
Patient M P48   1,24 0,09 0,80 -0,23 
 
Supplementary Information 
109 
 
Table 19: Summary of all values from methylation and mRNA analyzes in donors` IM. 
Type ID 
Fertiliza-
tion rate 
Outcome 
L1 meth. 
pyroseq. 
L1 meth. 
ELISA 
L1 
mRNA 
Log (L1 
mRNA) 
SIRT6 
meth.  
pyroseq. 
Donor IM DFG-US-30 unknown unknown 51,67 53,47 2,79 1,03 1,00 
Donor IM DFG-US-31 unknown unknown 52,00 40,63 2,88 1,06 1,20 
Donor IM DFG-US-32 unknown unknown 51,00 48,78 4,78 1,57 0,80 
Donor IM DFG-US-33 unknown unknown 51,33 54,25 15,67 2,75 0,80 
Donor IM DFG-US-34 unknown unknown 51,67 44,17 23,37 3,15   
Donor IM DFG-US-35 unknown unknown 54,33 66,13 0,95 -0,05 0,80 
Donor IM DFG-US-36 unknown unknown 50,33 50,23 0,02 -3,98 1,00 
Donor IM DFG-US-37 unknown unknown 47,00 71,98 0,01 -5,12   
Donor IM DFG-US-38 unknown unknown 51,00 61,04 0,92 -0,08 0,80 
Donor IM DFG-US-39 unknown unknown 56,33 56,74 2,19 0,79 0,80 
Donor IM DFG-US-40 unknown unknown 46,67 50,41 0,01 -4,77 1,20 
Donor IM DFG-US-41 unknown unknown 52,00 60,41 1,12 0,11 1,20 
Donor IM DFG-US-42 unknown unknown 49,33 50,83 23,48 3,16 1,00 
Donor IM DFG-US-43 unknown unknown 73,33 58,91 69,12 4,24 0,80 
Donor IM DFG-US-44 unknown unknown 53,33 47,89 21,93 3,09   
Donor IM DFG-US-45 unknown unknown 49,67 100,00 96,44 4,57 1,00 
Donor IM DFG-US-46 unknown unknown 51,00 63,29 168,04 5,12 1,00 
Donor IM DFG-US-47 unknown unknown 51,67 82,23     0,60 
Donor IM DFG-US-48 unknown unknown 41,67 65,55 100,47 4,61 0,80 
Donor IM DFG-US-49 unknown unknown 60,00 46,00 17,83 2,88 0,80 
Donor IM DFG-US-50 unknown unknown 44,00 47,60     1,20 
Donor IM DFG-US-51 unknown unknown 42,00 65,62     0,80 
Donor IM DFG-US-52 unknown unknown 39,00 65,03 18,56 2,92 1,20 
Donor IM DFG-US-53 unknown unknown 47,00 45,08     1,80 
Donor IM DFG-US-54 unknown unknown 54,33 47,49 117,29 4,76 1,00 
Donor IM DFG-US-55 unknown unknown 53,33 66,74 10,90 2,39 1,00 
Donor IM DFG-US-56 unknown unknown 41,67 57,94 15,38 2,73 0,80 
Donor IM DFG-US-57 unknown unknown 50,67 57,01 19,39 2,96 0,80 
Donor IM DFG-US-58 unknown unknown 54,33 58,30       
Donor IM DFG-US-60 unknown unknown 53,67 64,95     0,80 
Donor IM DFG-US-61 unknown unknown 27,33 60,51 26,60 3,28 0,80 
Donor IM DFG-US-62 unknown unknown 51,67 49,56     1,20 
Donor IM DFG-US-63 unknown unknown 49,67 55,82     0,80 
Donor IM DFG-US-64 unknown unknown 42,00 50,86     1,00 
Donor IM DFG-US-65 unknown unknown 53,33 55,99     1,20 
Donor IM DFG-US-66 unknown unknown 53,67 50,83 5,65 1,73 0,80 
Donor IM DFG-US-68 unknown unknown 57,33 41,86     1,10 
Donor IM DFG-US-69 unknown unknown 52,00 55,86 1,00 0,00 1,40 
Donor IM DFG-US-70 unknown unknown   59,16     0,80 
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Type ID 
MORC2 
mRNA 
Log 
(MORC2 
mRNA) 
KMT5A 
mRNA 
Log 
(KMT5A 
mRNA) 
KMT5B 
mRNA 
Log 
(KMT5B 
mRNA) 
Donor IM DFG-US-30 3,23 1,17 2,23 0,35 2,60 0,96 
Donor IM DFG-US-31 0,48 -0,74 5,10 0,71 5,54 1,71 
Donor IM DFG-US-32     4,98 0,70 5,98 1,79 
Donor IM DFG-US-33     0,02 -1,67 0,01 -4,24 
Donor IM DFG-US-34     1,03 0,01 0,98 -0,02 
Donor IM DFG-US-35             
Donor IM DFG-US-36     4,50 0,65 2,11 0,75 
Donor IM DFG-US-37 1,67 0,51 0,32 -0,49 0,26 -1,36 
Donor IM DFG-US-38     0,69 -0,16 0,33 -1,10 
Donor IM DFG-US-39     4,99 0,70 4,04 1,40 
Donor IM DFG-US-40 1,03 0,03 1,61 0,21 1,12 0,11 
Donor IM DFG-US-41            
Donor IM DFG-US-42            
Donor IM DFG-US-43    51,09 1,71     
Donor IM DFG-US-44        160,90 5,08 
Donor IM DFG-US-45    97,34 1,99 285,04 5,65 
Donor IM DFG-US-46    60,76 1,78 159,79 5,07 
Donor IM DFG-US-47            
Donor IM DFG-US-48            
Donor IM DFG-US-49            
Donor IM DFG-US-50            
Donor IM DFG-US-51            
Donor IM DFG-US-52    27,00 1,43 186,11 5,23 
Donor IM DFG-US-53            
Donor IM DFG-US-54            
Donor IM DFG-US-55            
Donor IM DFG-US-56            
Donor IM DFG-US-57            
Donor IM DFG-US-58            
Donor IM DFG-US-60            
Donor IM DFG-US-61            
Donor IM DFG-US-62            
Donor IM DFG-US-63            
Donor IM DFG-US-64            
Donor IM DFG-US-65            
Donor IM DFG-US-66            
Donor IM DFG-US-68            
Donor IM DFG-US-69            
Donor IM DFG-US-70            
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Type ID 
Fertiliza-
tion rate 
Outcome 
L1 meth. 
ELISA 
L1 
mRNA 
Log (L1 
mRNA) 
Donor IM DFG-US-73 unknown unknown 90,42 0,04 -3,14 
Donor IM DFG-US-74 unknown unknown 60,66 12,68 2,54 
Donor IM DFG-US-75 unknown unknown 86,16 2,53 0,93 
Donor IM DFG-US-76 unknown unknown 59,92 44,63 3,80 
Donor IM DFG-US-78 unknown unknown 58,82 32,34 3,48 
Donor IM DFG-US-79 unknown unknown 74,59 2,09 0,74 
Donor IM DFG-US-80 unknown unknown 76,83 4,41 1,48 
Donor IM DFG-US-81 unknown unknown 80,76 0,22 -1,50 
Donor IM DFG-US-82 unknown unknown 46,77 7,34 1,99 
Donor IM DFG-US-83 unknown unknown 58,10 146,53 4,99 
Donor IM DFG-US-84 unknown unknown 48,83 1,43 0,36 
Donor IM DFG-US-85 unknown unknown 56,64 8,52 2,14 
Donor IM DFG-US-86 unknown unknown 50,15 1,99 0,69 
Donor IM DFG-US-87 unknown unknown 48,47 12,55 2,53 
Donor IM DFG-US-88 unknown unknown 62,66 24,08 3,18 
Donor IM DFG-US-90 unknown unknown 63,05 0,15 -1,88 
Donor IM DFG-US-91 unknown unknown 69,12 1,87 0,62 
Donor IM DFG-US-92 unknown unknown 50,35 0,12 -2,11 
Donor IM DFG-US-93 unknown unknown 63,75     
Donor IM DFG-US-94 unknown unknown 45,10     
Donor IM DFG-US-95 unknown unknown 49,47 1,01 0,01 
Donor IM DFG-US-96 unknown unknown 47,30 0,39 -0,95 
Donor IM DFG-US-97 unknown unknown 51,87 0,11 -2,23 
Donor IM DFG-US-98 unknown unknown 100,00 0,97 -0,03 
Donor IM DFG-US-100 unknown unknown 65,37 2,50 0,91 
Donor IM DFG-US-101 unknown unknown 47,69     
Donor IM DFG-US-102 unknown unknown 52,97     
Donor IM DFG-US-103 unknown unknown 54,00     
Donor IM DFG-US-104 unknown unknown 33,73     
Donor IM DFG-US-105 unknown unknown -1,00     
Donor IM DFG-US-106 unknown unknown 85,81     
Donor IM DFG-US-107 unknown unknown 36,71     
Donor IM DFG-US-108 unknown unknown 37,15     
Donor IM DFG-US-109 unknown unknown 46,77     
Donor IM DFG-US-110 unknown unknown 43,09     
Donor IM DFG-US-111 unknown unknown 70,37     
Donor IM DFG-US-112 unknown unknown 62,70     
Donor IM DFG-US-113 unknown unknown 72,38     
Donor IM DFG-US-114 unknown unknown 45,14     
Donor IM DFG-US-115 unknown unknown 46,83     
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Table 20: Clinical data of patients` M. 
Type ID 
Age 
man 
Sperm concentra-
tion (Mio/ml) 
Total sperm con-
centration (Mio) 
Progressive 
motility (%) 
Total moti-
lity (%) 
Morphology 
(%) 
Patient M P01 42 13 20,8 28 48 0 
Patient M P02 47 4 14,8 18 39 0 
Patient M P03 39 11 64,9 29 55 0 
Patient M P04 37 18,4 31,28 23 50 0 
Patient M P05 50 36 136,8 28 46 0 
Patient M P06 41 3,2 18,24 41 59 0 
Patient M P07 32 2,4 9,12 12 32 0 
Patient M P08 29 46,6 219,02 40 71 4 
Patient M P09 33 48 110,4 43 67 4 
Patient M P10 43 3,2 10,24 14 25 0 
Patient M P11 38 10,2 55,08 13 30 0 
Patient M P12 43 6,5 22,75 54 66 0 
Patient M P13 38 2,5 5,75 31 52 0 
Patient M P14 38 8 5,12 16 52 0 
Patient M P15 45 219 394,2 60 82 5 
Patient M P16 37 126 491,4 60 82 6 
Patient M P17 47 4,3 22,36 40 61 0 
Patient M P18 32 33 135,3 26 53 0 
Patient M P19 47 57 68,4 26 46 0 
Patient M P20 37 10,8 30,24 24 35 1 
Patient M P21 45 17,7 157,53 53 76 0 
Patient M P22 31 4,8 15,84 26 51 0 
Patient M P23 39 1,2 6,84 9 30 0 
Patient M P24 30 84 310,8 41 63 1 
Patient M P25 38 31 213,9 55 82 0 
Patient M P26 37 34 268,6 30 60 0 
Patient M P27 35 23 85,1 59 81 0 
Patient M P28 46 25 87,5 51 75 0 
Patient M P29  11,6 85,84 43 58 0 
Patient M P30 36 78 163,8 31 61 2 
Patient M P31 40 58 63,8 59 77 0 
Patient M P32 44 155 294,5 36 70 0 
Patient M P33 40 10,1 36,36 34 56 0 
Patient M P34 43 11 71,5 43 66 0 
Patient M P35 43 45 585 60 83 0 
Patient M P36 45 68,4 177,84 34 64 0 
Patient M P37 40 63,9 166,14 54 80 0 
Patient M P38 39 14 51,8 60 79 0 
Patient M P39 38 81 186,3 41 72 0 
Patient M P40 33 21 52,5 31 61 2 
Patient M P41 40 17,7 72,57 38 53 0 
Patient M P42 35 15 130,5 62 83 0 
Patient M P43 38 19 72,2 42 74 0 
Patient M P44 33 11,6 27,84 46 62 0 
Patient M P45 42 3,4 8,16 26 51 0 
Patient M P46 31 44 233,2 47 72 0 
Patient M P47 43 49 176,4 45 70 0 
Patient M P48 37 16 75,2 39 59 0 
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Table 21: Clinical data of female partners from patients` M. Nd = not detectable. 
ID 
Age 
woman 
BMI FSH 
MTHFR677 
polymorphism 
Anti-Mülle-
rian hormone 
Vita-
min D 
Vitamin 
B12 
Fo-
late 
Estra-
diol 
Fertiliza-
tion rate 
P01 31 22 175 normal 2.9 29.9 939 19 2899 60 
P02 36 22 187 normo 1,2 32 319  1734 67 
P03 36 24 137 normo nd nd nd nd 5085 60 
P04 33   100   nd nd nd nd 1368 70 
P05 40 22 225 hetero 1.5 29 1026 20 5154 69 
P06 28 22 187 normo 3.0 26.6 491 0.8 4745 50 
P07 31 20 175 hetero 2.3 34,8 460 19,5 2675 78 
P08 31 22 150 normo 1.2 nd 656 20 3562 89 
P09 30 22 18 normo 1.5 33 491 20 2235 100 
P10 45 21 225 hetero 0,9 32 983 20 1276 60 
P11 35 23 200 hetero nd nd nd nd 3240 50 
P12 40 25 225 normo 0.2 32 500 20 1823 67 
P13 38 23 183 normo nd nd nd nd 2889 76 
P14 35 24  hetero 5,4 17,5 593 4,7 3203 60 
P15 28 20 132 hetero 7.3 34.2 872 20 2090 80 
P16 38 22 150   2.5 36.8 489 17.8 2893 67 
P17 41 23 225 hetero 0,7 21.2 800 20 2152 50 
P18 30 22 175 hetero 2,6 19.9 679 20 2902 86 
P19 33 21 225 hetero 0.5 nd 794 15.4 2142 80 
P20 36 23 75 normo 2.1 nd 583 13 3006 71 
P21 43 21 150 normo 3.2 42 583 17.9 6387 58 
P22 31 22 125 hetero 3.4 23.9 600 20 220.8   
P23 36 25 200 normo         1875 22 
P24 33 26 225 normo 0.5 nd 252 11 1434 100 
P25 34 35 225   0,5 nd nd nd 1772 100 
P26 35 23 225 hetero nd 29 1112 16 1566 83 
P27 37 22 225 normo 0.9 21 451 20 5850 75 
P28 34   150 hetero 4.7 49.6 426 11.1 3241 58 
P29 33 26 132 homo 7.4 23.5 410 13.0 1757 57 
P30 33 22 175 hetero 2.0 nd 1376 20 2710 56 
P31 38 24 100 normo 0,7 36,3 753 20     
P32 37 22 225 hetero 1.3 19.7 476 8.4 4101 38 
P33 39 22 225 normo   21 416 7.9 1572   
P34 37 24 200 hetero 0,5 19 523  1060 38 
P35 40 20 225 hetero 0.6 24.4 377 20 1433 56 
P36 43 24 175 normo 3.0 22.7 407 20 3345 79 
P37 37 22 225 hetero 0,6 nd nd nd 2394 57 
P38 37 21 225 hetero 1.7 60 397 20 4884 69 
P39 35 23 132 normo 3,8 25.2 786 20 1380 50 
P40 37 22   hetero 3.7 28 479 16.2 1629 100 
P41 33 22 225 hetero nd nd nd nd 5198 67 
P42 37 26,6 150 normo 4.0 21,2 485 16,8 2244 55 
P43 35 21 150 normo 0.7 13 413 19 3609 80 
P44 32 21 150 homo 2.8 nd 271  1602 77 
P45 36 20 225 hetero 1,0 26,4 426 16,4   0 
P46 28 24 50 normo nd nd nd nd 3970 64 
P47 44 24 200 hetero 0,8 17,2 615 20 3895 79 
P48 27 20 125 hetero 3.1 34 403 17 1506 53 
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10. List of abbreviations 
APS      Ammonium persulfate 
ART      Assisted reproductive technologies 
bp      Base pair 
BSA      Bovine serum albumin 
ChIP     Chromatin immunoprecipitation 
kDa      Kilo dalton 
ddH2O     Destilled water 
DEPC     Diethypyrocarbonate 
DNA      Desoxyribonucleic acid 
DNase I    Desoxyribonuclease I 
DNMT     DNA methyltransferase 
dNTP     2’-deoxynucleoside-5’-triphosphate 
DTT     Dithiolthreitol 
EDTA     Ethylenediaminetetraacetic acid 
EtOH      Ethanol 
FWD     Forward primer 
GAPDH    Glyceraldehyde 3-phosphate dehydrogenase 
h     Hour 
HeLa      Human cervix carcinoma cell line (from Henrietta Lacks) 
hESC      Human embryonic stem cells  
H2O2     Hydrogen peroxide 
HCl     Hydrochloric acid 
HDF      Human dermal fibroblasts 
HSA     Human serum albumin 
HTF     Human tubal fluid 
ICC      Immunocytochemistry 
ICSI     Intracytoplasmic sperm injection 
IHC     Immunohistochemistry 
Immot. / IM    Immotile (sperm cells) 
IVF     In vitro fertilization 
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L1/L1     Long interspersed nuclear element 1 
M      Molar (mol/L)  
MeOH     Methanol 
mg     Milligram 
min     Minute 
mio     Million 
L     Milliliter 
LIS     Lithium 3,5-diiodosalicylate 
mot. / M    Motile (sperm cells) 
NaAc     Sodium acetate 
NaCl      Sodium chloride 
NaOH     Sodium hydroxide 
nm     Nanometer 
NP-40      Nonyl phenoxypolyethoxylethanol 
n.s.     Not significant 
PBS     Phosphate buffered saline 
PFA     Paraformaldehyde 
PMSF      Phenylmethylsulfonyl fluoride  
PVDF     Polyvinylidene difluoride 
REV     Reverse primer 
RNA      Ribonucleic acid 
RNAse I     Ribonuclease I 
RT      Room temperature 
RT-qPCR    Real time-quantitative polymerase chain reaction 
s     Second 
SINE     Short interspersed nuclear element 
SDS-PAGE     Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TEMED    Tetramethylethylenediamine 
V     Volt 
WB     Western blot 
WHO     World Health Organization (guidelines) 
x     Time(s)  
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